Non    O
-    O
infectious    O
diseases    O
that    O
can    O
be    O
confused    O
with    O
MVD    O
are    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
hemolytic    B-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
snake    O
envenomation    O
,    O
clotting    O
factor    O
deficiencies    O
/    O
platelet    O
disorders    O
,    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
hereditary    O
hemorrhagic    O
telangiectasia    O
,    O
Kawasaki    O
disease    O
,    O
and    O
even    O
warfarin    O
intoxication    O
.    O

Hemolytic-uremic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
HUS    O
)    O
is    O
a    O
complication    O
that    O
occurs    O
when    O
bacteria    O
enter    O
the    O
digestive    O
system    O
and    O
produce    O
toxins    O
to    O
destroy    O
red    O
blood    O
cells    O
that    O
may    O
cause    O
bloody    O
diarrhea    O
as    O
a    O
symptom    O
.    O

Non    O
-    O
infectious    O
diseases    O
that    O
may    O
result    O
in    O
symptoms    O
similar    O
to    O
those    O
of    O
EVD    O
include    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
hemolytic    B-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
snake    O
envenomation    O
,    O
clotting    O
factor    O
deficiencies    O
/    O
platelet    O
disorders    O
,    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
hereditary    O
hemorrhagic    O
telangiectasia    O
,    O
Kawasaki    O
disease    O
,    O
and    O
warfarin    O
poisoning    O
.    O

These    O
complications    O
can    O
include    O
Haemolytic    B-BloodDyscrasia114053850
uraemic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
HUS    O
)    O
and    O
neurological    O
problems    O
.    O

Hemolytic-uremic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

It    O
is    O
particularly    O
advantageous    O
in    O
patients    O
with    O
kidney    O
transplants    O
for    O
hemolytic-uremic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
as    O
this    O
disease    O
is    O
likely    O
to    O
recur    O
in    O
the    O
transplanted    O
kidney    O
if    O
a    O
calcineurin    O
-    O
inhibitor    O
is    O
used    O
.    O

"    O
Escherichia    O
coli    O
O157:H7    O
"    O
enterohemorrhagic    O
(    O
EHEC    O
)    O
which    O
can    O
cause    O
hemolytic-uremic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Hemolytic-uremic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Pk    O
antigen    O
is    O
a    O
receptor    O
for    O
shiga    O
toxins    O
and    O
"    O
Escherichia    O
coli    O
"-    O
associated    O
hemolytic    B-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
HUS    O
)    O
.    O

Haemolytic    B-BloodDyscrasia114053850
uraemic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
HUS    O
)    O
is    O
a    O
disease    O
associated    O
with    O
microangiopathic    O
haemolytic    O
anemia    O
,    O
thrombocytopenia    O
and    O
acute    O
renal    O
failure    O
.    O

Bleeding    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850

Sometimes    O
,    O
lumbar    O
puncture    O
can    O
not    O
be    O
performed    O
safely    O
(    O
for    O
example    O
due    O
to    O
a    O
severe    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
tendency    I-BloodDyscrasia114053850
)    O
.    O

Bleeding    B-BloodDyscrasia114053850
diathesis    I-BloodDyscrasia114053850
(    O
relative    O
)    O

15    O
or    O
more    O
petechiae    O
indicate    O
capillary    O
fragility    O
,    O
which    O
occurs    O
due    O
to    O
poor    O
platelet    O
function    O
,    O
bleeding    B-BloodDyscrasia114053850
diathesis    I-BloodDyscrasia114053850
or    O
thrombocytopenia    O
,    O
and    O
can    O
be    O
seen    O
in    O
cases    O
of    O
scurvy    O
,    O
and    O
Dengue    O
fever    O
.    O

Monoclonal    B-BloodDyscrasia114053850
gammopathy    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
undetermined    I-BloodDyscrasia114053850
significance    I-BloodDyscrasia114053850

Monoclonal    B-BloodDyscrasia114053850
gammopathy    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
undetermined    I-BloodDyscrasia114053850
significance    I-BloodDyscrasia114053850

MGUS    O
polyneuropathy    O
or    O
polyneuropathy    O
associated    O
with    O
an    O
M    O
component    O
is    O
a    O
rare    O
neurological    O
disease    O
characterized    O
by    O
inflammation    O
of    O
the    O
peripheral    O
nervous    O
system    O
and    O
monoclonal    B-BloodDyscrasia114053850
gammopathy    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
undetermined    I-BloodDyscrasia114053850
significance    I-BloodDyscrasia114053850
(    O
MGUS    O
)    O
.    O

a    O
paraprotein    O
in    O
the    O
blood    O
(    O
an    O
MGUS    B-BloodDyscrasia114053850
in    O
approximately    O
80%    O
of    O
cases    O
)    O
.    O

In    O
1904    O
this    O
theory    O
was    O
challenged    O
by    O
the    O
discovery    O
of    O
a    O
substance    O
in    O
the    O
serum    O
of    O
patients    O
with    O
paroxysmal    B-BloodDyscrasia114053850
cold    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850
that    O
reacted    O
with    O
red    O
blood    O
cells    O
.    O

Autoanti    O
-    O
P    O
(    O
Donath    O
-    O
Landsteiner    O
)    O
is    O
an    O
autoantibody    O
of    O
P    O
specificity    O
and    O
is    O
seen    O
in    O
individuals    O
with    O
paroxysmal    B-BloodDyscrasia114053850
cold    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850
(    O
PCH    O
)    O
.    O

E.g.    O
Bite    O
cells    O
and/or    O
blistor    O
cells    O
for    O
oxidative    O
hemolysis    O
,    O
Acanthocytes    O
for    O
pyruvate    B-BloodDyscrasia114053850
kinase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
or    O
McLeod    B-BloodDyscrasia114053850
phenotype    I-BloodDyscrasia114053850
,    O
Sickle    O
cells    O
for    O
sickle    O
cell    O
anemia    O
,    O
Spherocytes    B-BloodDyscrasia114053850
for    O
immune    O
-    O
mediated    O
hemolysis    O
or    O
hereditary    B-BloodDyscrasia114053850
spherocytosis    I-BloodDyscrasia114053850
,    O
Elliptocytosis    O
for    O
iron    O
deficiency    O
or    O
hereditary    O
elliptocytosis    O
and    O
schistocytes    O
for    O
intravascular    O
hemolysis    O
.    O

Spherocytosis    B-BloodDyscrasia114053850
is    O
an    O
auto    O
-    O
hemolytic    O
anemia    B-BloodDyscrasia114053850
(    O
a    O
disease    O
of    O
the    O
blood    O
)    O
characterized    O
by    O
the    O
production    O
of    O
spherocytes    O
(    O
red    O
blood    O
cells    O
(    O
RBCs    O
)    O
)    O
or    O
erythrocytes    O
that    O
are    O
sphere    O
-    O
shaped    O
rather    O
than    O
bi    O
-    O
concave    O
disk    O
shaped    O
.    O

After    O
splenectomy    O
with    O
the    O
"    O
goal    O
"    O
of    O
interfering    O
with    O
splenic    O
function    O
,    O
as    O
a    O
treatment    O
for    O
diseases    O
(    O
e.g.    O
idiopathic    O
thrombocytopenic    O
purpura    O
,    O
thalassemia    O
,    O
spherocytosis    B-BloodDyscrasia114053850
)    O
,    O
in    O
which    O
the    O
spleen    O
's    O
usual    O
activity    O
exacerbates    O
the    O
disease    O

Cryoglobulinaemia    B-BloodDyscrasia114053850

Essential    B-BloodDyscrasia114053850
cryoglobulinemic    I-BloodDyscrasia114053850
vasculitis    I-BloodDyscrasia114053850
.    O

Most    O
often    O
due    O
to    O
hepatitis    O
C    O
infection    O
,    O
immune    O
complexes    O
of    O
cryoglobulins    B-BloodDyscrasia114053850
---    O
proteins    O
that    O
consists    O
of    O
immunoglobulins    O
and    O
complement    O
and    O
precipitate    O
in    O
the    O
cold    O
while    O
dissolving    O
upon    O
rewarming    O
---    O
are    O
deposited    O
in    O
walls    O
of    O
capillaries    O
,    O
venules    O
,    O
or    O
arterioles    O
.    O

Salvador    O
Cardenal    O
died    O
on    O
March    O
8    O
,    O
2010    O
after    O
a    O
long    O
battle    O
with    O
cryoglobulinemia    B-BloodDyscrasia114053850
.    O

Cryoglobulinemia    B-BloodDyscrasia114053850

Hematopoietic    O
ulcers    O
are    O
those    O
occurring    O
with    O
sickle    O
cell    O
anemia    O
,    O
congenital    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
thrombocytopenic    O
purpura    O
,    O
macroglobulinemia    B-BloodDyscrasia114053850
,    O
and    O
cryoglobulinemia    B-BloodDyscrasia114053850
.    O

Besides    O
being    O
an    O
early    O
prominent    O
advocator    O
of    O
the    O
low    O
-    O
carbohydrate    O
diet    O
as    O
"    O
one    O
of    O
the    O
leading    O
experts    O
on    O
dieting    O
"    O
,    O
according    O
to    O
"    O
Hemmets    O
veckotidning    O
"    O
(    O
1966    O
)    O
,    O
he    O
was    O
also    O
a    O
pioneer    O
in    O
the    O
study    O
of    O
the    O
restless    O
legs    O
syndrome    O
in    O
1953    O
,    O
treating    O
patients    O
by    O
injection    O
of    O
iron    O
according    O
to    O
his    O
casusal    O
theory    O
attributed    O
to    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

Iron    B-BloodDyscrasia114053850
frequently    O
is    O
seriously    O
deficient    O
,    O
particularly    O
in    O
menstruating    O
females    O
,    O
and    O
must    O
be    O
supplemented    O
.    O

There    O
have    O
been    O
reported    O
cases    O
in    O
which    O
pica    O
recurs    O
after    O
gastric    O
bypass    O
in    O
patients    O
with    O
a    O
pre    O
-    O
operative    O
history    O
of    O
the    O
disorder    O
,    O
which    O
are    O
possibly    O
due    O
to    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

In    O
medicine    O
,    O
Non    O
-    O
Anemic    O
Iron    B-BloodDyscrasia114053850
Deficiency    I-BloodDyscrasia114053850

Iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

Persons    O
with    O
short    O
bowel    O
syndrome    O
may    O
have    O
complications    O
caused    O
by    O
malabsorption    O
of    O
vitamins    O
and    O
minerals    O
,    O
such    O
as    O
deficiencies    O
in    O
vitamins    O
A    O
,    O
D    O
,    O
E    O
,    O
K    O
,    O
B9    B-BloodDyscrasia114053850
(folic    I-BloodDyscrasia114053850
acid)    I-BloodDyscrasia114053850
,    O
and    O
B12    B-BloodDyscrasia114053850
,    O
calcium    O
,    O
magnesium    O
,    O
iron    B-BloodDyscrasia114053850
,    O
and    O
zinc    O
.    O

Iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

Iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

Sideropenic    B-BloodDyscrasia114053850
dysphagia    O

Consequences    O
of    O
parasitic    O
infection    O
can    O
include    O
anemia    B-BloodDyscrasia114053850
due    O
to    O
blood    O
loss    O
and    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
malnutrition    O
,    O
growth    O
retardation    O
,    O
invasive    O
disease    O
,    O
and    O
death    O
.    O

Hypoferremia    B-BloodDyscrasia114053850

Some    O
of    O
the    O
most    O
common    O
diseases    O
that    O
these    O
young    O
children    O
are    O
facing    O
are    O
hunger    O
:    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    B-BloodDyscrasia114053850
,    O
vitamin    O
A    O
deficiency    O
,    O
and    O
mentally    O
impaired    O
(    O
iodine    O
deficiency    O
)    O
,    O
and    O
childhood    O
diseases    O
:    O
acute    O
respiratory    O
infections    O
,    O
diarrhoeal    O
disease    O
,    O
and    O
malaria    O
.    O

Heavy    O
infections    O
can    O
lead    O
to    O
the    O
development    O
of    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
and    O
hypochromic    O
microcytic    O
anemia    O
.    O

triose-phosphate    B-BloodDyscrasia114053850
isomerase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

It    O
has    O
acquired    O
a    O
very    O
favorable    O
reputation    O
for    O
treatment    O
of    O
blood    O
disorders    O
,    O
including    O
blood    B-BloodDyscrasia114053850
stasis    I-BloodDyscrasia114053850
,    O
bleeding    O
,    O
and    O
blood    O
deficiency    O
.    O

Some    O
of    O
the    O
diseases    O
are    O
beta    O
-    O
thalassemia    O
mutations    O
,    O
sickle    O
-    O
cell    O
disease    O
,    O
congenital    O
heart    O
-    O
disease    O
,    O
glucose-6-phosphate    O
dehydrogenase    O
deficiency    O
,    O
alpha-thalassemia    B-BloodDyscrasia114053850
,    O
molecular    O
characterization    O
,    O
recessive    O
osteoperosis    O
,    O
gluthanione    O
-    O
reducatsafe    O
DEf    O
.    O

Ankylosing    O
spondylitis    O
in    O
Egypt    O
&    O
East    O
block    O
,    O
Alpha-thalassemia    B-BloodDyscrasia114053850
in    O
all    O
countries    O
minus    O
Egypt    O
Syria    O
Iraq    O
,    O
Cystic    O
Fibrosis    O
in    O
Iraq    O
Saudi    O
Yemen    O
Libya    O
Morocco    O
,    O
Familial    O
Mediterranean    O
Fever    O
fmf    O
in    O
east    O
block    O
and    O
Libya    O
Morocco    O
,    O
beta    O
Thalassemia    O
in    O
all    O
countries    O
,    O
g6dh    O
deficiency    O
all    O
countries    O
.    O

Alpha    B-BloodDyscrasia114053850
thalassaemia    I-BloodDyscrasia114053850

CHORI    O
is    O
the    O
first    O
research    O
institute    O
in    O
North    O
America    O
to    O
transplant    O
and    O
cure    O
a    O
child    O
with    O
alpha    B-BloodDyscrasia114053850
thalassemia    I-BloodDyscrasia114053850
major    I-BloodDyscrasia114053850
,    O
is    O
a    O
leading    O
center    O
for    O
the    O
use    O
of    O
cord    O
blood    O
and    O
bone    O
marrow    O
transplantation    O
in    O
children    O
with    O
sickle    O
cell    O
anemia    O
and    O
thalassemia    O
,    O
and    O
offers    O
the    O
only    O
not    O
-    O
for    O
-    O
profit    O
Sibling    O
Donor    O
Cord    O
Blood    O
Program    O
in    O
the    O
world    O
.    O

Southeast    B-BloodDyscrasia114053850
Asian    I-BloodDyscrasia114053850
ovalocytosis    I-BloodDyscrasia114053850
is    O
a    O
form    O
of    O
hereditary    B-BloodDyscrasia114053850
elliptocytosis    I-BloodDyscrasia114053850
common    O
in    O
some    O
communities    O
in    O
Malaysia    O
and    O
Papua    O
New    O
Guinea    O
,    O
as    O
it    O
confers    O
some    O
resistance    O
to    O
cerebral    O
Falciparum    O
Malaria    O
.    O

It    O
is    O
rarer    O
than    O
hemophilia    B-BloodDyscrasia114053850
A    I-BloodDyscrasia114053850
As    O
noted    O
above    O
,    O
it    O
was    O
common    O
among    O
the    O
descendants    O
of    O
Queen    O
Victoria    O
.    O

Other    O
diseases    O
mentioned    O
are    O
high    O
altitude    O
pulmonary    O
edema    O
,    O
Vogt    O
-    O
Koyanagi    O
-    O
Harada    O
syndrome    O
(    O
DRB1    O
0405    O
,    O
see    O
above    O
table    O
for    O
Japanese    O
)    O
,    O
HIV    O
resistance    O
in    O
the    O
US    O
,    O
and    O
haemophilia    B-BloodDyscrasia114053850
A    I-BloodDyscrasia114053850
-    O
FVIII    O
inhibitor    O
response    O
)    O
.    O

Haemophilia    B-BloodDyscrasia114053850
A    I-BloodDyscrasia114053850

Hemophilia    B-BloodDyscrasia114053850
type    I-BloodDyscrasia114053850
A    I-BloodDyscrasia114053850
,    O
a    O
type    O
of    O
haemophilia    O

A    O
study    O
found    O
that    O
forty    O
percent    O
of    O
haemophilia    B-BloodDyscrasia114053850
A    I-BloodDyscrasia114053850
patients    O
had    O
a    O
factor    O
8    O
gene    O
inversion    O
of    O
a    O
certain    O
region    O
that    O
was    O
four    O
hundred    O
kb    O
in    O
size    O
.    O

In    O
the    O
name    O
Octapharma    O
,    O
the    O
“    O
octa    O
”    O
is    O
derived    O
from    O
the    O
Greek    O
word    O
for    O
eight    O
,    O
named    O
after    O
the    O
factor    O
which    O
is    O
deficient    O
in    O
haemophilia    B-BloodDyscrasia114053850
A    I-BloodDyscrasia114053850
patients    O
.    O

Three    O
case    O
reports    O
have    O
found    O
that    O
chromosome    O
translocations    O
between    O
"    O
FIP1L1    O
"    O
and    O
"    O
RARA    O
"    O
gene    O
loci    O
are    O
associated    O
with    O
two    O
cases    O
of    O
acute    O
promyelocytic    O
leukemia    O
and    O
one    O
case    O
of    O
juvenile    B-BloodDyscrasia114053850
myelomonocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

Juvenile    B-BloodDyscrasia114053850
myelomonocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850

Sickle    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
trait    I-BloodDyscrasia114053850
;    O

More    O
recent    O
studies    O
have    O
de    O
-    O
emphasized    O
physical    O
appearance    O
,    O
such    O
as    O
height    O
and    O
nose    O
width    O
,    O
in    O
favor    O
of    O
examining    O
blood    O
factors    O
,    O
the    O
presence    O
of    O
the    O
sickle    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
trait    I-BloodDyscrasia114053850
,    O
lactose    O
intolerance    O
in    O
adults    O
,    O
and    O
other    O
genotype    O
expressions    O
.    O

Sickle-cell    B-BloodDyscrasia114053850
trait    I-BloodDyscrasia114053850

One    O
-    O
third    O
of    O
all    O
indigenous    O
inhabitants    O
of    O
Sub    O
-    O
Saharan    O
Africa    O
carry    O
the    O
gene    O
,    O
because    O
,    O
in    O
areas    O
where    O
malaria    O
is    O
common    O
,    O
there    O
is    O
a    O
survival    O
value    O
in    O
carrying    O
only    O
a    O
single    O
sickle    O
-    O
cell    O
gene    O
(    O
sickle    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
trait    I-BloodDyscrasia114053850
)    O
.    O

This    O
would    O
be    O
similar    O
to    O
the    O
hemoglobin    O
allele    O
which    O
is    O
responsible    O
for    O
sickle    O
-    O
cell    O
disease    O
,    O
but    O
solely    O
in    O
people    O
with    O
two    O
copies    O
;    O
those    O
with    O
just    O
one    O
copy    O
of    O
the    O
allele    O
have    O
a    O
sickle    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
trait    I-BloodDyscrasia114053850
and    O
gain    O
partial    O
immunity    O
to    O
malaria    O
as    O
a    O
result    O
.    O

He    O
was    O
best    O
known    O
for    O
his    O
contribution    O
to    O
the    O
identification    O
and    O
naming    O
of    O
the    O
Imerslund-Gräsbeck    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Aggregation    O
in    O
TRAPtest    O
may    O
be    O
reduced    O
or    O
absent    O
in    O
Glanzmann's    B-BloodDyscrasia114053850
thrombasthenia    I-BloodDyscrasia114053850
,    O
where    O
GPIIb    O
/    O
IIIa    O
receptors    O
are    O
few    O
or    O
absent    O
,    O
or    O
if    O
the    O
patient    O
is    O
taking    O
a    O
GPIIb    O
/    O
IIIa    O
antagonist    O
.    O

Glanzmann's    B-BloodDyscrasia114053850
thrombasthenia    I-BloodDyscrasia114053850

Glanzmann's    B-BloodDyscrasia114053850
thrombasthenia    I-BloodDyscrasia114053850
,    O
a    O
rare    O
medical    O
condition    O

Hematologic    O
diseases    O
in    O
which    O
it    O
is    O
positive    O
include    O
ALL    O
,    O
angioimmunoblastic    O
T    O
cell    O
lymphoma    O
,    O
Burkitt    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
in    O
blast    O
crisis    O
(    O
90%    O
)    O
,    O
diffuse    O
large    O
B    O
-    O
cell    O
lymphoma    O
(    O
variable    O
)    O
,    O
follicular    O
center    O
cells    O
(    O
70%    O
)    O
,    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
10%    O
)    O
,    O
and    O
myeloma    O
(    O
some    O
)    O
.    O

March    O
10    O
:    O
Dave    O
Stevens    O
,    O
American    O
comics    O
artist    O
(    O
"    O
The    O
Rocketeer    O
"    O
)    O
,    O
dies    O
of    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
at    O
age    O
52    O
.    O

Cladribine    O
is    O
a    O
medication    O
used    O
to    O
treat    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
HCL    O
,    O
leukemic    O
reticuloendotheliosis    O
)    O
and    O
B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

Cladribine    O
is    O
used    O
for    O
as    O
a    O
first    O
and    O
second    O
-    O
line    O
treatment    O
for    O
symptomatic    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
and    O
for    O
B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
and    O
is    O
administered    O
by    O
intravenous    O
infusion    O
.    O

The    O
best    O
clinical    O
success    O
has    O
been    O
achieved    O
in    O
treating    O
patients    O
with    O
refractory    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

Excluded    O
diseases    O
include    O
:    O
Hodgkin’s    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
,    O
chronic    B-BloodDyscrasia114053850
lymphatic    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
malignant    O
melanoma    O
and    O
mesothelioma    O
.    O

One    O
of    O
these    O
,    O
HA22    O
or    O
Moxetumomab    O
pasudotox    O
(    O
Moxe    O
)    O
,    O
targets    O
CD22    O
on    O
B    O
cell    O
malignancies    O
;    O
it    O
has    O
produced    O
many    O
complete    O
and    O
durable    O
remissions    O
in    O
chemotherapy    O
resistant    O
Hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
and    O
is    O
now    O
in    O
a    O
phase    O
3    O
trial    O
to    O
gain    O
FDA    O
approval    O
.    O

Non    O
-    O
infectious    O
diseases    O
that    O
may    O
result    O
in    O
symptoms    O
similar    O
to    O
those    O
of    O
EVD    O
include    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
hemolytic    B-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
snake    O
envenomation    O
,    O
clotting    O
factor    O
deficiencies    O
/    O
platelet    O
disorders    O
,    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
hereditary    O
hemorrhagic    O
telangiectasia    O
,    O
Kawasaki    O
disease    O
,    O
and    O
warfarin    O
poisoning    O
.    O

This    O
happens    O
in    O
hematologic    O
disorders    O
like    O
chronic    B-BloodDyscrasia114053850
myelogeneous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
promyelocytic    B-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
and    O
also    O
the    O
hypereosinophilic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

In    O
combination    O
with    O
all    O
-    O
trans    O
retinoic    O
acid    O
,    O
it    O
is    O
FDA    O
-    O
approved    O
as    O
first    O
-    O
line    O
treatment    O
for    O
promyelocytic    B-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

By    O
contrast    O
,    O
arsenic    O
oxide    O
is    O
an    O
approved    O
and    O
effective    O
chemotherapeutic    O
drug    O
for    O
the    O
treatment    O
of    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
APL    O
)    O
.    O

Pagano    O
was    O
diagnosed    O
with    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
in    O
September    O
2012    O
,    O
and    O
took    O
an    O
indefinite    O
leave    O
of    O
absence    O
of    O
his    O
coaching    O
duties    O
.    O

Pandolfi    O
’s    O
elucidation    O
of    O
fusion    O
oncoproteins    O
and    O
genes    O
involved    O
in    O
the    O
chromosomal    O
translocations    O
of    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
APL    O
)    O
led    O
to    O
the    O
development    O
of    O
effective    O
therapies    O
.    O

While    O
a    O
medical    O
student    O
,    O
Pandolfi    O
cloned    O
and    O
characterized    O
PML    O
-    O
RARa    O
(    O
retinoic    O
acid    O
receptor    O
alpha    O
)    O
,    O
the    O
product    O
of    O
the    O
long    O
-    O
sought    O
after    O
t(15;17    O
)    O
chromosomal    O
translocation    O
of    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
APL    O
)    O
and    O
its    O
normal    O
counterpart    O
promyelocytic    O
leukemia    O
protein    O
(    O
PML    O
)    O
.    O

Mocetinostat    O
(    O
MGCD0103    O
)    O
is    O
undergoing    O
clinical    O
trials    O
for    O
treatment    O
of    O
various    O
cancers    O
(    O
including    O
follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
and    O
acute    O
myeloid    O
leukemia    O
)    O
.    O

In    O
February    O
2010    O
,    O
Christensen    O
announced    O
that    O
he    O
had    O
been    O
diagnosed    O
with    O
follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

It    O
was    O
in    O
Adams    O
'    O
lab    O
that    O
his    O
PhD    O
student    O
,    O
David    O
Vaux    O
,    O
made    O
the    O
connection    O
between    O
apoptosis    O
(    O
programmed    O
cell    O
death    O
)    O
and    O
cancer    O
,    O
while    O
studying    O
the    O
bcl-2    O
gene    O
in    O
follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
the    O
most    O
common    O
human    O
lymphoma    O
.    O

It    O
has    O
US    O
FDA    O
Breakthrough    O
Therapy    O
Designation    O
(    O
Dec    O
2015    O
)    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
refractory    O
diffuse    O
large    O
B    O
cell    O
lymphoma    O
(    O
DLBCL    O
)    O
,    O
primary    O
mediastinal    O
B    O
cell    O
lymphoma    O
(    O
PMBCL    O
)    O
,    O
and    O
transformed    B-BloodDyscrasia114053850
follicular    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
TFL    O
)    O
.    O

Follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
follicle    O
centre    O
cell    O
lymphoma    O
)    O
are    O
CD10    O
+    O
.    O

Follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
t14;18    O
)    O

A    O
centrocyte    O
generally    O
refers    O
to    O
a    O
B    O
cell    O
with    O
a    O
cleaved    O
nucleus    O
,    O
as    O
may    O
appear    O
in    O
e.g.    O
follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

After    O
leaving    O
Columbia    O
in    O
1932    O
,    O
Brandt    O
worked    O
briefly    O
for    O
several    O
different    O
firms    O
before    O
retiring    O
in    O
1935    O
due    O
to    O
Follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

As    O
of    O
2016    O
venetoclax    O
had    O
been    O
tested    O
to    O
treat    O
other    O
hematological    O
cancers    O
,    O
including    O
non-Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
multiple    O
myeloma    O
,    O
diffuse    O
large    O
B    O
-    O
cell    O
lymphoma    O
and    O
follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Blood    B-BloodDyscrasia114053850
hammer    I-BloodDyscrasia114053850

Metabolic    O
food    O
reactions    O
are    O
due    O
to    O
inborn    O
or    O
acquired    O
errors    O
of    O
metabolism    O
of    O
nutrients    O
,    O
such    O
as    O
in    O
diabetes    O
mellitus    O
,    O
lactase    O
deficiency    O
,    O
phenylketonuria    O
and    O
favism    B-BloodDyscrasia114053850
.    O

Favism    B-BloodDyscrasia114053850

G6PD    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Clinically    O
,    O
an    O
X    O
-    O
linked    O
genetic    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
G6PD    I-BloodDyscrasia114053850
predisposes    O
a    O
person    O
to    O
non    O
-    O
immune    O
.    O

More    O
than    O
40    O
severe    O
class    B-BloodDyscrasia114053850
I    I-BloodDyscrasia114053850
mutations    O
involve    O
mutations    O
near    O
the    O
structural    O
site    O
,    O
thus    O
affecting    O
the    O
long    O
term    O
stability    O
of    O
these    O
enzymes    O
in    O
the    O
body    O
,    O
ultimately    O
resulting    O
in    O
G6PD    O
deficiency    O
.    O

Glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
is    O
very    O
common    O
worldwide    O
,    O
and    O
causes    O
acute    O
hemolytic    O
anemia    O
in    O
the    O
presence    O
of    O
simple    O
infection    O
,    O
ingestion    O
of    O
fava    O
beans    O
,    O
or    O
reaction    O
with    O
certain    O
medicines    O
,    O
antibiotics    O
,    O
antipyretics    O
,    O
and    O
antimalarials    O
.    O

Glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

He    O
is    O
known    O
for    O
his    O
collaboration    O
with    O
William    O
H.    O
Zinkham    O
,    O
which    O
demonstrated    O
that    O
Glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
is    O
an    O
X    O
-    O
linked    O
recessive    O
genetic    O
disease    O
.    O

There    O
are    O
also    O
several    O
genetically    O
based    O
red    O
blood    O
cell    O
disorders    O
related    O
to    O
geographic    O
distribution    O
that    O
should    O
be    O
considered    O
when    O
assessing    O
an    O
anemic    O
condition    O
,    O
including    O
α    O
and    O
β-thalassemia    O
,    O
hemoglobin    O
E    O
,    O
sickle    O
cell    O
disease    O
,    O
hemoglobin    O
C    O
,    O
G6PD    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
and    O
red    O
blood    O
cell    O
membrane    O
defects    O
.    O

Patients    O
with    O
glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
should    O
avoid    O
taking    O
aminosalicylic    O
acid    O
as    O
it    O
causes    O
haemolysis    O
.    O

The    O
diagnosis    O
of    O
infantile    O
pyknocytosis    O
is    O
essentially    O
based    O
on    O
the    O
peripheral    O
blood    O
smear    O
,    O
with    O
additional    O
diagnostic    O
investigations    O
to    O
rule    O
out    O
similarly    O
presenting    O
conditions    O
such    O
as    O
glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
and    O
pyruvate    B-BloodDyscrasia114053850
kinase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

Glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
(    O
G6PD    O
)    O

Aspirin    O
is    O
known    O
to    O
cause    O
hemolytic    O
anemia    O
in    O
people    O
who    O
have    O
the    O
genetic    O
disease    O
glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
particularly    O
in    O
large    O
doses    O
and    O
depending    O
on    O
the    O
severity    O
of    O
the    O
disease    O
.    O

This    O
disease    O
is    O
worst    O
for    O
elderly    O
patients    O
,    O
males    O
,    O
African    O
-    O
Americans    O
,    O
alcoholics    O
,    O
and    O
patients    O
with    O
G6PD    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

HN-3    O
has    O
found    O
some    O
applications    O
in    O
chemotherapy    O
,    O
e.g.    O
,    O
for    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
and    O
in    O
some    O
compound    O
Semiconductor    O
research    O
but    O
it    O
is    O
mainly    O
of    O
interest    O
for    O
its    O
military    O
uses    O
and    O
is    O
the    O
only    O
one    O
of    O
these    O
agents    O
that    O
remains    O
anywhere    O
as    O
a    O
military    O
agent    O
.    O

Similarly    O
,    O
an    O
enlarged    O
right    O
supraclavicular    O
lymph    O
node    O
tends    O
to    O
drain    O
thoracic    O
malignancies    O
such    O
as    O
lung    O
and    O
esophageal    O
cancer    O
,    O
as    O
well    O
as    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

the    O
discovery    O
of    O
vinblastine    O
as    O
successful    O
chemotherapy    O
for    O
Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
the    O
1950s    O
,    O
also    O
a    O
treatment    O
for    O
cancer    O
still    O
used    O
today    O

He    O
became    O
world    O
famous    O
for    O
his    O
contribution    O
to    O
the    O
curability    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
to    O
cancer    O
education    O
.    O

Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
a    O
highly    O
treatable    O
hematological    O
malignancy    O
(    O
"    O
blood    O
cancer    O
"    O
)    O

On    O
April    O
30    O
,    O
2009    O
,    O
Zohn    O
was    O
diagnosed    O
with    O
a    O
rare    O
type    O
of    O
cancer    O
called    O
CD20-positive    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Homer    O
returns    O
to    O
Coalwood    O
as    O
a    O
hero    O
and    O
visits    O
Miss    O
Riley    O
,    O
who    O
is    O
dying    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

In    O
March    O
2008    O
he    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

His    O
name    O
was    O
attached    O
to    O
the    O
eponymous    O
Ebstein    O
's    O
anomaly    O
(    O
a    O
rare    O
congenital    O
heart    O
defect    O
)    O
and    O
Pel    O
-    O
Ebstein    O
fever    O
(    O
a    O
remittent    O
fever    O
associated    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
)    O
.    O

They    O
were    O
a    O
very    O
successful    O
duo    O
until    O
2000    O
,    O
releasing    O
One    O
Hell    O
of    O
a    O
Video    O
,    O
D'Unbelievables    O
,    O
D'Video    O
,    O
D'Telly    O
,    O
D'Mother    O
and    O
D'collection    O
but    O
the    O
group    O
stopped    O
touring    O
after    O
Kenny    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

They    O
toured    O
extensively    O
all    O
over    O
Ireland    O
for    O
almost    O
a    O
decade    O
until    O
Jon    O
Kenny    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
in    O
2000    O
.    O

Paul    O
Allen    O
resigned    O
from    O
Microsoft    O
in    O
1983    O
after    O
developing    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

In    O
Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
for    O
instance    O
,    O
the    O
typically    O
-    O
observed    O
eosinophilia    O
is    O
thought    O
to    O
be    O
attributable    O
to    O
an    O
increased    O
production    O
of    O
IL-5    O
.    O

Note    O
:    O
The    O
character    O
of    O
Daisy    O
,    O
played    O
by    O
Susan    O
Wokoma    O
,    O
was    O
introduced    O
when    O
Dominique    O
Moore    O
had    O
to    O
leave    O
the    O
show    O
during    O
recording    O
of    O
series    O
3    O
to    O
have    O
treatment    O
for    O
Hodgkin's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
.    O

Shortly    O
after    O
his    O
sophomore    O
year    O
in    O
1982    O
,    O
he    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
one    O
of    O
the    O
more    O
curable    O
types    O
of    O
cancer    O
when    O
discovered    O
in    O
its    O
early    O
stages    O
.    O

In    O
1965    O
,    O
he    O
discovered    O
he    O
had    O
Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Huggins    O
has    O
argued    O
that    O
amalgam    O
can    O
cause    O
digestive    O
problems    O
such    O
as    O
Crohn    O
's    O
disease    O
and    O
ulcers    O
,    O
mood    O
disorders    O
such    O
as    O
depression    O
and    O
fatigue    O
,    O
autoimmune    O
diseases    O
such    O
as    O
multiple    O
sclerosis    O
,    O
scleroderma    O
and    O
lupus    O
,    O
high    O
or    O
low    O
blood    O
pressure    O
,    O
arthritis    O
,    O
tachycardia    O
,    O
mononucleosis    O
,    O
and    O
cancers    O
such    O
as    O
leukemia    O
and    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

His    O
mother    O
died    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
when    O
he    O
was    O
eight    O
years    O
old    O
and    O
his    O
father    O
remarried    O
.    O

March    O
10    O
–    O
Louis    O
Sissman    O
,    O
48    O
,    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Mario    O
Lemieux    O
overcame    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
to    O
finish    O
his    O
NHL    O
career    O
with    O
more    O
than    O
1,700    O
points    O
and    O
two    O
championships    O
,    O
and    O
now    O
owns    O
the    O
Pittsburgh    O
Penguins    O
.    O

On    O
8    O
July    O
2003    O
,    O
at    O
the    O
age    O
of    O
18    O
,    O
Goodrem    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

The    O
drug    O
was    O
created    O
by    O
Tanox    O
under    O
the    O
name    O
"    O
TNX-650    O
"    O
,    O
and    O
a    O
phase    O
I    O
clinical    O
trial    O
for    O
refractory    O
Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
had    O
been    O
performed    O
when    O
Genentech    O
acquired    O
Tanox    O
in    O
2007    O
.    O

The    O
presence    O
of    O
these    O
cells    O
is    O
diagnostic    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Glutathione    O
conjugates    O
of    O
14,15-HxA3    O
and    O
14,15-HxB3    O
have    O
also    O
been    O
detected    O
the    O
human    O
Hodgkin    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
Reed–    O

He    O
died    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
in    O
Minneapolis    O
,    O
Minnesota    O
.    O

The    O
Deveraux    O
Family    O
hired    O
Kayla    O
to    O
be    O
Jack    O
's    O
private    O
nurse    O
when    O
he    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
and    O
quite    O
ill    O
.    O

According    O
to    O
his    O
official    O
Facebook    O
page    O
,    O
Miller    O
was    O
very    O
sick    O
while    O
working    O
on    O
"    O
Mortuary    O
Massacre    O
"    O
,    O
and    O
in    O
July    O
of    O
2016    O
while    O
finalizing    O
the    O
edits    O
,    O
he    O
was    O
diagnosed    O
with    O
stage    O
3    O
Hodgkin's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
.    O

In    O
May    O
2016    O
,    O
the    O
FDA    O
approved    O
nivolumab    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
classical    B-BloodDyscrasia114053850
Hodgkin    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
cHL    O
)    O
who    O
have    O
relapsed    O
or    O
progressed    O
after    O
autologous    O
hematopoietic    O
stem    O
cell    O
transplantation    O
(    O
auto    O
-    O
HSCT    O
)    O
and    O
post    O
-    O
transplantation    O
brentuximab    O
vedotin    O
.    O

In    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
Reed    O
-    O
Sternberg    O
cells    O
harbor    O
amplification    O
of    O
chromosome    O
9p24.1    O
,    O
which    O
encodes    O
PD    O
-    O
L1    O
and    O
PD    O
-    O
L2    O
and    O
leads    O
to    O
their    O
constitutive    O
expression    O
.    O

Hutchins    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
late    O
2012    O
,    O
which    O
was    O
treated    O
and    O
went    O
into    O
remission    O
by    O
July    O
2013    O
.    O

In    O
early    O
2013    O
Hutchins    O
announced    O
that    O
he    O
had    O
been    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Ross    O
Hutchins    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
December    O
2012    O
,    O
and    O
took    O
an    O
indefinite    O
break    O
from    O
tennis    O
while    O
he    O
recovered    O
.    O

She    O
is    O
well    O
known    O
as    O
a    O
survivor    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

While    O
in    O
college    O
,    O
Padilla    O
was    O
diagnosed    O
with    O
Hodgkins    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
and    O
underwent    O
several    O
rounds    O
of    O
chemotherapy    O
and    O
radiation    O
.    O

In    O
2011    O
Scheuer    O
,    O
who    O
was    O
at    O
the    O
time    O
twenty    O
-    O
eight    O
years    O
old    O
,    O
was    O
diagnosed    O
with    O
-    O
and    O
successfully    O
treated    O
for    O
-    O
stage    O
IV    O
Hodgkins    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
.    O

Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Chronic    O
lymphocytic    O
leukemia    O
may    O
transform    O
into    O
Richter    O
's    O
syndrome    O
,    O
the    O
development    O
of    O
fast    O
-    O
growing    O
diffuse    O
large    O
B    O
cell    O
lymphoma    O
,    O
prolymphocytic    O
leukemia    O
,    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
or    O
acute    O
leukemia    O
in    O
some    O
patients    O
.    O

December    O
2    O
–    O
Dinu    O
Lipatti    O
,    O
Romanian    O
pianist    O
and    O
composer    O
(    O
born    O
1917    O
;    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
)    O

Delta    O
Goodrem    O
is    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

Dakhlalla    O
's    O
mother    O
died    O
due    O
to    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
2016    O
.    O

Kasdan    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
when    O
he    O
was    O
a    O
17-year    O
-    O
old    O
junior    O
in    O
high    O
school    O
.    O

Tomography    O
,    O
often    O
assisted    O
by    O
a    O
computer    O
to    O
form    O
a    O
PET    O
/    O
CT    O
(    O
CT    O
stands    O
for    O
"    O
computer    O
tomography    O
"    O
)    O
machine    O
,    O
can    O
then    O
be    O
used    O
to    O
diagnose    O
or    O
monitor    O
treatment    O
of    O
cancers    O
,    O
especially    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
lung    O
cancer    O
,    O
and    O
breast    O
cancer    O
.    O

There    O
are    O
a    O
variety    O
of    O
conditions    O
that    O
cause    O
itching    O
and    O
skin    O
picking    O
including    O
:    O
eczema    O
,    O
psoriasis    O
,    O
diabetes    O
,    O
liver    O
disease    O
,    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
systemic    O
lupus    O
,    O
and    O
Prader    O
-    O
Willi    O
syndrome    O
.    O

He    O
was    O
also    O
involved    O
in    O
such    O
organizations    O
as    O
the    O
Houston    O
Area    O
Federal    O
Business    O
Association    O
,    O
the    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
Memorial    O
Research    O
Center    O
and    O
the    O
Texas    O
and    O
Harris    O
County    O
Young    O
Democrats    O
.    O

During    O
his    O
second    O
stint    O
with    O
the    O
Timberwolves    O
,    O
Saunders    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

On    O
August    O
11    O
,    O
2015    O
,    O
Saunders    O
announced    O
he    O
had    O
been    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
for    O
which    O
he    O
was    O
undergoing    O
treatment    O
;    O
Saunders    O
planned    O
to    O
remain    O
the    O
Timberwolves    O
'    O
head    O
coach    O
and    O
president    O
.    O

Interleukin-21    O
is    O
also    O
produced    O
by    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
HL    O
)    O
cancer    O
cells    O
(    O
which    O
is    O
surprising    O
because    O
IL-21    O
was    O
thought    O
to    O
be    O
produced    O
only    O
in    O
T    O
cells    O
)    O
.    O

McDowell    O
was    O
diagnosed    O
with    O
Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
March    O
and    O
Verzbicas    O
was    O
sure    O
that    O
he    O
would    O
have    O
won    O
the    O
world    O
title    O
in    O
2011    O
.    O

In    O
October    O
2003    O
,    O
Hall    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
;    O
he    O
died    O
on    O
14    O
February    O
2006    O
,    O
at    O
the    O
age    O
of    O
31    O
,    O
from    O
complications    O
resulting    O
from    O
the    O
stem    O
cell    O
transplant    O
he    O
received    O
in    O
January    O
2005    O
.    O

Thomas    O
Hodgkin    O
–    O
discoverer    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

It    O
is    O
important    O
in    O
the    O
treatment    O
of    O
acute    O
lymphoblastic    O
leukemia    O
,    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
multiple    O
myeloma    O
,    O
and    O
other    O
hormone    O
-    O
sensitive    O
tumors    O
,    O
in    O
combination    O
with    O
other    O
anticancer    O
drugs    O
.    O

Steinberg    O
's    O
father    O
died    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
when    O
he    O
was    O
a    O
child    O
.    O

It    O
is    O
also    O
associated    O
with    O
particular    O
forms    O
of    O
cancer    O
,    O
such    O
as    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
gastric    O
cancer    O
,    O
nasopharyngeal    O
carcinoma    O
,    O
and    O
conditions    O
associated    O
with    O
human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
,    O
such    O
as    O
hairy    O
leukoplakia    O
and    O
central    O
nervous    O
system    O
lymphomas    O
.    O

Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
stomach    O
cancer    O
,    O
nasopharyngeal    O
carcinoma    O
,    O
multiple    O
sclerosis    O
,    O
and    O
lymphomatoid    O
granulomatosis    O
.    O

So    O
far    O
,    O
SMAC    O
overexpression    O
has    O
been    O
observed    O
to    O
oppose    O
cancer    O
progression    O
in    O
head    O
and    O
neck    O
squamous    O
cell    O
carcinoma    O
,    O
hepatocellular    O
carcinoma    O
,    O
Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
breast    O
cancer    O
,    O
glioblastoma    O
,    O
thyroid    O
cancer    O
,    O
renal    O
cell    O
carcinoma    O
,    O
testicular    O
germ    O
cell    O
tumors    O
,    O
colorectal    O
cancer    O
,    O
lung    O
cancer    O
,    O
bladder    O
cancer    O
,    O
endometrioid    O
endometrial    O
cancer    O
,    O
and    O
other    O
sarcomas    O
.    O

On    O
January    O
18    O
,    O
2008    O
,    O
Buechlein    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
more    O
commonly    O
known    O
as    O
Hodgkin    O
's    O
disease    O
,    O
having    O
experienced    O
heavy    O
fatigue    O
and    O
a    O
swelling    O
under    O
his    O
right    O
arm    O
and    O
then    O
undergoing    O
medical    O
tests    O
on    O
the    O
previous    O
January    O
13    O
.    O

Teniposide    O
(    O
trade    O
name    O
Vumon    O
)    O
is    O
a    O
chemotherapeutic    O
medication    O
used    O
in    O
the    O
treatment    O
of    O
childhood    O
acute    O
lymphocytic    O
leukemia    O
(    O
ALL    O
)    O
,    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
certain    O
brain    O
tumours    O
,    O
and    O
other    O
types    O
of    O
cancer    O
.    O

In    O
1963    O
,    O
Helmut    O
Schmidt    O
moved    O
the    O
family    O
to    O
Sydney    O
after    O
contracting    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
they    O
found    O
a    O
home    O
in    O
the    O
suburb    O
of    O
West    O
Ryde    O
.    O

Zipnick    O
died    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
in    O
1991    O
just    O
as    O
the    O
company    O
was    O
beginning    O
to    O
take    O
off    O
.    O

Other    O
causes    O
are    O
radiation    O
therapy    O
involving    O
the    O
spleen    O
,    O
such    O
as    O
that    O
used    O
to    O
treat    O
Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Godfrey    O
has    O
a    O
tattoo    O
to    O
symbolize    O
her    O
successful    O
battle    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
which    O
the    O
producers    O
wrote    O
into    O
the    O
show    O
.    O

Stevens    O
died    O
in    O
2011    O
after    O
battling    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Bogdanović    O
was    O
elected    O
to    O
office    O
in    O
2004    O
and    O
served    O
until    O
his    O
death    O
in    O
2007    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

In    O
January    O
2011    O
Anton    O
Buslov    O
was    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

During    O
2015    O
,    O
as    O
Campbell    O
fought    O
his    O
battle    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
and    O
embarked    O
on    O
a    O
100    O
date    O
tour    O
with    O
Def    O
Leppard    O
in    O
support    O
of    O
their    O
2015    O
self    O
-    O
titled    O
effort    O
,    O
Last    O
in    O
Line    O
did    O
not    O
tour    O
,    O
instead    O
they    O
finished    O
the    O
recording    O
of    O
their    O
debut    O
album    O
"    O
Heavy    O
Crown    O
"    O
.    O

Near    O
the    O
end    O
of    O
her    O
life    O
,    O
she    O
retreated    O
to    O
a    O
hermitage    O
in    O
Aegina    O
,    O
but    O
when    O
she    O
developed    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
she    O
returned    O
to    O
Athens    O
.    O

The    O
Ki-67    O
protein    O
was    O
originally    O
defined    O
by    O
the    O
prototype    O
monoclonal    O
antibody    O
Ki-67    O
,    O
which    O
was    O
generated    O
by    O
immunizing    O
mice    O
with    O
nuclei    O
of    O
the    O
Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
cell    O
line    O
L428    O
.    O

Excluded    O
diseases    O
include    O
:    O
Hodgkin’s    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
,    O
chronic    B-BloodDyscrasia114053850
lymphatic    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
malignant    O
melanoma    O
and    O
mesothelioma    O
.    O

He    O
was    O
a    O
collaborator    O
and    O
biographer    O
of    O
the    O
"    O
Three    O
Great    O
"    O
,    O
contemporary    O
physicians    O
who    O
worked    O
at    O
Guy    O
's    O
Hospital    O
,    O
Dr.    O
Thomas    O
Addison    O
,    O
the    O
discoverer    O
of    O
Addison    O
's    O
disease    O
,    O
Dr.    O
Richard    O
Bright    O
,    O
discoverer    O
of    O
Bright    O
's    O
disease    O
and    O
Dr.    O
Thomas    O
Hodgkin    O
,    O
discoverer    O
of    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

He    O
specializes    O
in    O
lymphoma    O
,    O
including    O
Non-Hodgkin's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
,    O
Burkitt's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
and    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

A    O
particular    O
disappointment    O
was    O
the    O
running    O
game    O
,    O
which    O
due    O
to    O
injuries    O
to    O
the    O
offensive    O
line    O
(    O
including    O
tackle    O
Karl    O
Nelson    O
missing    O
the    O
entire    O
season    O
due    O
to    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
)    O
struggled    O
all    O
season    O
.    O

Secondary    O
lymphedema    O
is    O
a    O
condition    O
characterized    O
by    O
swelling    O
of    O
the    O
soft    O
tissues    O
in    O
which    O
an    O
excessive    O
amount    O
of    O
lymph    O
has    O
accumulated    O
,    O
and    O
is    O
caused    O
by    O
certain    O
malignant    O
diseases    O
such    O
as    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
Kaposi    O
sarcoma    O
.    O

Yeo    O
taught    O
himself    O
to    O
paint    O
in    O
his    O
twenties    O
while    O
recovering    O
from    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

Later    O
diagnosed    O
with    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
Pfost    O
was    O
admitted    O
to    O
Johns    O
Hopkins    O
Hospital    O
several    O
times    O
in    O
1965    O
,    O
and    O
died    O
there    O
on    O
August    O
11    O
at    O
age    O
59    O
.    O

22q11.2    O
distal    O
deletion    O
syndrome    O
appears    O
to    O
be    O
a    O
recurrent    O
genomic    O
disorder    O
distinct    O
from    O
DiGeorge    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
DGS    O
;    O
188400    O
)    O
and    O
velocardiofacial    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
VCFS    O
;    O
192430    O
)    O
.    O

22q11.2    B-BloodDyscrasia114053850
deletion    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

"    O
Partial    O
insufficiencies    O
"    O
of    O
T    O
cell    O
function    O
include    O
acquired    O
immune    O
deficiency    O
syndrome    O
(    O
AIDS    O
)    O
,    O
and    O
hereditary    O
conditions    O
such    O
as    O
DiGeorge    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
DGS    O
)    O
,    O
chromosomal    O
breakage    O
syndromes    O
(    O
CBSs    O
)    O
,    O
and    O
B    O
-    O
cell    O
and    O
T    O
-    O
cell    O
combined    O
disorders    O
such    O
as    O
ataxia    O
-    O
telangiectasia    O
(    O
AT    O
)    O
and    O
Wiskott–Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
WAS    O
)    O
.    O

DiGeorge    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
is    O
first    O
described    O
by    O
pediatric    O
endocrinologist    O
Angelo    O
DiGeorge    O
.    O

DiGeorge    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
or    O
velocardiofacial    O
syndrome    O
–    O
most    O
common    O
microdeletion    O
syndrome    O

DiGeorge    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Di    B-BloodDyscrasia114053850
George's    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

A    O
few    O
examples    O
of    O
loci    O
that    O
have    O
been    O
studied    O
are    O
the    O
17q21    O
region    O
,    O
the    O
3p24    O
-    O
26    O
locus    O
,    O
PTEN    O
,    O
15q11.2–q13    O
and    O
deletion    O
in    O
the    O
22q11.2    B-BloodDyscrasia114053850
area    O
.    O

However    O
,    O
increased    O
nuchal    O
translucency    O
measurements    O
are    O
also    O
associated    O
with    O
non    O
-    O
chromosomal    O
abnormalities    O
such    O
as    O
genetic    O
conditions    O
(    O
e.g.    O
Di    B-BloodDyscrasia114053850
George    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
)    O
and    O
non    O
-    O
genetic    O
ones    O
(    O
e.g.    O
Body    O
-    O
stalk    O
anomaly    O
)    O
.    O

The    O
gene    O
coding    O
for    O
C22orf25    O
is    O
located    O
on    O
chromosome    O
22    O
and    O
the    O
location    O
q11.21    O
,    O
so    O
it    O
is    O
often    O
associated    O
with    O
22q11.2    B-BloodDyscrasia114053850
deletion    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

There    O
is    O
a    O
1.5    O
-    O
3.0    O
Mb    O
deletion    O
containing    O
around    O
30    O
-    O
40    O
genes    O
,    O
spanning    O
this    O
region    O
that    O
causes    O
the    O
most    O
survivable    O
genetic    O
deletion    O
disorder    O
known    O
as    O
22q11.2    B-BloodDyscrasia114053850
deletion    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
which    O
is    O
most    O
commonly    O
known    O
as    O
DiGeorge    O
syndrome    O
or    O
Velocaridofacial    O
syndrome    O
.    O

Thymic    O
hypoplasia    O
as    O
may    O
be    O
seen    O
in    O
DiGeorge    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
results    O
in    O
no    O
T    O
-    O
cell    O
education    O
,    O
and    O
therefore    O
a    O
severe    O
compromise    O
in    O
T    O
-    O
cell    O
-    O
mediated    O
and    O
humoral    O
responses    O
.    O

Caused    O
by    O
glycoprotein    O
abnormalities    O
:    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
Velocardiofacial    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Primary    O
fibrinogenolysis    B-BloodDyscrasia114053850
is    O
a    O
medical    O
condition    O
that    O
appears    O
with    O
abnormal    O
production    O
of    O
fibrinogen    O
/    O
fibrin    O
degradation    O
products    O
(    O
FDP    O
)    O
,    O
degradation    O
of    O
coagulation    O
factors    O
V    O
,    O
VIII    O
,    O
IX    O
,    O
XI    O
and/or    O
degradation    O
of    O
the    O
fibrin    O
present    O
in    O
any    O
pre    O
-    O
existing    O
localized    O
thrombi    O
and    O
hemostatic    O
clots    O
.    O

Hematidrosis    B-BloodDyscrasia114053850

Hematidrosis    B-BloodDyscrasia114053850
–    O
blood    O
in    O
sweat    O

On    O
August    O
11    O
,    O
2015    O
,    O
morning    O
host    O
Scott    O
McKenzie    O
died    O
at    O
the    O
age    O
of    O
59    O
after    O
suffering    O
from    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
for    O
seven    O
years    O
.    O

Specialized    O
Program    O
of    O
Research    O
Excellence    O
(    O
SPORE    O
)    O
grant    O
for    O
translational    O
research    O
studies    O
for    O
Hodgkin    B-BloodDyscrasia114053850
and    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
-    O
Five    O
-    O
year    O
,    O
$    O
11.5    O
million    O
.    O

Upregulated    O
expression    O
of    O
"    O
Bcl-2    O
"    O
in    O
leukemic    O
cells    O
(    O
non-Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
)    O
resulted    O
in    O
decreased    O
levels    O
of    O
apoptosis    O
in    O
response    O
to    O
chemotherapeutic    O
agents    O
,    O
as    O
"    O
Bcl-2    O
"    O
is    O
a    O
pro    O
-    O
survival    O
oncogene    O
.    O

The    O
most    O
common    O
tumors    O
associated    O
with    O
this    O
syndrome    O
are    O
poorly    O
differentiated    O
lymphomas    O
(    O
such    O
as    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
)    O
,    O
other    O
Non-Hodgkin    B-BloodDyscrasia114053850
Lymphomas    I-BloodDyscrasia114053850
(    O
NHL    O
)    O
,    O
acute    O
lymphoblastic    O
leukemia    O
(    O
ALL    O
)    O
,    O
acute    O
myeloid    O
leukemia    O
(    O
AML    O
)    O
,    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
and    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CML    O
)    O
.    O

In    O
2017    O
,    O
Kennedy    O
and    O
his    O
partners    O
sued    O
Monsanto    O
in    O
federal    O
court    O
in    O
San    O
Francisco    O
,    O
on    O
behalf    O
of    O
plaintiffs    O
seeking    O
to    O
recover    O
damages    O
for    O
non-Hodgkins    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
that    O
,    O
the    O
plaintiffs    O
allege    O
,    O
were    O
a    O
result    O
of    O
exposure    O
to    O
Monsanto    O
's    O
glyphosate    O
-    O
based    O
herbicide    O
,    O
Roundup    O
.    O

Ćosić    O
died    O
in    O
Baltimore    O
,    O
Maryland    O
in    O
1995    O
of    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

McAndrew    O
's    O
father    O
,    O
Ted    O
,    O
was    O
diagnosed    O
with    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
2003    O
;    O
,    O
he    O
is    O
in    O
remission    O
.    O

He    O
played    O
in    O
Australia    O
's    O
1987    O
World    O
Cup    O
Final    O
victory    O
and    O
was    O
a    O
significant    O
wicket    O
-    O
taker    O
and    O
finished    O
the    O
World    O
cup    O
as    O
Australia    O
's    O
most    O
economical    O
bowler    O
,    O
but    O
soon    O
after    O
he    O
suffered    O
severe    O
pain    O
that    O
was    O
diagnosed    O
as    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

The    O
disease    O
,    O
however    O
,    O
is    O
not    O
a    O
fungal    O
infection    O
but    O
rather    O
a    O
type    O
of    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Her    O
first    O
husband    O
,    O
Joe    O
Shapiro    O
,    O
a    O
former    O
Walt    O
Disney    O
Company    O
lawyer    O
,    O
died    O
of    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
1999    O
.    O

HIV    O
disease    O
resulting    O
in    O
other    O
types    O
of    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

He    O
died    O
of    O
complications    O
from    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
at    O
St.    O
Lukes    O
-    O
Roosevelt    O
Hospital    O
in    O
2005    O
,    O
aged    O
75    O
.    O
[    O
6    O
]    O

In    O
October    O
2009    O
,    O
Daugherty    O
was    O
diagnosed    O
with    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
of    O
which    O
he    O
died    O
at    O
the    O
M.D.    O
Anderson    O
Cancer    O
Center    O
in    O
Houston    O
,    O
Texas    O
,    O
aged    O
57    O
on    O
November    O
22    O
,    O
2009    O
.    O

Lemieux    O
endured    O
22    O
radiation    O
treatments    O
in    O
30    O
days    O
to    O
treat    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Dacetuzumab    O
(    O
also    O
known    O
as    O
SGN-40    O
or    O
huS2C6    O
)    O
is    O
a    O
humanized    O
monoclonal    O
antibody    O
being    O
developed    O
for    O
the    O
treatment    O
of    O
CD40-positive    O
cancers    O
like    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
and    O
hematological    O
malignancies    O
.    O

Morris    O
died    O
of    O
Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
at    O
the    O
age    O
of    O
27    O
in    O
1979    O
.    O

In    O
2007    O
,    O
after    O
medical    O
treatment    O
of    O
an    O
ingrown    O
toe    O
nail    O
,    O
Sparkman    O
's    O
doctor    O
identified    O
a    O
cyst    O
which    O
led    O
to    O
his    O
diagnosis    O
of    O
Stage-3    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
cancer    O
.    O

According    O
to    O
reports    O
,    O
Sparkman    O
,    O
who    O
had    O
previously    O
battled    O
non-Hodgkins    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
was    O
suspected    O
to    O
have    O
believed    O
his    O
cancer    O
had    O
returned    O
,    O
and    O
just    O
prior    O
to    O
his    O
death    O
had    O
taken    O
out    O
life    O
insurance    O
policies    O
totalling    O
$    O
600,000    O
which    O
would    O
have    O
been    O
paid    O
to    O
his    O
financially    O
struggling    O
son    O
in    O
the    O
event    O
of    O
death    O
and    O
which    O
would    O
not    O
pay    O
out    O
for    O
suicide    O
or    O
death    O
from    O
cancer    O
.    O

Jay    O
was    O
diagnosed    O
with    O
Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
at    O
19    O
years    O
old    O
,    O
a    O
challenge    O
to    O
which    O
he    O
attributes    O
his    O
strategy    O
of    O
"    O
keeping    O
a    O
positive    O
mindset    O
and    O
always    O
pushing    O
forward    O
.    O
"    O

In    O
a    O
September    O
2010    O
visit    O
with    O
Falls    O
Church    O
,    O
Virginia    O
,    O
residents    O
,    O
Obama    O
referred    O
to    O
a    O
woman    O
with    O
an    O
eye    O
condition    O
and    O
a    O
woman    O
with    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
as    O
personal    O
examples    O
in    O
the    O
audience    O
of    O
those    O
benefiting    O
from    O
changing    O
pre    O
-    O
existing    O
condition    O
rules    O
.    O

Antall    O
became    O
ill    O
and    O
diagnosed    O
with    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
the    O
summer    O
of    O
1990    O
.    O

Most    O
noble    O
of    O
its    O
contributions    O
is    O
an    O
enzyme    O
,    O
asparaginase    O
,    O
is    O
being    O
used    O
in    O
conjunction    O
with    O
other    O
chemotherapeutic    O
agents    O
for    O
treatment    O
of    O
acute    O
lymphoblastic    O
leukemia    O
(    O
ALL    O
)    O
and    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
patients    O
who    O
have    O
had    O
allergic    O
reactions    O
to    O
"    O
E.    O
coli    O
"    O
derived    O
asparaginase    O
Elspar    O
or    O
pegaspargase    O
(    O
Oncaspar    O
)    O
.    O

He    O
was    O
diagnosed    O
with    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

After    O
being    O
diagnosed    O
with    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
2009    O
,    O
he    O
stepped    O
down    O
as    O
CEO    O
of    O
the    O
investment    O
bank    O
,    O
but    O
was    O
appointed    O
chairman    O
ten    O
months    O
later    O
.    O

Calello    O
died    O
at    O
the    O
age    O
of    O
49    O
on    O
November    O
16    O
,    O
2010    O
,    O
at    O
his    O
home    O
in    O
Brooklyn    O
due    O
to    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

On    O
February    O
19    O
,    O
2010    O
,    O
his    O
office    O
announced    O
that    O
Lautenberg    O
had    O
been    O
diagnosed    O
with    O
a    O
diffuse    O
large    O
b-cell    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
an    O
aggressive    O
but    O
curable    O
blood    O
cancer    O
that    O
appears    O
in    O
organs    O
like    O
the    O
stomach    O
)    O
at    O
Mount    O
Sinai    O
Medical    O
Center    O
in    O
New    O
York    O
.    O

Non-hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

Silagy    O
died    O
at    O
the    O
age    O
of    O
41    O
of    O
Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
leaving    O
his    O
wife    O
–    O

On    O
August    O
3    O
,    O
2014    O
,    O
Yu    O
-    O
Jose    O
died    O
after    O
a    O
six    O
-    O
year    O
-    O
long    O
battle    O
with    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Henson    O
continued    O
to    O
coach    O
the    O
Aggies    O
until    O
being    O
sidelined    O
by    O
Non-Hodgkin    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
prior    O
to    O
the    O
2004–05    O
season    O
.    O

The    O
first    O
international    O
Symposium    O
on    O
Childhood    O
and    O
Adolescent    O
Non-Hodgkin’s    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
was    O
held    O
in    O
New    O
York    O
,    O
and    O
was    O
sponsored    O
by    O
Columbia    O
University    O
and    O
Justus    O
-    O
Liebig    O
-    O
University    O
Giessen    O
.    O

The    O
lack    O
of    O
the    O
normal    O
distribution    O
of    O
these    O
B    O
cells    O
is    O
one    O
basis    O
for    O
demonstrating    O
clonality    O
,    O
the    O
key    O
element    O
for    O
establishing    O
a    O
diagnosis    O
of    O
any    O
B    O
cell    O
malignancy    O
(    O
B    O
cell    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
)    O
.    O

He    O
was    O
diagnosed    O
with    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
2009    O
.    O

While    O
helping    O
Donnie    O
train    O
,    O
Rocky    O
learns    O
he    O
has    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Benjie    O
visits    O
a    O
child    O
suffering    O
from    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
the    O
hospital    O
;    O
however    O
,    O
the    O
girl    O
later    O
dies    O
.    O

Studies    O
carried    O
out    O
by    O
the    O
Committee    O
on    O
Medical    O
Aspects    O
of    O
Radiation    O
in    O
the    O
Environment    O
(    O
COMARE    O
)    O
in    O
2003    O
reported    O
no    O
evidence    O
of    O
raised    O
childhood    O
cancer    O
in    O
general    O
around    O
nuclear    O
power    O
plants    O
,    O
but    O
did    O
report    O
an    O
excess    O
of    O
leukaemia    O
(    O
cancer    O
of    O
the    O
blood    O
or    O
bone    O
)    O
and    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
NHL    O
)    O
(    O
blood    O
cancer    O
)    O
near    O
two    O
other    O
nuclear    O
installations    O
including    O
Sellafield    O
,    O
the    O
Atomic    O
Weapons    O
Establishment    O
Burghfield    O
and    O
UKAEA    O
Dounreay    O
.    O

Near    O
the    O
end    O
of    O
his    O
Navy    O
career    O
he    O
was    O
diagnosed    O
with    O
Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
a    O
disease    O
he    O
was    O
able    O
to    O
survive    O
.    O

Mantle    O
cell    O
lymphoma    O
(    O
MCL    O
)    O
is    O
a    O
type    O
of    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
NHL    O
)    O
,    O
comprising    O
about    O
6%    O
of    O
NHL    O
cases    O
.    O

6%    O
of    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
cases    O
are    O
mantle    O
cell    O
lymphoma    O
.    O

In    O
some    O
cases    O
it    O
will    O
progress    O
to    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
and    O
may    O
be    O
fatal    O
.    O

It    O
is    O
important    O
in    O
the    O
treatment    O
of    O
acute    O
lymphoblastic    O
leukemia    O
,    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
multiple    O
myeloma    O
,    O
and    O
other    O
hormone    O
-    O
sensitive    O
tumors    O
,    O
in    O
combination    O
with    O
other    O
anticancer    O
drugs    O
.    O

PTCL    O
is    O
a    O
type    O
of    O
non-Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
NHL    O
)    O
.    O

Alemtuzumab    O
is    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
CTCL    O
)    O
and    O
T-cell    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
under    O
the    O
trade    O
names    O
Campath    O
,    O
MabCampath    O
and    O
Campath-1H    O
,    O
and    O
in    O
the    O
treatment    O
of    O
multiple    O
sclerosis    O
as    O
Lemtrada    O
.    O

A    O
2-time    O
cancer    O
survivor    O
,    O
Kalemis    O
was    O
diagnosed    O
with    O
Non-Hodgkin’s    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
in    O
1998    O
and    O
with    O
Chronic    B-BloodDyscrasia114053850
Myloed    I-BloodDyscrasia114053850
Leukemia    I-BloodDyscrasia114053850
in    O
2005    O
.    O

Kalemis    O
sold    O
Kaleo    O
Publications    O
to    O
a    O
partner    O
in    O
1998    O
when    O
he    O
was    O
diagnosed    O
with    O
Non-Hodgkin’s    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
at    O
age    O
24    O
.    O

The    O
drug    O
is    O
also    O
being    O
studied    O
for    O
treatment    O
of    O
B    O
-    O
cell    O
malignancies    O
,    O
including    O
multiple    O
myeloma    O
,    O
B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
and    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Justice    O
Konda    O
Madhava    O
Reddy    O
died    O
on    O
25    O
September    O
1997    O
,    O
after    O
suffering    O
from    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

In    O
an    O
interview    O
,    O
Chris    O
Geiger    O
stated    O
he    O
was    O
diagnosed    O
with    O
Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

In    O
an    O
interview    O
,    O
Chris    O
Geiger    O
stated    O
he    O
was    O
diagnosed    O
with    O
Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Morroni    O
was    O
treated    O
for    O
Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
in    O
2008    O
,    O
and    O
a    O
recurrence    O
in    O
2011    O
.    O

As    O
of    O
2016    O
venetoclax    O
had    O
been    O
tested    O
to    O
treat    O
other    O
hematological    O
cancers    O
,    O
including    O
non-Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
multiple    O
myeloma    O
,    O
diffuse    O
large    O
B    O
-    O
cell    O
lymphoma    O
and    O
follicular    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Targeted    O
monoclonal    O
antibody    O
therapy    O
is    O
employed    O
to    O
treat    O
diseases    O
such    O
as    O
rheumatoid    O
arthritis    O
,    O
multiple    O
sclerosis    O
,    O
psoriasis    O
,    O
and    O
many    O
forms    O
of    O
cancer    O
including    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
colorectal    O
cancer    O
,    O
head    O
and    O
neck    O
cancer    O
and    O
breast    O
cancer    O
.    O

He    O
specializes    O
in    O
lymphoma    O
,    O
including    O
Non-Hodgkin's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
,    O
Burkitt's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
and    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

In    O
2006    O
,    O
the    O
68-year    O
-    O
old    O
Nagurski    O
was    O
diagnosed    O
with    O
non-Hodgkin’s    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
awareness    O

Chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850

The    O
most    O
common    O
tumors    O
associated    O
with    O
this    O
syndrome    O
are    O
poorly    O
differentiated    O
lymphomas    O
(    O
such    O
as    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
)    O
,    O
other    O
Non-Hodgkin    B-BloodDyscrasia114053850
Lymphomas    I-BloodDyscrasia114053850
(    O
NHL    O
)    O
,    O
acute    O
lymphoblastic    O
leukemia    O
(    O
ALL    O
)    O
,    O
acute    O
myeloid    O
leukemia    O
(    O
AML    O
)    O
,    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
and    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CML    O
)    O
.    O

Liquori    O
was    O
diagnosed    O
with    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
which    O
is    O
now    O
in    O
remission    O
.    O

In    O
1980    O
he    O
was    O
diagnosed    O
with    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
.    O

MicroRNA-223    O
is    O
commonly    O
repressed    O
in    O
hepatocellular    O
carcinoma    O
,    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
acute    O
lymphoblastic    O
leukemia    O
,    O
acute    O
myeloid    O
leukemia    O
,    O
gastric    B-BloodDyscrasia114053850
MALT    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
and    O
recurrent    O
ovarian    O
cancer    O
.    O

Chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850

Mutations    O
of    O
"    O
BRCA2    O
"    O
are    O
also    O
found    O
in    O
many    O
T    O
-    O
cell    O
lymphomas    O
and    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
B-CLL    B-BloodDyscrasia114053850
)    O
,    O
also    O
known    O
as    O
chronic    B-BloodDyscrasia114053850
lymphoid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    B-BloodDyscrasia114053850
)    O
,    O
is    O
the    O
most    O
common    O
type    O
of    O
leukemia    O
(    O
a    O
type    O
of    O
cancer    O
of    O
the    O
white    O
blood    O
cells    O
)    O
in    O
adults    O
.    O

It    O
tends    O
to    O
be    O
negative    O
in    O
acute    O
myeloid    O
leukemia    O
,    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
mantle    O
cell    O
lymphoma    O
,    O
and    O
marginal    O
zone    O
lymphoma    O
.    O

In    O
1990    O
,    O
Benn    O
was    O
diagnosed    O
with    O
chronic    B-BloodDyscrasia114053850
lymphatic    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
and    O
given    O
three    O
or    O
four    O
years    O
to    O
live    O
;    O
at    O
this    O
time    O
,    O
he    O
kept    O
the    O
news    O
of    O
his    O
leukaemia    O
from    O
everyone    O
except    O
his    O
immediate    O
family    O
.    O

Monoclonal    O
B    O
-    O
cell    O
lymphocytosis    O
,    O
a    O
condition    O
that    O
resembles    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O

Other    O
products    O
in    O
development    O
are    O
Tolevamer    O
for    O
Clostridium    O
difficile    O
colitis    O
and    O
Campath    O
for    O
Chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

ZAP-70    O
in    O
B    O
cells    O
is    O
used    O
as    O
a    O
prognostic    O
marker    O
in    O
identifying    O
different    O
forms    O
of    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
.    O

Oblimersen    O
(    O
INN    O
,    O
trade    O
name    O
Genasense    O
;    O
also    O
known    O
as    O
Augmerosen    O
and    O
bcl-2    O
antisense    O
oligodeoxynucleotide    O
G3139    O
)    O
is    O
an    O
antisense    O
oligodeoxyribonucleotide    O
being    O
studied    O
as    O
a    O
possible    O
treatment    O
for    O
several    O
types    O
of    O
cancer    O
,    O
including    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
B    O
-    O
cell    O
lymphoma    O
,    O
and    O
breast    O
cancer    O
.    O

Germ    O
-    O
line    O
mutations    O
in    O
miR-16    O
-    O
1    O
and    O
miR-15    O
primary    O
precursors    O
have    O
been    O
shown    O
to    O
be    O
much    O
more    O
frequent    O
in    O
patients    O
with    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
compared    O
to    O
control    O
populations    O
.    O

Cladribine    O
is    O
a    O
medication    O
used    O
to    O
treat    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
HCL    O
,    O
leukemic    O
reticuloendotheliosis    O
)    O
and    O
B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

Cladribine    O
is    O
used    O
for    O
as    O
a    O
first    O
and    O
second    O
-    O
line    O
treatment    O
for    O
symptomatic    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
and    O
for    O
B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
and    O
is    O
administered    O
by    O
intravenous    O
infusion    O
.    O

Lymphomas    O
arising    O
from    O
the    O
mantle    O
zone    O
are    O
generally    O
negative    O
for    O
CD23    O
,    O
but    O
most    O
B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphomocytic    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
and    O
low    O
-    O
grade    O
B    O
-    O
cell    O
lymphomas    O
are    O
positive    O
,    O
allowing    O
immunohistochemistry    O
to    O
distinguish    O
these    O
conditions    O
,    O
which    O
otherwise    O
have    O
a    O
similar    O
appearance    O
.    O

Alemtuzumab    O
is    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
CTCL    O
)    O
and    O
T-cell    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
under    O
the    O
trade    O
names    O
Campath    O
,    O
MabCampath    O
and    O
Campath-1H    O
,    O
and    O
in    O
the    O
treatment    O
of    O
multiple    O
sclerosis    O
as    O
Lemtrada    O
.    O

The    O
drug    O
is    O
also    O
being    O
studied    O
for    O
treatment    O
of    O
B    O
-    O
cell    O
malignancies    O
,    O
including    O
multiple    O
myeloma    O
,    O
B-cell    B-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
and    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Venetoclax    O
(    O
INN    O
,    O
trade    O
name    O
Venclexta    O
in    O
the    O
US    O
and    O
Venclyxto    O
in    O
Europe    O
)    O
is    O
a    O
small    O
molecule    O
oral    O
drug    O
that    O
treats    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
in    O
those    O
with    O
a    O
specific    O
chromosomal    O
abnormality    O
.    O

Venetoclax    O
is    O
used    O
a    O
second    O
line    O
treatment    O
for    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
only    O
if    O
there    O
is    O
a    O
17p    O
deletion    O
as    O
determined    O
by    O
an    O
approved    O
test    O
.    O

Competition    O
is    O
expected    O
from    O
other    O
drugs    O
such    O
as    O
Imbruvica    O
(    O
ibrutinib    O
)    O
and    O
Zydelig    O
(    O
idelalisib    O
)    O
,    O
both    O
of    O
which    O
were    O
also    O
approved    O
in    O
2014    O
to    O
treat    O
CLL    O
(    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
)    O
.    O

Excluded    O
diseases    O
include    O
:    O
Hodgkin’s    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
,    O
chronic    B-BloodDyscrasia114053850
lymphatic    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
malignant    O
melanoma    O
and    O
mesothelioma    O
.    O

Specifically    O
,    O
one    O
patient    O
with    O
BENTA    O
disease    O
was    O
reported    O
as    O
having    O
developed    O
B    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
B    O
-    O
CLL    O
)    O
as    O
an    O
adult    O
.    O

Selective    O
vitamin    O
B12    O
malabsorption    O
(    O
congenital    O
—    O
juvenile    B-BloodDyscrasia114053850
megaloblastic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
1    I-BloodDyscrasia114053850
drug    O
-    O
induced    O
)    O

Anaemia    B-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
prematurity    I-BloodDyscrasia114053850

Neonatal    B-BloodDyscrasia114053850
alloimmune    I-BloodDyscrasia114053850
thrombocytopenia    I-BloodDyscrasia114053850

It    O
is    O
possible    O
for    O
a    O
newborn    O
with    O
this    O
disease    O
to    O
have    O
neutropenia    O
and    O
neonatal    B-BloodDyscrasia114053850
alloimmune    I-BloodDyscrasia114053850
thrombocytopenia    I-BloodDyscrasia114053850
as    O
well    O
.    O

Type    O
2    O
is    O
characterised    O
by    O
immune    O
-    O
complex    O
-    O
mediated    O
damage    O
,    O
and    O
may    O
be    O
associated    O
with    O
systemic    O
lupus    O
erythematosus    O
,    O
post    O
-    O
infective    O
glomerulonephritis    O
,    O
IgA    O
nephropathy    O
,    O
and    O
IgA    B-BloodDyscrasia114053850
vasculitis    I-BloodDyscrasia114053850
.    O

Henoch–Schönlein    B-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850

IgA    B-BloodDyscrasia114053850
vasculitis    I-BloodDyscrasia114053850
(    O
IgAV    O
;    O
formerly    O
known    O
as    O
Henoch    O
-    O
Schönlein    O
purpura    O
)    O
–    O
Affects    O
small    O
-    O
sized    O
vessels    O
and    O
produces    O
palpable    O
purpura    O
and    O
proteinuria    O
from    O
immunocomplex    O
(    O
IgA    O
)    O
deposition    O
.    O

:*    O
IgA    B-BloodDyscrasia114053850
vasculitis    I-BloodDyscrasia114053850
(    O
Henoch    O
-    O
Schönlein    O
purpura    O
)    O

Henoch–Schönlein    B-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850

Wiskott-Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Dr.    O
Ochs    O
'    O
research    O
focuses    O
on    O
the    O
molecular    O
basis    O
of    O
Primary    O
immunodeficiency    O
diseases    O
with    O
special    O
interest    O
in    O
the    O
genes    O
that    O
have    O
been    O
linked    O
to    O
the    O
Wiskott-Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
Hyper    O
IgM    O
syndrome    O
,    O
X-linked    B-BloodDyscrasia114053850
agammaglobulinemia    I-BloodDyscrasia114053850
,    O
IPEX    O
syndrome    O
and    O
autosomal    O
dominante    O
Hyper    B-BloodDyscrasia114053850
IgE    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

He    O
initiated    O
and    O
maintained    O
a    O
successful    O
cooperation    O
with    O
the    O
bone    O
marrow    O
transplant    O
unit    O
of    O
the    O
Fred    O
Hutchinson    O
Cancer    O
Research    O
Center    O
since    O
the    O
early    O
70s    O
and    O
participated    O
in    O
the    O
design    O
of    O
protocols    O
related    O
to    O
stem    O
cell    O
transplantation    O
for    O
patients    O
with    O
SCID    O
,    O
Wiskott-Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
Chronic    O
Granulomatous    O
Disease    O
,    O
and    O
X    O
-    O
linked    O
hyper    O
-    O
immunoglobulin    O
M    O
syndrome    O
.    O

Inherited    O
immune    O
deficiency    O
-    O
severe    O
combined    O
immunodeficiency    O
,    O
common    B-BloodDyscrasia114053850
variable    I-BloodDyscrasia114053850
immune    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
ataxia    O
-    O
telangiectasia    O
,    O
Wiskott-Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
immunodeficiency    O
with    O
short    O
-    O
limbed    O
dwarfism    O
,    O
immunodeficiency    O
with    O
thymoma    O
,    O
purine    O
nucleoside    O
phosphorylase    O
deficiency    O
,    O
genetic    O
polymorphism    O

Wiskott–Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Wiskott–Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

However    O
,    O
some    O
mutations    O
are    O
seen    O
with    O
one    O
notable    O
example    O
being    O
Pyruvate    B-BloodDyscrasia114053850
kinase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
leading    O
to    O
chronic    O
hemolytic    O
anemia    O
.    O

pyruvate    B-BloodDyscrasia114053850
kinase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

The    O
diagnosis    O
of    O
infantile    O
pyknocytosis    O
is    O
essentially    O
based    O
on    O
the    O
peripheral    O
blood    O
smear    O
,    O
with    O
additional    O
diagnostic    O
investigations    O
to    O
rule    O
out    O
similarly    O
presenting    O
conditions    O
such    O
as    O
glucose-6-phosphate    B-BloodDyscrasia114053850
dehydrogenase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
and    O
pyruvate    B-BloodDyscrasia114053850
kinase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

Panmyelophthisis    B-BloodDyscrasia114053850

Autopsy    O
revealed    O
fatal    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
which    O
was    O
blamed    O
on    O
stress    O
(    O
after    O
the    O
accident    O
other    O
zoos    O
confirmed    O
that    O
blacktip    O
sharks    O
are    O
,    O
indeed    O
,    O
prone    O
to    O
stress    O
injury    O
)    O
.    O

Following    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
,    O
he    O
died    O
on    O
10    O
March    O
2012    O
.    O

Tan    O
,    O
who    O
had    O
suffered    O
from    O
Parkinson    O
's    O
disease    O
for    O
the    O
last    O
15    O
years    O
of    O
his    O
life    O
,    O
collapsed    O
suddenly    O
from    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
and    O
died    O
on    O
10    O
March    O
2012    O
,    O
aged    O
83    O
.    O

There    O
were    O
slight    O
traces    O
of    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
in    O
the    O
muscle    O
,    O
indicating    O
that    O
the    O
man    O
may    O
have    O
been    O
cut    O
while    O
still    O
alive    O
.    O

In    O
late    O
December    O
2010/early    O
January    O
2011    O
,    O
Olivia    O
,    O
who    O
was    O
filling    O
in    O
for    O
Carly    O
,    O
is    O
among    O
those    O
caught    O
in    O
the    O
ski    O
resort    O
bus    O
crash    O
and    O
is    O
one    O
of    O
those    O
who    O
takes    O
the    O
worst    O
of    O
it    O
,    O
suffering    O
from    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
.    O

At    O
this    O
time    O
,    O
some    O
people    O
begin    O
to    O
bleed    O
both    O
internally    B-BloodDyscrasia114053850
and    O
externally    O
.    O

Five    O
hours    O
later    O
she    O
died    O
,    O
presumably    O
from    O
concealed    O
inner    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
.    O

In    O
December    O
2002    O
,    O
Raduyev    O
died    O
in    O
the    O
White    O
Swan    O
penal    O
colony    O
in    O
Solikamsk    O
from    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
.    O

Malaise    O
is    O
a    O
non    O
-    O
specific    O
symptom    O
and    O
can    O
present    O
in    O
the    O
slightest    O
ailment    O
,    O
such    O
as    O
an    O
emotion    O
(    O
causing    O
fainting    O
,    O
a    O
vasovagal    O
response    O
)    O
or    O
hunger    O
(    O
light    O
hypoglycemia    O
)    O
,    O
to    O
the    O
most    O
serious    O
conditions    O
(    O
cancer    O
,    O
stroke    O
,    O
heart    O
attack    O
,    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
,    O
etc    O
.    O
)    O
.    O

Kathy    O
begins    O
vomiting    O
up    O
blood    O
and    O
realizes    O
she    O
has    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
that    O
will    O
likely    O
kill    O
her    O
soon    O
.    O

He    O
crashed    O
into    O
a    O
telephone    O
booth    O
and    O
appeared    O
to    O
have    O
minor    O
injuries    O
but    O
his    O
haemophilia    O
led    O
to    O
fatal    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
.    O

internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
caused    O
by    O
a    O
fractured    O
pelvis    O
and    O
an    O
ruptured    B-BloodDyscrasia114053850
spleen    I-BloodDyscrasia114053850
.    O

Mutations    O
in    O
the    O
"    O
RPS10    O
"    O
gene    O
can    O
cause    O
Diamond-Blackfan    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
a    O
congenital    O
anemia    B-BloodDyscrasia114053850
sometimes    O
associated    O
with    O
bone    B-BloodDyscrasia114053850
marrow    I-BloodDyscrasia114053850
failure    I-BloodDyscrasia114053850
.    O

Blackfan-Diamond    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Diamond–Blackfan    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
(    O
DBA    O
)    O
,    O
also    O
known    O
as    O
Blackfan-Diamond    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
inherited    B-BloodDyscrasia114053850
pure    I-BloodDyscrasia114053850
red    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
aplasia    I-BloodDyscrasia114053850
and    O
as    O
inherited    B-BloodDyscrasia114053850
erythroblastopenia    I-BloodDyscrasia114053850
,    O
is    O
a    O
congenital    O
erythroid    O
aplasia    O
that    O
usually    O
presents    O
in    O
infancy    O
.    O

Castleman    O
disease    O
is    O
seen    O
in    O
POEMS    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
is    O
implicated    O
in    O
10%    O
of    O
cases    O
of    O
paraneoplastic    O
pemphigus    O
.    O

According    O
to    O
a    O
WPVI    O
special    O
report    O
from    O
November    O
,    O
2005    O
,    O
Lisa    O
finally    O
ended    O
up    O
at    O
the    O
Mayo    O
Clinic    O
in    O
Minnesota    O
,    O
where    O
she    O
got    O
the    O
right    O
diagnosis    O
:    O
she    O
was    O
suffering    O
from    O
a    O
syndrome    O
called    O
POEMS    B-BloodDyscrasia114053850
Syndrome    I-BloodDyscrasia114053850
,    O
which    O
can    O
cause    O
nerve    O
damage    O
,    O
organ    O
enlargement    O
,    O
hormonal    O
imbalances    O
,    O
and    O
skin    O
changes    O
.    O

Deficiency    O
of    O
factor    O
IX    O
causes    O
Christmas    O
disease    O
(    O
hemophilia    B-BloodDyscrasia114053850
B    I-BloodDyscrasia114053850
)    O
.    O

Christmas    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Haemophilia    B-BloodDyscrasia114053850
B    I-BloodDyscrasia114053850

However    O
,    O
as    O
Michael    O
suffered    O
from    O
Christmas    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
a    O
form    O
of    O
haemophilia    O
,    O
he    O
had    O
to    O
be    O
educated    O
at    O
home    O
.    O

He    O
was    O
one    O
of    O
the    O
two    O
people    O
in    O
1951    O
establishing    O
that    O
Haemophilia    O
split    O
into    O
two    O
groups    O
:    O
isolating    O
what    O
is    O
now    O
commonly    O
called    O
Haemophilia    B-BloodDyscrasia114053850
B    I-BloodDyscrasia114053850
,    O
then    O
known    O
as    O
Christmas    O
disease    O
after    O
its    O
first    O
known    O
host    O
,    O
Stephen    O
Christmas    O
.    O

After    O
this    O
period    O
he    O
worked    O
in    O
the    O
Blood    O
Coagulation    O
Research    O
Unit    O
in    O
Oxford    O
with    O
Robert    O
Gwyn    O
Macfarlane    O
.    O
Jointly    O
they    O
isolated    O
and    O
identified    O
the    O
condition    O
now    O
known    O
as    O
Haemophilia    B-BloodDyscrasia114053850
B    I-BloodDyscrasia114053850
,    O
but    O
then    O
known    O
as    O
Christmas    O
Disease    O
after    O
its    O
first    O
identified    O
sufferer    O
,    O
Stephen    O
Christmas    O
.    O

Hirszfeld    O
was    O
the    O
first    O
to    O
foresee    O
the    O
serological    B-BloodDyscrasia114053850
conflict    I-BloodDyscrasia114053850
between    O
mother    O
and    O
child    O
,    O
which    O
was    O
confirmed    O
by    O
the    O
discovery    O
of    O
the    O
Rhesus    O
factor    O
.    O

James    O
Christopher    O
Harrison    O
,    O
OAM    O
,    O
also    O
known    O
as    O
the    O
Man    O
with    O
the    O
golden    O
arm    O
,    O
is    O
a    O
blood    O
plasma    O
donor    O
from    O
Australia    O
whose    O
unusual    O
plasma    O
composition    O
has    O
been    O
used    O
to    O
make    O
a    O
treatment    O
for    O
Rhesus    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

This    O
antigen    O
sensitization    O
and    O
subsequent    O
incompatibility    O
phenomenon    O
causes    O
Rhesus    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
the    O
most    O
common    O
form    O
of    O
HDN    O
.    O

The    O
loss    O
of    O
this    O
small    O
amount    O
of    O
blood    O
may    O
however    O
be    O
a    O
sensitising    O
event    O
and    O
stimulate    O
antibody    O
production    O
to    O
the    O
foetal    O
red    O
blood    O
cells    O
,    O
an    O
example    O
of    O
which    O
is    O
Rhesus    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    O
the    O
newborn    O
.    O

Rho(D    O
)    O
Immune    O
Globulin    O
treatment    O
prevents    O
sensitization    O
that    O
can    O
lead    O
to    O
Rh    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
but    O
does    O
not    O
prevent    O
or    O
treat    O
the    O
underlying    O
disease    O
itself    O
.    O

In    O
order    O
of    O
incidence    O
,    O
the    O
types    O
include    O
ABO    O
,    O
anti-RhD    B-BloodDyscrasia114053850
,    O
anti    O
-    O
RhE    O
,    O
anti    O
-    O
Rhc    O
,    O
anti    O
-    O
Rhe    O
,    O
anti    O
-    O
RhC    O
,    O
multiantigen    O
combinations    O
,    O
and    O
anti    O
-    O
Kell    O
.    O

Rhesus    B-BloodDyscrasia114053850
D    I-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
(    O
often    O
called    O
Rh    O
disease    O
)    O
is    O
the    O
most    O
common    O
form    O
of    O
severe    O
HDN    O
.    O

Rh    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Anaplastic    B-BloodDyscrasia114053850
large    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

Anaplastic    B-BloodDyscrasia114053850
large-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
ALCL    B-BloodDyscrasia114053850
)    O
is    O
a    O
type    O
of    O
non-Hodgkin    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
involving    O
aberrant    O
T    O
cells    O
or    O
null    O
lymphocytes    O
.    O

Foreman    O
believes    O
this    O
patient    O
has    O
anaplastic    B-BloodDyscrasia114053850
large    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
but    O
his    O
boss    O
tells    O
him    O
to    O
stick    O
to    O
the    O
rules    O
/    O
protocol    O
and    O
treat    O
for    O
infection    O
.    O

The    O
FDA    O
has    O
identified    O
that    O
breast    O
implants    O
may    O
cause    O
a    O
rare    O
form    O
of    O
cancer    O
called    O
anaplastic    B-BloodDyscrasia114053850
large-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
notably    O
when    O
the    O
implants    O
are    O
textured    O
.    O

When    O
Boston    O
Red    O
Sox    O
rookie    O
left    O
-    O
handed    O
pitcher    O
Jon    O
Lester    O
,    O
a    O
Washington    O
native    O
,    O
was    O
diagnosed    O
with    O
anaplastic    B-BloodDyscrasia114053850
large    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
during    O
the    O
season    O
,    O
he    O
chose    O
to    O
undergo    O
chemotherapy    O
at    O
the    O
Seattle    O
facility    O
.    O

It    O
can    O
appear    O
very    O
similar    O
to    O
anaplastic    B-BloodDyscrasia114053850
large    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Beta-thalassemia    B-BloodDyscrasia114053850
(    O
due    O
to    O
expansion    O
of    O
bone    O
marrow    O
secondary    O
to    O
increased    O
hematopoiesis    O
)    O

Mutations    O
in    O
the    O
gene    O
produce    O
several    O
variants    O
of    O
the    O
proteins    O
which    O
are    O
implicated    O
with    O
genetic    O
disorders    O
such    O
as    O
sickle    O
-    O
cell    O
disease    O
and    O
beta    B-BloodDyscrasia114053850
thalassemia    I-BloodDyscrasia114053850
,    O
as    O
well    O
as    O
beneficial    O
traits    O
such    O
as    O
genetic    O
resistance    O
to    O
malaria    O
.    O

Total    O
or    O
partial    O
absence    O
of    O
HBB    O
causes    O
a    O
genetic    O
disease    O
called    O
beta    B-BloodDyscrasia114053850
thalassemia    I-BloodDyscrasia114053850
.    O

According    O
to    O
a    O
recent    O
study    O
,    O
the    O
stop    O
gain    O
mutation    O
Gln40stop    O
in    O
HBB    O
gene    O
is    O
a    O
common    O
cause    O
of    O
autosomal    O
recessive    O
Beta-    B-BloodDyscrasia114053850
thalassemia    I-BloodDyscrasia114053850
in    O
Sardinian    O
people    O
(    O
almost    O
exclusive    O
in    O
Sardinia    O
)    O
.    O

Beta    B-BloodDyscrasia114053850
thalassaemia    I-BloodDyscrasia114053850

These    O
are    O
difficult    O
to    O
distinguish    O
from    O
the    O
red    O
marrow    O
hyperplasia    O
of    O
hematopoiesis    O
,    O
as    O
can    O
occur    O
with    O
tobacco    O
smoking    O
,    O
chronically    O
anemic    B-BloodDyscrasia114053850
disease    O
states    O
like    O
sickle    O
cell    O
anemia    O
or    O
beta    B-BloodDyscrasia114053850
thalassemia    I-BloodDyscrasia114053850
,    O
medications    O
such    O
as    O
granulocyte    O
colony    O
-    O
stimulating    O
factors    O
,    O
or    O
during    O
recovery    O
from    O
chronic    O
nutritional    O
anemias    O
or    O
therapeutic    O
bone    O
marrow    O
suppression    O
.    O

His    O
contributions    O
to    O
biology    O
include    O
numerous    O
researches    O
in    O
genetic    O
predisposition    O
to    O
diseases    O
such    O
as    O
type    O
1    O
diabetes    O
and    O
β-thalassemia    B-BloodDyscrasia114053850
.    O

The    O
best    O
-    O
known    O
example    O
of    O
a    O
disease    O
caused    O
by    O
a    O
splicing    O
error    O
is    O
Beta-thalassemia    B-BloodDyscrasia114053850
,    O
in    O
which    O
extra    O
intronic    O
material    O
is    O
erroneously    O
spliced    O
into    O
the    O
gene    O
for    O
making    O
hemoglobin    O
.    O

John    O
G.    O
Kelton    O
,    O
Dean    O
of    O
Medicine    O
(    O
2001–2016    O
)    O
,    O
Dean    O
and    O
Vice    O
-    O
President    O
of    O
the    O
Faculty    O
of    O
Health    O
Sciences    O
(    O
2001–2016    O
)    O
,    O
hematologist    O
and    O
expert    O
in    O
heparin-induced    B-BloodDyscrasia114053850
thrombocytopenia    I-BloodDyscrasia114053850

Major    O
side    O
effects    O
of    O
tinzaparin    O
are    O
osteoporosis    O
(    O
occurring    O
in    O
up    O
to    O
1%    O
of    O
cases    O
)    O
,    O
thrombocytopenia    O
(    O
heparin-induced    B-BloodDyscrasia114053850
thrombocytopenia    I-BloodDyscrasia114053850
)    O
,    O
haemorrhage    O
,    O
hair    O
loss    O
and    O
drug    O
allergy    O
.    O

In    O
2000    O
,    O
argatroban    O
was    O
licensed    O
by    O
the    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
for    O
prophylaxis    O
or    O
treatment    O
of    O
thrombosis    O
in    O
patients    O
with    O
heparin-induced    B-BloodDyscrasia114053850
thrombocytopenia    I-BloodDyscrasia114053850
(    O
HIT    O
)    O
.    O

Drug    O
-    O
induced    O
thrombocytopenic    O
purpura    O
(    O
five    O
known    O
drugs    O
–    O
most    O
problematic    O
is    O
heparin-induced    B-BloodDyscrasia114053850
thrombocytopenia    I-BloodDyscrasia114053850
(    O
HIT    O
)    O

This    O
phenomenon    O
was    O
discovered    O
by    O
Jonathan    O
Towne    O
,    O
a    O
vascular    O
surgeon    O
in    O
Milwaukee    O
,    O
who    O
was    O
also    O
the    O
first    O
to    O
report    O
the    O
"    O
white    O
clot    O
syndrome    O
"    O
(    O
now    O
called    O
heparin    B-BloodDyscrasia114053850
induced    I-BloodDyscrasia114053850
thrombocytopenia    I-BloodDyscrasia114053850
[    O
HIT    O
]    O
)    O
.    O

Homozygous    O
inheritance    O
of    O
defective    O
"    O
PRF1    O
"    O
alleles    O
result    O
in    O
the    O
development    O
of    O
familial    B-BloodDyscrasia114053850
hemophagocytic    I-BloodDyscrasia114053850
lymphohistiocytosis    I-BloodDyscrasia114053850
type    O
2    O
(    O
FHL2    O
)    O
,    O
a    O
rare    O
and    O
lethal    O
autosomal    O
recessive    O
disorder    O
of    O
infancy    O
.    O

Haemophagocytic    B-BloodDyscrasia114053850
lymphohistiocytosis    I-BloodDyscrasia114053850

Haemophagocytic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
infection    O
-    O
associated    O

It    O
is    O
part    O
of    O
the    O
presentation    O
of    O
hemophagocytic    B-BloodDyscrasia114053850
lymphohistiocytosis    I-BloodDyscrasia114053850
.    O

It    O
is    O
a    O
phenomenon    O
most    O
commonly    O
witnessed    O
in    O
sepsis    O
,    O
and    O
less    O
frequently    O
in    O
autoimmune    O
diseases    O
,    O
differentiation    O
syndrome    O
,    O
engraftment    O
syndrome    O
,    O
hemophagocytic    B-BloodDyscrasia114053850
lymphohistiocytosis    I-BloodDyscrasia114053850
,    O
the    O
ovarian    O
hyperstimulation    O
syndrome    O
,    O
viral    O
hemorrhagic    O
fevers    O
,    O
and    O
snakebite    O
and    O
ricin    O
poisoning    O
.    O

Pure    B-BloodDyscrasia114053850
red    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
aplasia    I-BloodDyscrasia114053850

Several    O
cases    O
of    O
pure    B-BloodDyscrasia114053850
red    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
aplasia    I-BloodDyscrasia114053850
(    O
PRCA    O
)    O
have    O
also    O
been    O
reported    O
.    O

Acquired    B-BloodDyscrasia114053850
pure    I-BloodDyscrasia114053850
red    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
aplasia    I-BloodDyscrasia114053850

Chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850

The    O
most    O
common    O
tumors    O
associated    O
with    O
this    O
syndrome    O
are    O
poorly    O
differentiated    O
lymphomas    O
(    O
such    O
as    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
)    O
,    O
other    O
Non-Hodgkin    B-BloodDyscrasia114053850
Lymphomas    I-BloodDyscrasia114053850
(    O
NHL    O
)    O
,    O
acute    O
lymphoblastic    O
leukemia    O
(    O
ALL    O
)    O
,    O
acute    O
myeloid    O
leukemia    O
(    O
AML    O
)    O
,    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
and    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CML    O
)    O
.    O

The    O
Philadelphia    O
chromosome    O
or    O
Philadelphia    O
translocation    O
is    O
a    O
specific    O
genetic    O
abnormality    O
in    O
chromosome    O
22    O
of    O
leukemia    O
cancer    O
cells    O
(    O
particularly    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CML    O
)    O
cells    O
)    O
.    O

p190    O
is    O
generally    O
associated    O
with    O
acute    O
lymphoblastic    O
leukemia    O
(    O
ALL    O
)    O
,    O
while    O
p210    O
is    O
generally    O
associated    O
with    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
but    O
can    O
also    O
be    O
associated    O
with    O
ALL    O
.    O

Although    O
it    O
did    O
not    O
eradicate    O
CML    O
cells    O
,    O
it    O
did    O
greatly    O
limit    O
the    O
growth    O
of    O
the    O
tumor    O
clone    O
and    O
decreased    O
the    O
risk    O
of    O
the    O
feared    O
"    O
blast    B-BloodDyscrasia114053850
crisis    I-BloodDyscrasia114053850
"    O
.    O

The    O
T315I    O
mutation    O
in    O
the    O
fusion    O
gene    O
confers    O
resistance    O
to    O
other    O
tyrosine    O
kinase    O
inhibitors    O
such    O
as    O
imatinib    O
,    O
however    O
axitinib    O
has    O
been    O
successfully    O
been    O
used    O
to    O
treat    O
a    O
patient    O
with    O
ALL    O
carrying    O
this    O
mutation    O
,    O
as    O
well    O
as    O
CML    B-BloodDyscrasia114053850
cells    O
in    O
culture    O
.    O

Chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850

KBM-7    O
(    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
)    O

"    O
BRCA1    O
"    O
mutations    O
are    O
associated    O
acute    O
myelogenous    O
leukemia    O
and    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

In    O
2010    O
,    O
Mullica    O
was    O
diagnosed    O
with    O
acute    O
myelogenous    B-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

This    O
treatment    O
can    O
be    O
used    O
in    O
hematological    O
malignancy    O
;    O
leukemia    O
and    O
lymphomas    O
including    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
nodular    O
lymphoma    O
,    O
and    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

In    O
2001    O
,    O
O'Neal    O
was    O
diagnosed    O
with    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CML    O
)    O
.    O

Hematologic    O
diseases    O
in    O
which    O
it    O
is    O
positive    O
include    O
ALL    O
,    O
angioimmunoblastic    O
T    O
cell    O
lymphoma    O
,    O
Burkitt    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
in    O
blast    O
crisis    O
(    O
90%    O
)    O
,    O
diffuse    O
large    O
B    O
-    O
cell    O
lymphoma    O
(    O
variable    O
)    O
,    O
follicular    O
center    O
cells    O
(    O
70%    O
)    O
,    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
10%    O
)    O
,    O
and    O
myeloma    O
(    O
some    O
)    O
.    O

This    O
happens    O
in    O
hematologic    O
disorders    O
like    O
chronic    B-BloodDyscrasia114053850
myelogeneous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
promyelocytic    B-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
and    O
also    O
the    O
hypereosinophilic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Leukemia    O
(    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
(CML))    I-BloodDyscrasia114053850
and    O
other    O
myeloproliferative    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850

This    O
enzyme    O
participates    O
in    O
7    O
metabolic    O
pathways    O
:    O
MAPK    O
signaling    O
pathway    O
,    O
cytokine    O
-    O
cytokine    O
receptor    O
interaction    O
,    O
TGF    O
beta    O
signaling    O
pathway    O
,    O
adherens    O
junction    O
,    O
colorectal    O
cancer    O
,    O
pancreatic    O
cancer    O
,    O
and    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

This    O
enzyme    O
participates    O
in    O
29    O
metabolic    O
pathways    O
:    O
inositol    O
phosphate    O
metabolism    O
,    O
erbb    O
signaling    O
pathway    O
,    O
phosphatidylinositol    O
signaling    O
system    O
,    O
mtor    O
signaling    O
pathway    O
,    O
apoptosis    O
,    O
VEGF    O
signaling    O
pathway    O
,    O
focal    O
adhesion    O
,    O
toll    O
-    O
like    O
receptor    O
signaling    O
pathway    O
,    O
jak    O
-    O
stat    O
signaling    O
pathway    O
,    O
natural    O
killer    O
cell    O
mediated    O
cytotoxicity    O
,    O
t    O
cell    O
receptor    O
signaling    O
pathway    O
,    O
b    O
cell    O
receptor    O
signaling    O
pathway    O
,    O
fc    O
epsilon    O
ri    O
signaling    O
pathway    O
,    O
leukocyte    O
transendothelial    O
migration    O
,    O
regulation    O
of    O
actin    O
cytoskeleton    O
,    O
insulin    O
signaling    O
pathway    O
,    O
progesterone    O
-    O
mediated    O
oocyte    O
maturation    O
,    O
Type    O
II    O
diabetes    O
mellitus    O
,    O
colorectal    O
cancer    O
,    O
renal    O
cell    O
carcinoma    O
,    O
pancreatic    O
cancer    O
,    O
endometrial    O
cancer    O
,    O
glioma    O
,    O
prostate    O
cancer    O
,    O
melanoma    O
,    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
acute    O
myeloid    O
leukemia    O
,    O
small    O
cell    O
lung    O
cancer    O
,    O
and    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
.    O

Bcr    O
-    O
Abl    O
tyrosine    O
-    O
kinase    O
inhibitors    O
(    O
TKI    O
)    O
are    O
the    O
first    O
-    O
line    O
therapy    O
for    O
most    O
patients    O
with    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CML    O
)    O
.    O

Mutational    O
frequencies    O
appear    O
to    O
increase    O
as    O
the    O
disease    O
,    O
CML    B-BloodDyscrasia114053850
,    O
progresses    O
from    O
chronic    O
phase    O
to    O
the    O
blast    O
phase    O
.    O

The    O
treatment    O
options    O
for    O
imatinib    O
resistant    O
or    O
intolerant    O
CML    B-BloodDyscrasia114053850
patients    O
may    O
include    O
strategies    O
such    O
as    O
increasing    O
the    O
dose    O
of    O
imatinib    O
or    O
the    O
use    O
of    O
second    O
-    O
generation    O
drugs    O
.    O

Also    O
new    O
antibody    O
clones    O
against    O
rigorously    O
selected    O
epitopes    O
of    O
proteins    O
involved    O
in    O
chromosomal    O
translocations    O
were    O
developed    O
for    O
detection    O
of    O
most    O
frequent    O
fusion    O
proteins    O
in    O
acute    O
leukemia    O
and    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

A    O
2-time    O
cancer    O
survivor    O
,    O
Kalemis    O
was    O
diagnosed    O
with    O
Non-Hodgkin’s    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
in    O
1998    O
and    O
with    O
Chronic    B-BloodDyscrasia114053850
Myloed    I-BloodDyscrasia114053850
Leukemia    I-BloodDyscrasia114053850
in    O
2005    O
.    O

A    O
specialist    O
in    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
,    O
Goldman    O
conducted    O
pioneering    O
research    O
into    O
leukaemia    O
treatment    O
–    O
he    O
was    O
instrumental    O
in    O
the    O
development    O
of    O
bone    O
marrow    O
transplantation    O
as    O
a    O
clinical    O
method    O
,    O
and    O
later    O
in    O
the    O
development    O
of    O
the    O
drug    O
imatinib    O
.    O

In    O
1971    O
Goldman    O
joined    O
the    O
staff    O
of    O
Hammersmith    O
Hospital    O
,    O
London    O
,    O
and    O
became    O
a    O
specialist    O
in    O
the    O
treatment    O
of    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukaemia    I-BloodDyscrasia114053850
.    O

As    O
a    O
graduate    O
student    O
working    O
with    O
Nobelist    O
Dr.    O
David    O
Baltimore    O
,    O
Dr.    O
Daley    O
demonstrated    O
that    O
the    O
BCR    O
/    O
ABL    O
oncogene    O
induces    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CML    O
)    O
in    O
a    O
mouse    O
model    O
,    O
which    O
validated    O
BCR    O
/    O
ABL    O
as    O
a    O
target    O
for    O
drug    O
blockade    O
and    O
encouraged    O
the    O
development    O
of    O
imatinib    O
(    O
Gleevec    O
;    O
Novartis    O
)    O
,    O
a    O
magic    O
-    O
bullet    O
chemotherapy    O
that    O
induces    O
remissions    O
in    O
virtually    O
every    O
CML    O
patient    O
.    O

He    O
died    O
15    O
days    O
later    O
on    O
February    O
22    O
,    O
1984    O
,    O
from    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
at    O
age    O
12    O
.    O

HIV    O
disease    O
resulting    O
in    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

The    O
INCTR    O
Challenge    O
Fund    O
is    O
prioritizing    O
INCTR    O
projects    O
in    O
children    O
’s    O
cancer    O
(    O
especially    O
African    O
Burkitt    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
)    O
and    O
palliative    O
care    O
.    O

This    O
is    O
tragic    O
as    O
common    O
childhood    O
cancers    O
such    O
as    O
African    O
Burkitt    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
can    O
be    O
cured    O
cheaply    O
and    O
efficiently    O
if    O
they    O
are    O
detected    O
early    O
enough    O
.    O

One    O
project    O
researched    O
cancer    O
cells    O
taken    O
from    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
patients    O
in    O
Papua    O
New    O
Guinea    O
,    O
and    O
found    O
they    O
were    O
infected    O
with    O
Epstein    O
-    O
Barr    O
virus    O
(    O
EBV    O
)    O
.    O

January    O
2    O
–    O
Nick    O
Venet    O
,    O
record    O
producer    O
,    O
61    O
(    O
Burkitt's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
)    O

Hematologic    O
diseases    O
in    O
which    O
it    O
is    O
positive    O
include    O
ALL    O
,    O
angioimmunoblastic    O
T    O
cell    O
lymphoma    O
,    O
Burkitt    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
in    O
blast    O
crisis    O
(    O
90%    O
)    O
,    O
diffuse    O
large    O
B    O
-    O
cell    O
lymphoma    O
(    O
variable    O
)    O
,    O
follicular    O
center    O
cells    O
(    O
70%    O
)    O
,    O
hairy    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
10%    O
)    O
,    O
and    O
myeloma    O
(    O
some    O
)    O
.    O

Changes    O
in    O
CCDC109B    O
expression    O
are    O
also    O
present    O
in    O
other    O
diseases    O
such    O
as    O
glioblastomas    O
,    O
Daudi    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
Duchenne    O
muscular    O
dystrophy    O
,    O
breast    O
carcinomas    O
,    O
and    O
promyelocytic    O
leukemia    O
HL-60    O
.    O

Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
t8;14    O
)    O

It    O
is    O
also    O
associated    O
with    O
particular    O
forms    O
of    O
cancer    O
,    O
such    O
as    O
Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
gastric    O
cancer    O
,    O
nasopharyngeal    O
carcinoma    O
,    O
and    O
conditions    O
associated    O
with    O
human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
,    O
such    O
as    O
hairy    O
leukoplakia    O
and    O
central    O
nervous    O
system    O
lymphomas    O
.    O

EBV    O
has    O
been    O
implicated    O
in    O
several    O
diseases    O
,    O
including    O
infectious    O
mononucleosis    O
,    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O

"    O
This    O
lecture    O
,    O
by    O
Denis    O
Parsons    O
Burkitt    O
,    O
a    O
surgeon    O
practicing    O
in    O
Uganda    O
,    O
was    O
the    O
description    O
of    O
the    O
"    O
endemic    O
variant    O
"    O
(    O
pediatric    O
form    O
)    O
of    O
the    O
disease    O
that    O
bears    B-BloodDyscrasia114053850
his    I-BloodDyscrasia114053850
name    I-BloodDyscrasia114053850
.    O

Eva    O
Klein    O
(    O
born    O
Eva    O
Fischer    O
;    O
January    O
22    O
,    O
1925    O
)    O
is    O
a    O
Hungarian    O
-    O
Swedish    O
scientist    O
best    O
known    O
for    O
leading    O
the    O
discovery    O
of    O
natural    O
killer    O
cells    O
and    O
developing    O
Burkitt    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
cell    O
lines    O
in    O
the    O
1960s    O
.    O

Klein    O
has    O
had    O
a    O
longstanding    O
interest    O
in    O
virology    O
as    O
well    O
as    O
immunology    O
,    O
studying    O
the    O
role    O
of    O
the    O
Epstein    O
-    O
Barr    O
Virus    O
in    O
Burkitt    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
.    O

On    O
May    O
30    O
,    O
2007    O
,    O
Andruzzi    O
was    O
diagnosed    O
with    O
non    O
-    O
Hodgkin    O
's    O
Burkitt's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
predicted    O
to    O
double    O
in    O
size    O
in    O
just    O
24    O
hours    O
.    O

He    O
specializes    O
in    O
lymphoma    O
,    O
including    O
Non-Hodgkin's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
,    O
Burkitt's    B-BloodDyscrasia114053850
Lymphoma    I-BloodDyscrasia114053850
and    O
Hodgkin's    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

Congenital    B-BloodDyscrasia114053850
dyserythropoietic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
type    I-BloodDyscrasia114053850
III    I-BloodDyscrasia114053850
(    O
CDA    B-BloodDyscrasia114053850
III    I-BloodDyscrasia114053850
)    O
is    O
a    O
rare    O
autosomal    O
dominant    O
disorder    O
characterized    O
by    O
macrocytic    O
anemia    O
,    O
bone    O
marrow    O
erythroid    O
hyperplasia    O
and    O
giant    O
multinucleate    O
erythroblasts    O
.    O

Methaemoglobinaemia    B-BloodDyscrasia114053850

Congenital    B-BloodDyscrasia114053850
methaemoglobinaemia    I-BloodDyscrasia114053850

Methaemoglobinaemia    B-BloodDyscrasia114053850
,    O
hereditary    O

Other    O
methaemoglobinaemia    B-BloodDyscrasia114053850

Methaemoglobinaemia    B-BloodDyscrasia114053850
,    O
unspecified    O

It    O
is    O
a    O
pulmonary    O
irritant    O
with    O
a    O
toxicity    O
considerably    O
lower    O
than    O
nitrogen    O
oxides    O
,    O
and    O
overexposure    O
via    O
inhalation    O
causes    O
the    O
conversion    O
of    O
hemoglobin    O
in    O
blood    O
to    O
methemoglobin    O
,    O
which    O
can    O
lead    O
to    O
the    O
condition    O
methemoglobinemia    B-BloodDyscrasia114053850
.    O

He    O
also    O
described    O
the    O
blood    O
disorder    O
methaemoglobinaemia    B-BloodDyscrasia114053850
.    O

Ingestion    O
of    O
alkyl    O
nitrites    O
can    O
cause    O
methemoglobinemia    B-BloodDyscrasia114053850
,    O
although    O
inhalation    O
does    O
not    O
.    O

The    O
"    O
Blue    O
Fugates    O
"    O
,    O
a    O
family    O
of    O
hereditary    O
sufferers    O
from    O
methemoglobinemia    B-BloodDyscrasia114053850
,    O
so    O
called    O
because    O
some    O
of    O
them    O
had    O
blue    O
skin    O
,    O
lived    O
in    O
the    O
area    O
in    O
the    O
19th    O
and    O
20th    O
centuries    O
.    O

The    O
topical    O
use    O
of    O
higher    O
concentration    O
(    O
14    O
-    O
20%    O
)    O
benzocaine    O
spray    O
products    O
applied    O
to    O
the    O
mouth    O
or    O
mucous    O
membranes    O
has    O
been    O
found    O
to    O
be    O
a    O
cause    O
of    O
methemoglobinemia    B-BloodDyscrasia114053850
,    O
a    O
disorder    O
in    O
which    O
the    O
amount    O
of    O
oxygen    O
carried    O
by    O
the    O
blood    O
is    O
greatly    O
reduced    O
.    O

Excessive    O
nitrates    O
in    O
drinking    O
water    O
is    O
thought    O
to    O
cause    O
methemoglobinemia    B-BloodDyscrasia114053850
in    O
infants    O
,    O
which    O
decreases    O
the    O
blood    O
's    O
oxygen    O
transport    O
ability    O
.    O

The    O
Fugates    O
,    O
a    O
family    O
that    O
lived    O
in    O
the    O
hills    O
of    O
Kentucky    O
,    O
commonly    O
known    O
as    O
the    O
"    O
Blue    O
Fugates    O
"    O
or    O
the    O
Blue    O
People    O
of    O
Kentucky    O
,    O
are    O
notable    O
for    O
having    O
been    O
carriers    O
of    O
a    O
genetic    O
trait    O
that    O
led    O
to    O
the    O
disease    O
methemoglobinemia    B-BloodDyscrasia114053850
,    O
which    O
gives    O
sufferers    O
blue    O
-    O
tinged    O
skin    O
.    O

Its    O
overall    O
pathology    O
resembles    O
a    O
combination    O
of    O
autoimmune    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
and    O
immune    O
thrombocytopenic    O
purpura    O
.    O

It    O
has    O
been    O
variously    O
reported    O
that    O
between    O
10%    O
and    O
23%    O
of    O
patients    O
who    O
have    O
autoimmune    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
will    O
also    O
have    O
thrombocytopenia    O
and    O
thus    O
Evans    O
syndrome    O
.    O

:    O
:    O
:    O
:    O
Autoimmune    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

Prior    O
to    O
1996    O
MCD    O
carried    O
a    O
poor    O
prognosis    O
of    O
about    O
2    O
years    O
,    O
due    O
to    O
autoimmune    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
and    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
which    O
may    O
arise    O
as    O
a    O
result    O
of    O
proliferation    O
of    O
infected    O
cells    O
.    O

Other    O
autoimmune    B-BloodDyscrasia114053850
haemolytic    I-BloodDyscrasia114053850
anaemias    I-BloodDyscrasia114053850

Autoimmune    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

If    O
the    O
person    O
has    O
inborn    O
errors    O
in    O
the    O
methyltransfer    O
pathway    O
(    O
cobalamin    O
C    O
disease    O
,    O
combined    O
methylmalonic    O
aciduria    O
and    O
homocystinuria    B-BloodDyscrasia114053850
)    O
,    O
treatment    O
with    O
intravenous    O
,    O
intramuscular    O
hydroxocobalamin    O
or    O
transdermal    O
B12    O
is    O
needed    O
.    O

At    O
the    O
same    O
time    O
,    O
since    O
DNA    O
synthetic    O
-    O
sensitive    O
tests    O
for    O
anemia    B-BloodDyscrasia114053850
and    O
erythrocyte    O
size    O
are    O
routinely    O
done    O
in    O
even    O
simple    O
medical    O
test    O
clinics    O
(    O
so    O
that    O
these    O
folate    O
-    O
mediated    O
biochemical    O
effects    O
are    O
more    O
often    O
directly    O
detected    O
)    O
,    O
the    O
MTR    O
-    O
dependent    O
effects    O
of    O
B12    O
deficiency    O
are    O
becoming    O
apparent    O
not    O
as    O
anemia    O
due    O
to    O
DNA    O
-    O
synthetic    O
problems    O
(    O
as    O
they    O
were    O
classically    O
)    O
,    O
but    O
now    O
mainly    O
as    O
a    O
simple    O
and    O
less    O
obvious    O
elevation    O
of    O
homocysteine    O
in    O
the    O
blood    O
and    O
urine    O
(    O
homocysteinuria    B-BloodDyscrasia114053850
)    O
.    O

Homocystinuria    B-BloodDyscrasia114053850

Homocystinuria    B-BloodDyscrasia114053850

The    O
"    O
CBS    O
"    O
gene    O
is    O
the    O
most    O
common    O
locus    O
for    O
mutations    O
associated    O
with    O
homocystinuria    B-BloodDyscrasia114053850
.    O

Homocystinuria    B-BloodDyscrasia114053850
due    O
to    O
CBS    O
deficiency    O
is    O
a    O
special    O
type    O
of    O
hyperhomocysteinemia    O
.    O

Homocystinuria    B-BloodDyscrasia114053850

MicroRNA-223    O
is    O
commonly    O
repressed    O
in    O
hepatocellular    O
carcinoma    O
,    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
acute    O
lymphoblastic    O
leukemia    O
,    O
acute    O
myeloid    O
leukemia    O
,    O
gastric    B-BloodDyscrasia114053850
MALT    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
and    O
recurrent    O
ovarian    O
cancer    O
.    O

gastric    B-BloodDyscrasia114053850
MALT    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

:*    O
Mucosa-associated    B-BloodDyscrasia114053850
lymphoid    I-BloodDyscrasia114053850
tissue    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

"    O
H.    O
pylori    O
"    O
infection    O
is    O
associated    O
with    O
MALT    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
and    O
gastric    O
adenocarcinoma    O
and    O
CagA    O
is    O
thought    O
to    O
be    O
involved    O
in    O
cancer    O
development    O
.    O

The    O
Le(b    O
)    O
and    O
H    O
antigens    O
are    O
receptors    O
for    O
the    O
bacteria    O
"    O
Helicobacter    O
pylori    O
"    O
,    O
a    O
gram    O
-    O
negative    O
bacterium    O
that    O
can    O
cause    O
gastritis    O
and    O
has    O
been    O
implicated    O
in    O
peptic    O
ulcer    O
disease    O
,    O
gastric    O
adenocarcinoma    O
,    O
mucosa    O
-    O
associated    O
lymphoma    O
(    O
or    O
mucosal    B-BloodDyscrasia114053850
associated    I-BloodDyscrasia114053850
lymphatic    I-BloodDyscrasia114053850
tissue    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
–    O
MALToma    O
)    O
and    O
idiopathic    O
thrombocytopenic    O
purpura    O
(    O
ITP    O
)    O
.    O

Pyknocytosis    B-BloodDyscrasia114053850
is    O
a    O
hematologic    O
state    O
characterized    O
by    O
the    O
presence    O
of    O
pyknocytes    O
in    O
the    O
blood    O
.    O

Giant    O
platelet    O
disorder    O
occurs    O
for    O
inherited    O
diseases    O
like    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
gray    B-BloodDyscrasia114053850
platelet    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
May-Hegglin    B-BloodDyscrasia114053850
anomaly    I-BloodDyscrasia114053850
.    O

Caused    O
by    O
alpha    O
granules    O
defect    O
:    O
Gray    B-BloodDyscrasia114053850
platelet    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Abnormalities    O
of    O
the    O
GPIb    O
-    O
V    O
-    O
IX    O
complex    O
result    O
in    O
abnormal    O
appearance    O
and    O
functioning    O
of    O
platelets    O
resulting    O
in    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
BSS    O
)    O
,    O
a    O
condition    O
first    O
described    O
by    O
Bernard    O
J    O
and    O
Soulier    O
J.P.    O
It    O
is    O
a    O
rare    O
hereditary    O
bleeding    O
disorder    O
most    O
commonly    O
with    O
an    O
autosomal    O
recessive    O
inheritance    O
and    O
diagnosed    O
based    O
on    O
prolonged    O
skin    O
-    O
bleeding    O
time    O
,    O
a    O
reduced    O
number    O
of    O
very    O
large    O
platelets    O
(    O
macrothrombocytopenia    O
)    O
and    O
defective    O
ristocetin    O
-    O
induced    O
platelet    O
agglutination    O
.    O

It    O
is    O
deficient    O
in    O
the    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Giant    O
platelet    O
disorder    O
occurs    O
for    O
inherited    O
diseases    O
like    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
gray    B-BloodDyscrasia114053850
platelet    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
May-Hegglin    B-BloodDyscrasia114053850
anomaly    I-BloodDyscrasia114053850
.    O

Caused    O
by    O
glycoprotein    O
abnormalities    O
:    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
Velocardiofacial    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Hematopoietic    O
ulcers    O
are    O
those    O
occurring    O
with    O
sickle    O
cell    O
anemia    O
,    O
congenital    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
thrombocytopenic    O
purpura    O
,    O
macroglobulinemia    B-BloodDyscrasia114053850
,    O
and    O
cryoglobulinemia    B-BloodDyscrasia114053850
.    O

McFall    B-BloodDyscrasia114053850
v.    I-BloodDyscrasia114053850
Shimp    I-BloodDyscrasia114053850
,    O
10    O
Pa.    O
D.    O
&    O
C.    O
3d    O
90    O
(    O
July    O
26    O
,    O
1978    O
)    O
was    O
an    O
Allegheny    O
County    O
,    O
Pennsylvania    O
,    O
court    O
case    O
.    O

Then    O
,    O
the    O
organism    O
is    O
cultured    O
on    O
blood    O
agar    O
with    O
an    O
added    O
bacitracin    O
antibiotic    O
disk    O
to    O
show    O
beta-hemolytic    B-BloodDyscrasia114053850
colonies    O
and    O
sensitivity    O
(    O
zone    O
of    O
inhibition    O
around    O
the    O
disk    O
)    O
for    O
the    O
antibiotic    O
.    O

The    O
viridans    O
streptococci    O
are    O
a    O
large    O
group    O
of    O
commensal    O
streptococcal    O
Gram    O
-    O
positive    O
bacteria    O
species    O
that    O
are    O
either    O
α-hemolytic    B-BloodDyscrasia114053850
,    O
producing    O
a    O
green    O
coloration    O
on    O
blood    O
agar    O
plates    O
(    O
hence    O
the    O
name    O
"    O
viridans    O
"    O
,    O
from    O
Latin    O
"    O
vĭrĭdis    O
"    O
,    O
green    O
)    O
,    O
or    O
nonhemolytic    O
.    O

These    O
two    O
proteins    O
had    O
previously    O
been    O
proposed    O
to    O
comprise    O
a    O
hemolysis    B-BloodDyscrasia114053850
system    O
,    O
but    O
Damman    O
et    O
al    O
.    O

When    O
grown    O
on    O
Bordet    O
-    O
Gengou    O
agar    O
,    O
which    O
is    O
the    O
standard    O
agar    O
for    O
"    O
Bordetella    O
"    O
isolation    O
,    O
colonies    O
are    O
convex    O
,    O
pearly    O
,    O
smooth    O
,    O
almost    O
transparent    O
,    O
and    O
glistening    O
,    O
and    O
are    O
surrounded    O
by    O
a    O
zone    O
of    O
hemolysis    B-BloodDyscrasia114053850
.    O

Post-transfusion    B-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
a    O
type    O
of    O
adverse    O
reaction    O
to    O
a    O
blood    O
transfusion    O

Activated    B-BloodDyscrasia114053850
protein    I-BloodDyscrasia114053850
C    I-BloodDyscrasia114053850
resistance    I-BloodDyscrasia114053850
that    O
is    O
not    O
attributable    O
to    O
factor    O
V    O
mutations    O
is    O
probably    O
caused    O
by    O
other    O
factors    O
and    O
remains    O
a    O
risk    O
factor    O
for    O
thrombosis    O
.    O

Activated    B-BloodDyscrasia114053850
protein    I-BloodDyscrasia114053850
C    I-BloodDyscrasia114053850
resistance    I-BloodDyscrasia114053850
-    O
a    O
hemostatic    O
disorder    O

It    O
is    O
therefore    O
also    O
called    O
symptomatic    B-BloodDyscrasia114053850
hyperleukocytosis    I-BloodDyscrasia114053850
.    O

Paterson-Kelly    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

He    O
is    O
best    O
known    O
for    O
his    O
contribution    O
to    O
medicine    O
in    O
the    O
study    O
of    O
Plummer-Vinson    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Sideropenic    B-BloodDyscrasia114053850
dysphagia    I-BloodDyscrasia114053850
can    O
cause    O
glossitis    O
,    O
angular    O
cheilitis    O
.    O

Chronic    O
diseases    O
might    O
include    O
congenital    O
diseases    O
such    O
as    O
Zenker    O
's    O
diverticulum    O
and    O
esophageal    B-BloodDyscrasia114053850
webbing    I-BloodDyscrasia114053850
,    O
and    O
oesophageal    O
motility    O
disorders    O
including    O
the    O
nutcracker    O
oesophagus    O
,    O
achalasia    O
,    O
diffuse    O
oesophageal    O
spasm    O
,    O
and    O
oesophageal    O
stricture    O
.    O

Constitutional    B-BloodDyscrasia114053850
aplastic    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Normochromic    B-BloodDyscrasia114053850
is    O
a    O
form    O
of    O
anemia    B-BloodDyscrasia114053850
in    O
which    O
the    O
concentration    O
of    O
hemoglobin    O
in    O
the    O
red    O
blood    O
cells    O
is    O
within    O
the    O
standard    O
range    O
.    O

Job    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Dr.    O
Ochs    O
'    O
research    O
focuses    O
on    O
the    O
molecular    O
basis    O
of    O
Primary    O
immunodeficiency    O
diseases    O
with    O
special    O
interest    O
in    O
the    O
genes    O
that    O
have    O
been    O
linked    O
to    O
the    O
Wiskott-Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
Hyper    O
IgM    O
syndrome    O
,    O
X-linked    B-BloodDyscrasia114053850
agammaglobulinemia    I-BloodDyscrasia114053850
,    O
IPEX    O
syndrome    O
and    O
autosomal    O
dominante    O
Hyper    B-BloodDyscrasia114053850
IgE    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Recently    O
,    O
he    O
focused    O
on    O
the    O
gene    O
Uracil    O
-    O
DNA    O
glycosylase    O
,    O
causing    O
a    O
rare    O
form    O
of    O
autosomal    O
recessive    O
Hyper    O
IgM    O
syndrome    O
,    O
and    O
on    O
STAT3    O
,    O
the    O
gene    O
causing    O
autosomal    O
dominant    O
Hyper    B-BloodDyscrasia114053850
IgE    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
if    O
mutated    O
.    O

The    O
molecular    O
consequences    O
of    O
heterozygous    O
dominant    O
negative    O
STAT3    O
mutations    O
and    O
their    O
relationship    O
to    O
autosomal    O
dominant    O
Hyper    B-BloodDyscrasia114053850
IgE    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

However    O
,    O
ferritin    O
levels    O
may    O
be    O
artificially    O
high    O
in    O
cases    O
of    O
anemia    B-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
where    O
ferritin    O
is    O
elevated    O
in    O
its    O
capacity    O
as    O
an    O
inflammatory    O
acute    O
phase    O
protein    O
and    O
not    O
as    O
a    O
marker    O
for    O
iron    O
overload    O
.    O

Abnormally    O
low    O
numbers    O
of    O
reticulocytes    O
can    O
be    O
attributed    O
to    O
chemotherapy    O
,    O
aplastic    O
anemia    O
,    O
pernicious    O
anemia    O
,    O
bone    O
marrow    O
malignancies    O
,    O
problems    O
of    O
erythropoietin    O
production    O
,    O
various    O
vitamin    O
or    O
mineral    O
deficiencies    O
(    O
iron    B-BloodDyscrasia114053850
,    O
vitamin    O
B12    O
,    O
folic    O
acid    O
)    O
,    O
disease    O
states    O
(    O
anemia    B-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
)    O
and    O
other    O
causes    O
of    O
anemia    O
due    O
to    O
poor    O
RBC    O
production    O
.    O

Moreover    O
,    O
cytokines    O
stimulate    O
hepcidin    O
release    O
from    O
the    O
liver    O
,    O
which    O
is    O
eventually    O
responsible    O
for    O
the    O
anemia    B-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
chronic    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

Heterozygous    O
individuals    O
may    O
produce    O
bisalbuminemia    B-BloodDyscrasia114053850
-    O
two    O
equally    O
staining    O
bands    O
,    O
the    O
product    O
of    O
two    O
genes    O
.    O

In    O
contemporary    O
times    O
,    O
"    O
P.    O
aurea    O
"    O
is    O
not    O
much    O
used    O
due    O
to    O
its    O
saturated    O
pyrrolizidine    O
alkaloids    O
which    O
can    O
cause    O
liver    O
veno-occlusive    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
upon    O
metabolism    O
.    O

Hepatic    B-BloodDyscrasia114053850
veno-occlusive    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Hepatic    O
venous    O
occlusion    O
:    O
Budd    O
–    O
Chiari    O
syndrome    O
or    O
veno-occlusive    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

PAs    O
also    O
cause    O
hepatic    B-BloodDyscrasia114053850
veno-occlusive    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
liver    O
cancer    O
.    O

Cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

Cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

Cutaneous    O
B    O
-    O
cell    O
lymphomas    O
constitute    O
a    O
group    O
of    O
diseases    O
that    O
occur    O
less    O
commonly    O
than    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
and    O
are    O
characterized    O
histologically    O
by    O
B    O
-    O
cells    O
that    O
appear    O
similar    O
to    O
those    O
normally    O
found    O
in    O
germinal    O
centers    O
of    O
lymph    O
nodes    O
.    O

Cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

Alemtuzumab    O
is    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
chronic    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
(    O
CLL    O
)    O
,    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
(    O
CTCL    O
)    O
and    O
T-cell    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
under    O
the    O
trade    O
names    O
Campath    O
,    O
MabCampath    O
and    O
Campath-1H    O
,    O
and    O
in    O
the    O
treatment    O
of    O
multiple    O
sclerosis    O
as    O
Lemtrada    O
.    O

A    O
recent    O
Phase    O
I    O
study    O
of    O
Resimmune    O
found    O
an    O
89%    O
response    O
rate    O
in    O
a    O
subgroup    O
of    O
nine    O
patients    O
with    O
cutaneous    B-BloodDyscrasia114053850
T    I-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

Resimmune    O
,    O
or    O
A    O
-    O
dmDT390-bisFv(UCHT1    O
)    O
,    O
an    O
experimental    O
anti    O
-    O
T    O
cell    O
immunotoxin    O
in    O
clinical    O
trials    O
to    O
treat    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
and    O
metastatic    O
melanoma    O
.    O

Photopheresis    O
–    O
used    O
to    O
treat    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
and    O
rejection    O
in    O
heart    O
transplantation    O
.    O

A    O
pilot    O
screening    O
program    O
for    O
four    O
lysosomal    O
storage    O
diseases    O
(    O
Gaucher    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
Pompe    O
disease    O
,    O
Fabry    O
disease    O
and    O
Niemann    O
-    O
Pick    O
disease    O
was    O
undertaken    O
using    O
anonymised    O
dried    O
blood    O
spots    O
was    O
completed    O
in    O
Austria    O
in    O
2010    O
.    O

Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Approximately    O
1    O
in    O
4    O
Ashkenazi    O
Jews    O
are    O
carriers    O
for    O
at    O
least    O
one    O
genetic    O
disorder    O
,    O
which    O
include    O
Tay    O
-    O
Sachs    O
disease    O
,    O
familial    O
dysautonomia    O
,    O
and    O
Gaucher    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

It    O
may    O
have    O
an    O
increased    O
prevalence    O
in    O
Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

This    O
discovery    O
assisted    O
other    O
scientists    O
in    O
the    O
elucidation    O
of    O
similar    O
glycolipid    O
storage    O
diseases    O
such    O
as    O
Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
Tay    O
–    O
Sachs    O
disease    O
and    O
in    O
their    O
prenatal    O
diagnosis    O
.    O

Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

In    O
1984    O
,    O
Robin    O
Berman    O
,    O
MD    O
,    O
who    O
volunteered    O
at    O
the    O
NIH    O
,    O
had    O
a    O
three    O
-    O
year    O
-    O
old    O
son    O
Brian    O
,    O
who    O
had    O
Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

Ceredase    O
was    O
the    O
first    O
effective    O
treatment    O
for    O
Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
a    O
previously    O
rare    O
,    O
untreatable    O
and    O
potentially    O
fatal    O
genetic    O
disorder    O
.    O

The    O
first    O
orphan    O
-    O
drug    O
for    O
Genzyme    O
that    O
FDA    O
approved    O
was    O
Ceredase    O
,    O
a    O
drug    O
for    O
treating    O
Gaucher    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

The    O
FDA    O
found    O
these    O
materials    O
in    O
Cerezyme    O
,    O
Genzyme    O
's    O
treatment    O
for    O
Gaucher    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
a    O
rare    O
genetic    O
disorder    O
that    O
can    O
lead    O
to    O
life    O
-    O
threatening    O
organ    O
damage    O
.    O

For    O
example    O
,    O
two    O
different    O
mutations    O
in    O
the    O
glucocerebrosidase    O
gene    O
causes    O
Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
in    O
Ashkenazis    O
,    O
which    O
is    O
their    O
most    O
common    O
genetic    O
disease    O
,    O
but    O
only    O
one    O
of    O
these    O
mutations    O
is    O
found    O
in    O
non    O
-    O
Jewish    O
groups    O
.    O

Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
in    O
which    O
lipids    O
accumulate    O
in    O
inappropriate    O
locations    O
,    O
occurs    O
most    O
frequently    O
among    O
Ashkenazi    O
Jews    O
;    O
the    O
mutation    O
is    O
carried    O
by    O
roughly    O
one    O
in    O
every    O
15    O
Ashkenazi    O
Jews    O
,    O
compared    O
to    O
one    O
in    O
100    O
of    O
the    O
general    O
American    O
population    O
.    O

Gaucher    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
which    O
is    O
caused    O
by    O
deficiency    O
of    O
the    O
enzyme    O
glucocerebrosidase    O
.    O

Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Gaucher    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

He    O
is    O
remembered    O
for    O
providing    O
a    O
description    O
of    O
a    O
disorder    O
that    O
was    O
to    O
become    O
known    O
as    O
'    O
Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
"    O
.    O

HELLP    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

HELLP    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

If    O
delivery    O
is    O
unavoidable    O
(    O
e.g.    O
because    O
of    O
placental    O
abruption    O
,    O
or    O
pre    O
-    O
eclampsia    O
/    O
HELLP    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
)    O
,    O
then    O
glucocorticoids    O
(    O
e.g.    O
cortisol    O
)    O
can    O
be    O
administered    O
.    O

These    O
include    O
preeclampsia    O
,    O
the    O
HELLP    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
and    O
acute    O
fatty    O
liver    O
of    O
pregnancy    O
.    O

Problems    O
still    O
arose    O
,    O
however    O
,    O
with    O
air    O
embolism    O
,    O
coagulopathy    B-BloodDyscrasia114053850
,    O
and    O
hemolysis    O
.    O

The    O
washed    O
autotransfusion    O
system    O
removes    O
the    O
plasma    O
and    O
platelets    O
to    O
eliminate    O
activated    O
clotting    O
factors    O
and    O
activated    O
platelets    O
which    O
would    O
cause    O
coagulopathy    B-BloodDyscrasia114053850
if    O
they    O
were    O
reinfused    O
to    O
the    O
patient    O
,    O
generating    O
a    O
packed    O
red    O
blood    O
cell    O
(    O
PRBC    O
)    O
product    O
.    O

Fatal    O
cases    O
continue    O
to    O
deteriorate    O
,    O
experiencing    O
continued    O
fever    O
,    O
obtundation    O
,    O
coma    O
,    O
convulsions    O
,    O
diffuse    O
coagulopathy    B-BloodDyscrasia114053850
,    O
metabolic    O
disturbances    O
,    O
shock    O
and    O
death    O
,    O
with    O
death    O
typically    O
occurring    O
between    O
Days    O
8    O
and    O
16    O
.    O

Late    O
complications    O
of    O
cirrhosis    O
or    O
liver    O
failure    O
include    O
portal    O
hypertension    O
(    O
high    O
blood    O
pressure    O
in    O
the    O
portal    O
vein    O
due    O
to    O
the    O
increased    O
flow    O
resistance    O
through    O
the    O
damaged    O
liver    O
)    O
,    O
coagulation    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850
(    O
due    O
to    O
impaired    O
production    O
of    O
coagulation    O
factors    O
)    O
,    O
ascites    O
(    O
heavy    O
abdominal    O
swelling    O
due    O
to    O
buildup    O
of    O
fluids    O
in    O
the    O
tissues    O
)    O
and    O
other    O
complications    O
,    O
including    O
hepatic    O
encephalopathy    O
and    O
the    O
hepatorenal    O
syndrome    O
.    O

The    O
Canadian    O
Hemophilia    O
Society    O
(    O
CHS    O
)    O
is    O
a    O
non    O
-    O
profit    O
organization    O
founded    O
in    O
1953    O
whose    O
mission    O
is    O
to    O
lead    O
the    O
fight    O
against    O
inherited    O
bleeding    B-BloodDyscrasia114053850
disorder    I-BloodDyscrasia114053850
by    O
helping    O
people    O
affected    O
live    O
healthy    O
lives    O
while    O
searching    O
for    O
a    O
cure    O
.    O

Coagulopathy    B-BloodDyscrasia114053850

All    O
infected    O
people    O
show    O
some    O
decreased    B-BloodDyscrasia114053850
blood    I-BloodDyscrasia114053850
clotting    I-BloodDyscrasia114053850
.    O

This    O
damage    O
occurs    O
due    O
to    O
the    O
synthesis    O
of    O
Ebola    O
virus    O
glycoprotein    O
(    O
GP    O
)    O
,    O
which    O
reduces    O
the    O
availability    O
of    O
specific    O
integrins    O
responsible    O
for    O
cell    O
adhesion    O
to    O
the    O
intercellular    O
structure    O
and    O
causes    O
liver    O
damage    O
,    O
leading    O
to    O
improper    B-BloodDyscrasia114053850
clotting    I-BloodDyscrasia114053850
.    O

It    O
also    O
increases    O
the    O
risk    O
of    O
yeast    O
infections    O
,    O
headaches    O
,    O
and    O
blood    B-BloodDyscrasia114053850
clotting    I-BloodDyscrasia114053850
problems    I-BloodDyscrasia114053850
.    O

Haematology    O
:    O
high    O
-    O
purity    O
coagulation    O
factor    O
concentrates    O
for    O
patients    O
with    O
bleeding    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850
Haemophilia    O
A    O
,    O
B    O
and    O
von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

The    O
success    O
of    O
platelets    O
has    O
been    O
attributed    O
to    O
the    O
fact    O
that    O
they    O
may    O
prevent    O
coagulopathy    B-BloodDyscrasia114053850
from    O
developing    O
.    O

For    O
severe    O
bleeding    O
,    O
for    O
example    O
from    O
bleeding    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850
,    O
recombinant    O
factor    O
VIIaa    O
protein    O
that    O
assists    O
blood    O
clottingmay    O
be    O
appropriate    O
.    O

Platelet    O
transfusion    O
is    O
contraindicated    O
in    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
(    O
TTP    O
)    O
,    O
as    O
it    O
fuels    O
the    O
coagulopathy    B-BloodDyscrasia114053850
.    O

For    O
this    O
reason    O
it    O
is    O
effective    O
in    O
treatment    O
of    O
certain    O
bleeding    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850
,    O
and    O
it    O
is    O
marketed    O
as    O
Amicar    O
.    O

Coagulation    B-BloodDyscrasia114053850
disorder    I-BloodDyscrasia114053850
(    O
congenital    O
or    O
acquired    O
)    O

Combined    O
coagulation    B-BloodDyscrasia114053850
defects    I-BloodDyscrasia114053850

The    O
causes    O
of    O
Haemobilia    O
include    O
trauma    O
(    O
which    O
can    O
be    O
accidental    O
or    O
iatrogenic    O
due    O
to    O
procedures    O
such    O
as    O
cholecystectomy    O
)    O
,    O
instrumentation    O
(    O
especially    O
after    O
ERCP    O
)    O
,    O
gallstone    O
,    O
inflammatory    O
conditions    O
ranging    O
from    O
ascariasis    O
to    O
PAN    O
,    O
vascular    O
malformation    O
,    O
tumors    O
,    O
coagulopathy    B-BloodDyscrasia114053850
,    O
and    O
liver    O
biopsy    O
.    O

Hyperviscosity    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

As    O
the    O
bone    O
marrow    O
increases    O
erythropoiesis    O
,    O
the    O
systemic    O
reticulocyte    O
count    O
and    O
the    O
risk    O
for    O
hyperviscosity    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
increases    O
.    O

It    O
is    O
often    O
misdiagnosed    O
as    O
polycythemia    O
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
hyperviscosity    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
or    O
sepsis    O
.    O

Acute    B-BloodDyscrasia114053850
posthaemorrhagic    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Zieve's    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
is    O
an    O
acute    O
metabolic    O
condition    O
that    O
can    O
occur    O
during    O
withdrawal    O
from    O
prolonged    O
alcohol    O
abuse    O
.    O

Higher    O
levels    O
are    O
seen    O
in    O
the    O
physiological    O
response    O
,    O
the    B-BloodDyscrasia114053850
leukemoid    I-BloodDyscrasia114053850
reaction    I-BloodDyscrasia114053850
,    O
and    O
in    O
pathologies    O
that    O
include    O
mature    O
white    O
blood    O
cells    O
,    O
such    O
as    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
(    O
PV    O
)    O
,    O
essential    B-BloodDyscrasia114053850
thrombocytosis    I-BloodDyscrasia114053850
(    O
ET    O
)    O
,    O
and    O
in    O
primary    O
myelofibrosis    O
(    O
PM    O
)    O
.    O

Essential    B-BloodDyscrasia114053850
thrombocytosis    I-BloodDyscrasia114053850
(    O
ET    O
-    O
Also    O
known    O
as    O
essential    B-BloodDyscrasia114053850
thrombocythemia    I-BloodDyscrasia114053850
)    O
is    O
a    O
disorder    O
characterized    O
by    O
extremely    O
high    O
numbers    O
of    O
circulating    O
platelets    O
.    O

Essential    B-BloodDyscrasia114053850
thrombocytosis    I-BloodDyscrasia114053850

Essential    B-BloodDyscrasia114053850
thrombocytosis    I-BloodDyscrasia114053850

Thrombocytapheresis    O
–    O
removal    O
of    O
platelets    O
in    O
people    O
with    O
symptoms    O
from    O
extreme    O
elevations    O
in    O
platelet    O
count    O
such    O
as    O
those    O
with    O
essential    B-BloodDyscrasia114053850
thrombocythemia    I-BloodDyscrasia114053850
or    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
.    O

Because    O
the    O
risks    O
of    O
warfarin    O
–    O
which    O
is    O
used    O
to    O
treat    O
blood    O
clots    O
–    O
in    O
a    O
relatively    O
young    O
and    O
otherwise    O
healthy    O
population    O
are    O
low    O
,    O
while    O
the    O
risk    O
of    O
adverse    O
physical    O
and    O
psychological    O
outcomes    O
for    O
untreated    O
transgender    O
patients    O
is    O
high    O
,    O
pro    O
-    O
thrombotic    O
mutations    O
(    O
such    O
as    O
factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
,    O
antithrombin    O
III    O
,    O
and    O
protein    B-BloodDyscrasia114053850
C    I-BloodDyscrasia114053850
or    O
S    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
)    O
are    O
not    O
absolute    O
contraindications    O
for    O
hormonal    O
therapy    O
.    O

Screening    O
for    O
protein    B-BloodDyscrasia114053850
C    I-BloodDyscrasia114053850
,    O
protein    B-BloodDyscrasia114053850
S    I-BloodDyscrasia114053850
,    O
or    O
antithrombin    O
III    O
deficiency    O
is    O
sometimes    O
recommended    O
but    O
these    O
are    O
more    O
usually    O
responsible    O
for    O
venous    O
thrombosis    O
than    O
arterial    O
problems    O
.    O

Among    O
researchers    O
using    O
the    O
term    O
,    O
it    O
has    O
been    O
described    O
as    O
a    O
coagulation    O
disorder    O
that    O
can    O
present    O
in    O
conjunction    O
with    O
protein    B-BloodDyscrasia114053850
S    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
and    O
Factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
.    O

In    O
May    O
2007    O
,    O
Susan    O
Hoover    O
,    O
Latimer    O
's    O
wife    O
,    O
announced    O
through    O
the    O
Camel    O
Productions    O
website    O
and    O
newsletter    O
that    O
Latimer    O
had    O
suffered    O
from    O
a    O
progressive    O
blood    O
disorder    O
polycythaemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
since    O
1992    O
,    O
which    O
had    O
later    O
progressed    O
to    O
myelofibrosis    O
.    O

This    O
happens    O
in    O
hematologic    O
disorders    O
like    O
chronic    B-BloodDyscrasia114053850
myelogeneous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
promyelocytic    B-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
and    O
also    O
the    O
hypereosinophilic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

He    O
had    O
been    O
diagnosed    O
in    O
1998    O
with    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
(    O
a    O
rare    O
blood    O
cancer    O
)    O
and    O
received    O
a    O
blood    O
marrow    O
transplant    O
soon    O
after    O
.    O

Particular    O
blood    O
disorders    O
,    O
especially    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
and    O
paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850

Polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850

Polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
a    O
condition    O
in    O
which    O
there    O
is    O
an    O
increase    O
in    O
the    O
number    O
of    O
red    O
blood    O
cells    O
in    O
the    O
body    O

Thrombocytapheresis    O
–    O
removal    O
of    O
platelets    O
in    O
people    O
with    O
symptoms    O
from    O
extreme    O
elevations    O
in    O
platelet    O
count    O
such    O
as    O
those    O
with    O
essential    B-BloodDyscrasia114053850
thrombocythemia    I-BloodDyscrasia114053850
or    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
.    O

Hematopoietic    O
ulcers    O
are    O
those    O
occurring    O
with    O
sickle    O
cell    O
anemia    O
,    O
congenital    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
thrombocytopenic    O
purpura    O
,    O
macroglobulinemia    B-BloodDyscrasia114053850
,    O
and    O
cryoglobulinemia    B-BloodDyscrasia114053850
.    O

It    O
is    O
often    O
misdiagnosed    O
as    O
polycythemia    O
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
hyperviscosity    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
or    O
sepsis    O
.    O

Dormant    O
cancer    O
cells    O
are    O
thought    O
to    O
be    O
present    O
in    O
early    O
tumor    O
progression    O
,    O
in    O
micrometastases    O
,    O
or    O
left    O
behind    O
in    O
minimal    B-BloodDyscrasia114053850
residual    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(MRD)    I-BloodDyscrasia114053850
after    O
what    O
was    O
thought    O
to    O
be    O
a    O
successful    O
treatment    O
of    O
the    O
primary    O
tumor    O
.    O

Diamond    O
–    O
Blackfan    O
anemia    O
is    O
characterized    O
by    O
normocytic    B-BloodDyscrasia114053850
or    O
macrocytic    O
anemia    B-BloodDyscrasia114053850
(    O
low    O
red    O
blood    O
cell    O
counts    O
)    O
with    O
decreased    O
erythroid    O
progenitor    O
cells    O
in    O
the    O
bone    O
marrow    O
.    O

Antiuricosuric    O
drugs    O
are    O
useful    O
for    O
treatment    O
of    O
hypouricemia    B-BloodDyscrasia114053850
and    O
perhaps    O
also    O
hyperuricosuria    O
,    O
but    O
are    O
contraindicated    O
in    O
persons    O
with    O
conditions    O
including    O
hyperuricemia    O
and    O
gout    O
.    O

Hypouricemia    B-BloodDyscrasia114053850

Congenital    B-BloodDyscrasia114053850
dyserythropoietic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
type    I-BloodDyscrasia114053850
II    I-BloodDyscrasia114053850
(    O
CDA    O
II    O
)    O
,    O
or    O
hereditary    B-BloodDyscrasia114053850
erythroblastic    I-BloodDyscrasia114053850
multinuclearity    I-BloodDyscrasia114053850
with    I-BloodDyscrasia114053850
positive    I-BloodDyscrasia114053850
acidified    I-BloodDyscrasia114053850
serum    I-BloodDyscrasia114053850
lysis    I-BloodDyscrasia114053850
test    I-BloodDyscrasia114053850
(    O
HEMPAS    O
)    O
is    O
a    O
rare    O
genetic    O
anemia    O
in    O
humans    O
characterized    O
by    O
hereditary    O
erythroblastic    O
multinuclearity    O
with    O
positive    O
acidified    O
serum    O
lysis    O
test    O
.    O

At    O
2.08    O
m    O
,    O
she    O
was    O
one    O
of    O
the    O
tallest    O
female    O
Chinese    O
basketball    O
players    O
ever    O
,    O
but    O
cerebral    O
thrombosis    O
and    O
anemia    B-BloodDyscrasia114053850
forced    O
her    O
to    O
retire    O
in    O
1985    O
at    O
the    O
age    O
of    O
22    O
.    O

Its    O
symptoms    O
include    O
profuse    O
diarrhoea    O
,    O
anaemia    B-BloodDyscrasia114053850
,    O
lethargy    O
,    O
and    O
often    O
result    O
in    O
death    O
if    O
untreated    O
.    O

Its    O
symptoms    O
include    O
profuse    O
diarrhoea    O
,    O
anaemia    B-BloodDyscrasia114053850
,    O
lethargy    O
,    O
and    O
often    O
result    O
in    O
death    O
if    O
untreated    O
.    O

Its    O
symptoms    O
include    O
fetid    O
diarrhoea    O
,    O
anaemia    B-BloodDyscrasia114053850
,    O
lethargy    O
,    O
and    O
often    O
result    O
in    O
death    O
if    O
untreated    O
.    O

It    O
is    O
often    O
accompanied    O
by    O
pronounced    O
diarrhoea    O
,    O
dehydration    O
,    O
oedema    O
,    O
polydipsia    O
,    O
anaemia    B-BloodDyscrasia114053850
,    O
listlessness    O
and    O
weight    O
loss    O
.    O

These    O
drugs    O
are    O
sometimes    O
used    O
with    O
ABVD    O
to    O
prevent    O
neutropenia    O
(    O
low    O
white    O
blood    O
cell    O
count    O
)    O
and    O
anemia    B-BloodDyscrasia114053850
related    O
to    O
the    O
chemotherapy    O
,    O
although    O
their    O
use    O
is    O
not    O
universal    O
.    O

In    O
failing    O
health    O
,    O
in    O
May    O
1956    O
he    O
was    O
submitted    O
to    O
the    O
South    O
Western    O
Hospital    O
in    O
Stockwell    O
with    O
a    O
burst    O
appendix    O
;    O
the    O
doctor    O
noted    O
that    O
he    O
had    O
also    O
been    O
suffering    O
from    O
anaemia    B-BloodDyscrasia114053850
,    O
bronchitis    O
,    O
high    O
blood    O
pressure    O
and    O
gall    O
stones    O
.    O

Infiltration    O
of    O
the    O
bone    O
marrow    O
may    O
cause    O
pallor    O
from    O
anemia    B-BloodDyscrasia114053850
.    O

In    O
rare    O
cases    O
,    O
a    O
highly    O
malignant    O
tumor    O
is    O
present    O
,    O
and    O
signs    O
may    O
include    O
loss    O
of    O
appetite    O
,    O
vomiting    O
,    O
diarrhea    O
,    O
and    O
anemia    B-BloodDyscrasia114053850
.    O

Many    O
of    O
the    O
women    O
later    O
began    O
to    O
suffer    O
from    O
anemia    B-BloodDyscrasia114053850
,    O
bone    O
fractures    O
and    O
necrosis    O
of    O
the    O
jaw    O
,    O
a    O
condition    O
now    O
known    O
as    O
radium    O
jaw    O
.    O

Hookworms    O
feed    O
on    O
blood    O
and    O
those    O
infected    O
with    O
hookworms    O
may    O
suffer    O
from    O
chronic    O
anaemia    B-BloodDyscrasia114053850
and    O
malnutrition    O
.    O

The    O
alkylation    O
effects    O
cause    O
damage    O
to    O
the    O
spleen    O
,    O
bone    O
marrow    O
,    O
and    O
lymph    O
nodes    O
,    O
which    O
causes    O
anemia    B-BloodDyscrasia114053850
,    O
low    O
white    O
cell    O
counts    O
,    O
and    O
internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
.    O

The    O
constellation    O
of    O
thrombocytopenia    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
leukopenia    O
is    O
common    O
in    O
patients    O
with    O
hepatosplenic    O
T    O
-    O
cell    O
lymphoma    O
.    O

Clinical    O
studies    O
have    O
shown    O
it    O
to    O
be    O
effective    O
in    O
treating    O
anemia    B-BloodDyscrasia114053850
,    O
osteoporosis    O
and    O
some    O
forms    O
of    O
neoplasia    O
including    O
breast    O
cancer    O
,    O
and    O
also    O
acts    O
as    O
a    O
progestin    O
-    O
based    O
contraceptive    O
.    O

However    O
,    O
serious    O
forms    O
can    O
result    O
in    O
stunted    O
growth    O
,    O
deformity    O
,    O
and    O
increased    O
likelihood    O
of    O
fractures    O
;    O
also    O
,    O
patients    O
suffer    O
anemia    B-BloodDyscrasia114053850
,    O
recurrent    O
infections    O
,    O
and    O
hepatosplenomegaly    O
due    O
to    O
bone    O
expansion    O
leading    O
to    O
bone    O
marrow    O
narrowing    O
and    O
extramedullary    O
hematopoiesis    O
.    O

If    O
complications    O
occur    O
in    O
children    O
,    O
patients    O
can    O
be    O
treated    O
with    O
vitamin    O
D.    O
Gamma    O
interferon    O
has    O
also    O
been    O
shown    O
to    O
be    O
effective    O
,    O
and    O
it    O
can    O
be    O
associated    O
to    O
vitamin    O
D.    O
Erythropoetin    O
has    O
been    O
used    O
to    O
treat    O
any    O
associated    O
anemia    B-BloodDyscrasia114053850
.    O

The    O
school    O
was    O
established    O
on    O
the    O
former    O
property    O
of    O
the    O
San    O
Fernando    O
Sanitarium    O
Company    O
,    O
which    O
in    O
1915    O
-    O
16    O
had    O
offered    O
"    O
A    O
Beautiful    O
Remedial    O
Home    O
for    O
the    O
Treatment    O
of    O
Non    O
-    O
Infectious    O
Diseases    O
"    O
like    O
"    O
anemia    B-BloodDyscrasia114053850
,    O
stomach    O
and    O
bowel    O
troubles    O
,    O
nervous    O
disorders    O
,    O
liver    O
and    O
kidney    O
affections    O
,    O
rheumatism    O
,    O
eczema    O
and    O
other    O
skin    O
diseases    O
,    O
high    O
and    O
low    O
blood    O
pressure    O
,    O
certain    O
forms    O
of    O
heart    O
disease    O
,    O
constipation    O
and    O
emaciation    O
.    O
"    O

An    O
abnormally    O
low    O
hematocrit    O
may    O
suggest    O
anemia    B-BloodDyscrasia114053850
,    O
a    O
decrease    O
in    O
the    O
total    O
amount    O
of    O
red    O
blood    O
cells    O
,    O
while    O
an    O
abnormally    O
high    O
hematocrit    O
is    O
called    O
polycythemia    O
.    O

There    O
is    O
also    O
often    O
anemia    B-BloodDyscrasia114053850
and    O
marked    O
elevation    O
of    O
the    O
ESR    O
or    O
C    O
-    O
reactive    O
protein    O
(    O
nonspecific    O
markers    O
of    O
inflammation    O
)    O
.    O

As    O
expected    O
,    O
this    O
malnutrition    O
resulted    O
in    O
many    O
positive    O
metabolic    O
adaptations    O
(    O
e.g.    O
decreased    O
body    O
fat    O
,    O
blood    O
pressure    O
,    O
improved    O
lipid    O
profile    O
,    O
low    O
serum    O
T3    O
concentration    O
,    O
and    O
decreased    O
resting    O
heart    O
rate    O
and    O
whole    O
-    O
body    O
resting    O
energy    O
expenditure    O
)    O
,    O
but    O
also    O
caused    O
a    O
wide    O
range    O
of    O
negative    O
effects    O
,    O
such    O
as    O
anemia    B-BloodDyscrasia114053850
,    O
lower    O
extremity    O
edema    O
,    O
muscle    O
wasting    O
,    O
weakness    O
,    O
neurological    O
deficits    O
,    O
dizziness    O
,    O
irritability    O
,    O
lethargy    O
,    O
and    O
depression    O
.    O

Complications    O
can    O
include    O
anemia    B-BloodDyscrasia114053850
and    O
kidney    O
stones    O
.    O

These    O
may    O
appear    O
as    O
anemia    B-BloodDyscrasia114053850
,    O
hyperkeratosis    O
(    O
scaling    O
of    O
the    O
skin    O
)    O
,    O
easy    O
bruising    O
,    O
muscle    O
spasms    O
,    O
poor    O
blood    O
clotting    O
,    O
and    O
bone    O
pain    O
.    O

Elderly    O
,    O
anemic    B-BloodDyscrasia114053850
and    O
malnourished    O
patients    O
may    O
absorb    O
the    O
suture    O
more    O
quickly    O
.    O

Megaloblastic    O
anemia    O
(    O
or    O
megaloblastic    O
anaemia    O
)    O
is    O
an    O
anemia    B-BloodDyscrasia114053850
(    O
of    O
macrocytic    O
classification    O
)    O
that    O
results    O
from    O
inhibition    O
of    O
DNA    O
synthesis    O
during    O
red    O
blood    O
cell    O
production    O
.    O

If    O
the    O
blood    O
is    O
not    O
visible    O
,    O
it    O
is    O
still    O
possible    O
for    O
the    O
patient    O
to    O
develop    O
anemia    B-BloodDyscrasia114053850
due    O
to    O
gradually    O
developing    O
iron    O
deficiency    O
.    O

Acepromazine    O
also    O
lowers    O
blood    O
pressure    O
,    O
and    O
should    O
therefore    O
be    O
used    O
with    O
caution    O
in    O
horses    O
that    O
are    O
experiencing    O
anemia    B-BloodDyscrasia114053850
,    O
dehydration    O
,    O
shock    O
,    O
or    O
colic    O
.    O

Prior    O
to    O
each    O
donation    O
,    O
the    O
donor    O
's    O
iron    O
level    O
is    O
checked    O
to    O
make    O
sure    O
they    O
are    O
not    O
anaemic    B-BloodDyscrasia114053850
.    O

=    O
=    O
=    O
(    O
D50–D53    O
)    O
Nutritional    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
=    O
=    O
=    O

Vitamin    O
B12    O
deficiency    O
anaemia    B-BloodDyscrasia114053850

Vitamin    O
B12    O
deficiency    O
anaemia    B-BloodDyscrasia114053850
due    O
to    O
intrinsic    O
factor    O
deficiency    O

Folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    B-BloodDyscrasia114053850

Dietary    B-BloodDyscrasia114053850
folate    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Drug-induced    B-BloodDyscrasia114053850
folate    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Other    O
folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemias    I-BloodDyscrasia114053850

Protein    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Anaemia    B-BloodDyscrasia114053850
due    O
to    O
enzyme    O
disorders    O

Anaemia    B-BloodDyscrasia114053850
due    O
to    O
glucose-6-phosphate    O
dehydrogenase    O
(    O
G6PD    O
)    O
deficiency    O

Anaemia    B-BloodDyscrasia114053850
due    O
to    O
other    O
disorders    O
of    O
glutathione    O
metabolism    O

Anaemia    B-BloodDyscrasia114053850
due    O
to    O
disorders    O
of    O
glycolytic    O
enzymes    O

Anaemia    B-BloodDyscrasia114053850
due    O
to    O
disorders    O
of    O
nucleotide    O
metabolism    O

Other    O
anaemias    B-BloodDyscrasia114053850
due    O
to    O
enzyme    O
disorders    O

Anaemia    B-BloodDyscrasia114053850
due    O
to    O
enzyme    O
disorder    O
,    O
unspecified    O

=    O
=    O
=    O
(    O
D60–D64    O
)    O
Aplastic    O
and    O
other    O
anaemia    B-BloodDyscrasia114053850
=    O
=    O
=    O

Hypoplastic    B-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850
NOS    O

Anaemia    B-BloodDyscrasia114053850
in    O
chronic    O
diseases    O
classified    O
elsewhere    O

Other    O
anaemias    B-BloodDyscrasia114053850

Other    O
specified    O
anaemias    B-BloodDyscrasia114053850

Anaemia    B-BloodDyscrasia114053850
,    O
unspecified    O

The    O
substance    O
is    O
used    O
in    O
the    O
production    O
of    O
jet    O
fuel    O
,    O
in    O
pesticides    O
,    O
plastics    O
,    O
pulp    O
mills    O
and    O
oil    O
refineries    O
and    O
can    O
cause    O
irritation    O
of    O
the    O
skin    O
and    O
eyes    O
,    O
nausea    O
,    O
vomiting    O
,    O
increases    O
in    O
pulse    O
rate    O
and    O
blood    O
pressure    O
,    O
hemolytic    O
anemia    B-BloodDyscrasia114053850
,    O
respiratory    O
problems    O
,    O
narcosis    O
,    O
dizziness    O
,    O
convulsions    O
,    O
staggering    O
gait    O
and    O
weakness    O
in    O
the    O
muscles    O
.    O

Ruminants    O
that    O
consume    O
high    O
levels    O
of    O
molybdenum    O
suffer    O
from    O
diarrhea    O
,    O
stunted    O
growth    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
achromotrichia    O
(    O
loss    O
of    O
fur    O
pigment    O
)    O
.    O

Today    O
CIM    O
produces    O
biopharmaceutical    O
products    O
,    O
such    O
as    O
anti    O
-    O
CD3    O
monoclonal    O
antibody    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
organ    O
transplant    O
rejection    O
,    O
human    O
recombinant    O
erythropoietin    O
for    O
the    O
treatment    O
of    O
anemia    B-BloodDyscrasia114053850
,    O
granulocyte    O
colony    O
-    O
stimulating    O
factor    O
for    O
the    O
treatment    O
of    O
neutropenia    O
,    O
and    O
a    O
humanized    O
monoclonal    O
antibody    O
that    O
recognizes    O
the    O
epidermal    O
growth    O
factor    O
receptor    O
for    O
cancer    O
treatment    O
,    O
as    O
well    O
as    O
other    O
monoclonal    O
antibodies    O
for    O
tumor    O
imaging    O
.    O

DBA    O
causes    O
low    O
red    O
blood    O
cell    O
counts    O
(    O
anemia    B-BloodDyscrasia114053850
)    O
,    O
without    O
substantially    O
affecting    O
the    O
other    O
blood    O
components    O
(    O
the    O
platelets    O
and    O
the    O
white    O
blood    O
cells    O
)    O
,    O
which    O
are    O
usually    O
normal    O
.    O

Diamond    O
–    O
Blackfan    O
anemia    O
is    O
characterized    O
by    O
normocytic    B-BloodDyscrasia114053850
or    O
macrocytic    O
anemia    B-BloodDyscrasia114053850
(    O
low    O
red    O
blood    O
cell    O
counts    O
)    O
with    O
decreased    O
erythroid    O
progenitor    O
cells    O
in    O
the    O
bone    O
marrow    O
.    O

DKC    O
can    O
be    O
characterized    O
by    O
cutaneous    O
pigmentation    O
,    O
premature    O
graying    O
,    O
dystrophy    O
of    O
the    O
nails    O
,    O
leukoplakia    O
of    O
the    O
oral    O
mucosa    O
,    O
continuous    O
lacrimation    O
due    O
to    O
atresia    O
of    O
the    O
lacrimal    O
ducts    O
,    O
often    O
thrombocytopenia    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
testicular    O
atrophy    O
in    O
the    O
male    O
carriers    O
,    O
and    O
predisposition    O
to    O
cancer    O
.    O

These    O
factors    O
conspire    O
to    O
produce    O
a    O
hemoglobin    O
variant    O
that    O
does    O
not    O
provide    O
sufficient    O
oxygen    O
and    O
manifests    O
itself    O
as    O
low    O
oxygen    O
saturation    O
,    O
episodes    O
of    O
cyanosis    O
and    O
anemia    B-BloodDyscrasia114053850
(    O
Abdulmalik    O
et    O
al    O
.    O
,    O

He    O
was    O
author    O
of    O
"    O
Blood    O
-    O
Vessel    O
Surgery    O
and    O
its    O
Applications    O
"    O
(    O
1912    O
)    O
and    O
of    O
contributions    O
on    O
blood    O
reactions    O
and    O
alterations    O
,    O
resuscitation    O
,    O
cerebral    O
and    O
other    O
anæmias    B-BloodDyscrasia114053850
,    O
isolated    O
and    O
ungrafted    O
tissues    O
,    O
and    O
sutures    O
and    O
anastomosis    O
of    O
blood    O
vessels    O
.    O

She    O
wrote    O
that    O
she    O
had    O
had    O
a    O
ruptured    O
appendix    O
and    O
anemia    B-BloodDyscrasia114053850
.    O

Diseases    O
that    O
may    O
present    O
similar    O
to    O
an    O
anxiety    O
disorder    O
,    O
including    O
certain    O
endocrine    O
diseases    O
(    O
hypo-    O
and    O
hyperthyroidism    O
,    O
hyperprolactinemia    O
)    O
,    O
metabolic    O
disorders    O
(    O
diabetes    O
)    O
,    O
deficiency    O
states    O
(    O
low    O
levels    O
of    O
vitamin    O
D    O
,    O
B2    O
,    O
B12    O
,    O
folic    O
acid    O
)    O
,    O
gastrointestinal    O
diseases    O
(    O
celiac    O
disease    O
,    O
non    O
-    O
celiac    O
gluten    O
sensitivity    O
,    O
inflammatory    O
bowel    O
disease    O
)    O
,    O
heart    O
diseases    O
,    O
blood    O
diseases    O
(    O
anemia    B-BloodDyscrasia114053850
)    O
,    O
and    O
brain    O
degenerative    O
diseases    O
(    O
Parkinson    O
's    O
disease    O
,    O
dementia    O
,    O
multiple    O
sclerosis    O
,    O
Huntington    O
's    O
disease    O
)    O
.    O

Consequences    O
of    O
parasitic    O
infection    O
can    O
include    O
anemia    B-BloodDyscrasia114053850
due    O
to    O
blood    O
loss    O
and    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
malnutrition    O
,    O
growth    O
retardation    O
,    O
invasive    O
disease    O
,    O
and    O
death    O
.    O

Anemia    B-BloodDyscrasia114053850
is    O
a    O
common    O
blood    O
disorder    O
worldwide    O
.    O

On    O
May    O
13    O
,    O
1985    O
,    O
Joy    O
died    O
from    O
acute    O
anemia    B-BloodDyscrasia114053850
at    O
the    O
High    O
Ridge    O
House    O
Christian    O
Science    O
nursing    O
home    O
in    O
Riverdale    O
,    O
Bronx    O
,    O
New    O
York    O
.    O

Without    O
daylight    O
the    O
rhubarb    O
leaves    O
are    O
an    O
anaemic    B-BloodDyscrasia114053850
green    O
-    O
yellow    O
,    O
and    O
the    O
stalks    O
,    O
measuring    O
two    O
feet    O
(    O
60    O
cm    O
)    O
,    O
are    O
smooth    O
textured    O
and    O
crimson    O
.    O

In    O
more    O
extreme    O
cases    O
,    O
anemia    B-BloodDyscrasia114053850
can    O
result    O
from    O
the    O
presence    O
of    O
the    O
louse    O
.    O

Beginning    O
to    O
crave    O
blood    O
,    O
as    O
everyday    O
food    O
no    O
longer    O
cures    O
his    O
hunger    O
,    O
Jacob    O
suspects    O
he    O
may    O
be    O
a    O
vampire    O
,    O
though    O
his    O
physician    O
,    O
Dr.    O
Barnes    O
(    O
Kevin    O
McCorkle    O
)    O
,    O
diagnoses    O
him    O
to    O
be    O
anemic    B-BloodDyscrasia114053850
.    O

Infants    O
and    O
young    O
children    O
experiencing    O
dehydration    O
induced    O
RVT    O
,    O
may    O
experience    O
dehydration    O
symptoms    O
(    O
dry    O
mouth    O
,    O
low    O
urine    O
output    O
,    O
loss    O
of    O
skin    O
turgidity    O
)    O
as    O
while    O
as    O
vomiting    O
,    O
nausea    O
and    O
fever    O
,    O
and    O
the    O
usual    O
RVT    O
symptoms    O
like    O
flank    O
pain    O
,    O
blood    O
in    O
the    O
urine    O
,    O
anaemia    B-BloodDyscrasia114053850
,    O
edema    O
,    O
enlarged    O
kidneys    O
and    O
kidney    O
failure    O
.    O

Anemia    B-BloodDyscrasia114053850

High    O
lead    O
levels    O
cause    O
decreased    O
vitamin    O
D    O
and    O
haemoglobin    O
synthesis    O
as    O
well    O
as    O
anemia    B-BloodDyscrasia114053850
,    O
acute    O
central    O
nervous    O
system    O
disorders    O
,    O
and    O
possibly    O
death    O
.    O

She    O
agreed    O
to    O
testify    O
against    O
Steinberg    O
,    O
and    O
medical    O
examination    O
revealed    O
that    O
Nussbaum    O
was    O
anemic    B-BloodDyscrasia114053850
,    O
malnourished    O
,    O
and    O
suffering    O
from    O
broken    O
bones    O
and    O
chronic    O
infections    O
.    O

In    O
1904    O
he    O
delivered    O
the    O
prestigious    O
Goulstonian    O
lectures    O
on    O
anaemia    B-BloodDyscrasia114053850
of    O
infancy    O
to    O
the    O
Royal    O
College    O
of    O
Physicians    O
and    O
in    O
1931    O
gave    O
their    O
Harveian    O
Oration    O
.    O

CRHP    O
trained    O
the    O
Village    O
Health    O
Workers    O
particularly    O
in    O
the    O
methods    O
pregnancy    O
care    O
,    O
such    O
as    O
monitoring    O
blood    O
-    O
pressure    O
and    O
checking    O
for    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
in    O
safe    O
and    O
hygienic    O
childbirth    O
.    O

Hypothyroidism    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
coeliac    O
disease    O
(    O
that    O
can    O
occur    O
without    O
gastrointestinal    O
symptoms    O
)    O
,    O
diabetes    O
and    O
certain    O
psychiatric    O
disorders    O
are    O
a    O
few    O
of    O
the    O
diseases    O
that    O
must    O
be    O
ruled    O
out    O
if    O
the    O
patient    O
presents    O
with    O
appropriate    O
symptoms    O
.    O

Traditional    O
herbal    O
medicine    O
stem    O
and    O
root    O
dry    O
plant    O
for    O
the    O
treatment    O
of    O
anemia    B-BloodDyscrasia114053850
,    O
anorexia    O
,    O
weakness    O
,    O
anxiety    O
,    O
depression    O
and    O
diabetes    O
.    O

Cachexia    O
physically    O
weakens    O
patients    O
to    O
a    O
state    O
of    O
immobility    O
stemming    O
from    O
loss    O
of    O
appetite    O
,    O
asthenia    O
,    O
and    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
response    O
to    O
standard    O
treatment    O
is    O
usually    O
poor    O
.    O

In    O
a    O
fully    O
developed    O
stage    O
,    O
the    O
patient    O
shows    O
emaciation    O
and    O
anaemia    B-BloodDyscrasia114053850
.    O

He    O
is    O
also    O
credited    O
with    O
discovering    O
Cabot    O
rings    O
,    O
and    O
for    O
describing    O
,    O
along    O
with    O
his    O
colleague    O
,    O
Locke    O
,    O
the    O
eponymous    O
Cabot    O
-    O
Locke    O
murmur    O
,    O
a    O
diastolic    O
murmur    O
occasionally    O
heard    O
in    O
severe    O
anemia    B-BloodDyscrasia114053850
,    O
unrelated    O
to    O
heart    O
valve    O
abnormalities    O
.    O

People    O
with    O
recurrent    O
boils    O
are    O
as    O
well    O
more    O
likely    O
to    O
have    O
a    O
positive    O
family    O
history    O
,    O
take    O
antibiotics    O
,    O
and    O
to    O
have    O
been    O
hospitalised    O
,    O
anemic    B-BloodDyscrasia114053850
,    O
or    O
diabetic    O
;    O
they    O
are    O
also    O
more    O
likely    O
to    O
have    O
associated    O
skin    O
diseases    O
and    O
multiple    O
lesions    O
.    O

It    O
is    O
also    O
used    O
in    O
combination    O
with    O
5-fluorouracil    O
to    O
treat    O
colorectal    O
cancer    O
,    O
may    O
be    O
used    O
to    O
treat    O
folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
that    O
results    O
in    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
methanol    O
poisoning    O
.    O

As    O
it    O
advances    O
,    O
CLL    O
results    O
in    O
swollen    O
lymph    O
nodes    O
,    O
spleen    O
,    O
and    O
liver    O
,    O
and    O
eventually    O
anemia    B-BloodDyscrasia114053850
and    O
infections    O
.    O

In    O
some    O
individuals    O
,    O
the    O
disease    O
comes    O
to    O
light    O
only    O
after    O
the    O
cancerous    O
cells    O
overwhelm    O
the    O
bone    O
marrow    O
resulting    O
in    O
anemia    B-BloodDyscrasia114053850
producing    O
tiredness    O
or    O
weakness    O
.    O

"    O
Stage    O
0    O
"    O
:    O
characterized    O
by    O
absolute    O
lymphocytosis    O
(    O
>    O
15,000/mm3    O
)    O
without    O
adenopathy    O
,    O
hepatosplenomegaly    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
or    O
thrombocytopenia    O

Orthostatic    O
hypotension    O
may    O
be    O
caused    O
by    O
low    O
blood    O
volume    O
,    O
resulting    O
from    O
bleeding    O
,    O
the    O
excessive    O
use    O
of    O
diuretics    O
,    O
vasodilators    O
,    O
or    O
other    O
types    O
of    O
drugs    O
,    O
dehydration    O
,    O
or    O
prolonged    O
bed    O
rest(immobility    O
)    O
;    O
as    O
well    O
as    O
occurring    O
in    O
people    O
with    O
anemia    B-BloodDyscrasia114053850
.    O

Some    O
of    O
the    O
most    O
common    O
diseases    O
that    O
these    O
young    O
children    O
are    O
facing    O
are    O
hunger    O
:    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    B-BloodDyscrasia114053850
,    O
vitamin    O
A    O
deficiency    O
,    O
and    O
mentally    O
impaired    O
(    O
iodine    O
deficiency    O
)    O
,    O
and    O
childhood    O
diseases    O
:    O
acute    O
respiratory    O
infections    O
,    O
diarrhoeal    O
disease    O
,    O
and    O
malaria    O
.    O

Another    O
successful    O
collaboration    O
,    O
this    O
one    O
with    O
researchers    O
at    O
Harvard    O
University    O
and    O
the    O
University    O
of    O
Rochester    O
for    O
drugs    O
to    O
treat    O
anemia    B-BloodDyscrasia114053850
,    O
built    O
on    O
the    O
lessons    O
learned    O
from    O
the    O
insulin    O
project    O
and    O
earned    O
the    O
university    O
scientists    O
,    O
George    O
R.    O
Minot    O
,    O
William    O
P.    O
Murphy    O
,    O
and    O
George    O
Whipple    O
,    O
the    O
Nobel    O
Prize    O
for    O
medicine    O
in    O
1934    O
.    O

Chemotherapy    O
-    O
induced    O
peripheral    O
neuropathy    O
(    O
a    O
progressive    O
,    O
enduring    O
and    O
often    O
irreversible    O
tingling    O
numbness    O
,    O
intense    O
pain    O
,    O
and    O
hypersensitivity    O
to    O
cold    O
,    O
beginning    O
in    O
the    O
hands    O
and    O
feet    O
and    O
sometimes    O
involving    O
the    O
arms    O
and    O
legs    O
)    O
,    O
lowered    O
resistance    O
to    O
infection    O
,    O
bruising    O
or    O
bleeding    O
,    O
anaemia    B-BloodDyscrasia114053850
,    O
constipation    O
,    O
vomitings    O
,    O
diarrhea    O
,    O
nausea    O
,    O
tiredness    O
and    O
a    O
general    O
feeling    O
of    O
weakness    O
(    O
asthenia    O
)    O
,    O
inflammation    O
of    O
the    O
vein    O
into    O
which    O
it    O
was    O
injected    O
(    O
phlebitis    O
)    O
.    O

His    O
health    O
fluctuated    O
for    O
several    O
weeks    O
but    O
progressively    O
worsened    O
with    O
anaemia    B-BloodDyscrasia114053850
and    O
low    O
blood    O
pressure    O
due    O
to    O
heart    O
and    O
kidney    O
complications    O
,    O
internal    O
bleeding    O
,    O
fluid    O
on    O
his    O
lungs    O
,    O
and    O
blood    O
in    O
his    O
faeces    O
and    O
urine    O
which    O
caused    O
a    O
haemoglobin    O
drop    O
.    O

Common    O
causes    O
of    O
cellular    O
hypoxia    O
resulting    O
in    O
elevated    O
levels    O
of    O
EPO    O
(    O
up    O
to    O
10,000    O
mU    O
/    O
ml    O
)    O
include    O
any    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
hypoxemia    O
due    O
to    O
chronic    O
lung    O
disease    O
.    O

ESAs    O
are    O
used    O
in    O
the    O
treatment    O
of    O
anemia    B-BloodDyscrasia114053850
in    O
chronic    O
kidney    O
disease    O
,    O
anemia    O
in    O
myelodysplasia    B-BloodDyscrasia114053850
,    O
and    O
in    O
anemia    O
from    O
cancer    O
chemotherapy    O
.    O

Erythropoietins    O
available    O
for    O
use    O
as    O
therapeutic    O
agents    O
are    O
produced    O
by    O
recombinant    O
DNA    O
technology    O
in    O
cell    O
culture    O
,    O
and    O
include    O
Epogen    O
/    O
Procrit    O
(    O
epoetin    O
alfa    O
)    O
and    O
Aranesp    O
(    O
darbepoetin    O
alfa    O
)    O
;    O
they    O
are    O
used    O
in    O
treating    O
anemia    B-BloodDyscrasia114053850
resulting    O
from    O
chronic    O
kidney    O
disease    O
,    O
chemotherapy    O
induced    O
anemia    O
in    O
patients    O
with    O
cancer    O
,    O
inflammatory    O
bowel    O
disease    O
(    O
Crohn    O
's    O
disease    O
and    O
ulcerative    O
colitis    O
)    O
and    O
myelodysplasia    B-BloodDyscrasia114053850
from    O
the    O
treatment    O
of    O
cancer    O
(    O
chemotherapy    O
and    O
radiation    O
)    O
.    O

A    O
number    O
of    O
medical    O
conditions    O
are    O
subject    O
to    O
exacerbation    O
at    O
menstruation    O
,    O
a    O
process    O
called    O
"    O
menstrual    O
magnification    O
.    O
"    O
These    O
conditions    O
may    O
lead    O
the    O
woman    O
to    O
believe    O
that    O
she    O
has    O
PMS    O
,    O
when    O
the    O
underlying    O
disorder    O
may    O
be    O
some    O
other    O
problem    O
,    O
such    O
as    O
anemia    B-BloodDyscrasia114053850
,    O
hypothyroidism    O
,    O
eating    O
disorders    O
and    O
substance    O
abuse    O
.    O

Classified    O
as    O
an    O
inborn    O
error    O
of    O
metabolism    O
,    O
mevalonate    O
kinase    O
deficiency    O
usually    O
results    O
in    O
developmental    O
delay    O
,    O
hypotonia    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
hepatosplenomegaly    O
,    O
various    O
dysmorphic    O
features    O
,    O
mental    O
retardation    O
,    O
an    O
overall    O
failure    O
to    O
thrive    O
and    O
several    O
other    O
features    O
.    O

At    O
the    O
same    O
time    O
,    O
since    O
DNA    O
synthetic    O
-    O
sensitive    O
tests    O
for    O
anemia    B-BloodDyscrasia114053850
and    O
erythrocyte    O
size    O
are    O
routinely    O
done    O
in    O
even    O
simple    O
medical    O
test    O
clinics    O
(    O
so    O
that    O
these    O
folate    O
-    O
mediated    O
biochemical    O
effects    O
are    O
more    O
often    O
directly    O
detected    O
)    O
,    O
the    O
MTR    O
-    O
dependent    O
effects    O
of    O
B12    O
deficiency    O
are    O
becoming    O
apparent    O
not    O
as    O
anemia    O
due    O
to    O
DNA    O
-    O
synthetic    O
problems    O
(    O
as    O
they    O
were    O
classically    O
)    O
,    O
but    O
now    O
mainly    O
as    O
a    O
simple    O
and    O
less    O
obvious    O
elevation    O
of    O
homocysteine    O
in    O
the    O
blood    O
and    O
urine    O
(    O
homocysteinuria    B-BloodDyscrasia114053850
)    O
.    O

George    O
Whipple    O
had    O
been    O
doing    O
experiments    O
in    O
which    O
he    O
induced    O
anemia    B-BloodDyscrasia114053850
in    O
dogs    O
by    O
bleeding    O
them    O
,    O
and    O
then    O
fed    O
them    O
various    O
foods    O
to    O
observe    O
which    O
diets    O
allowed    O
them    O
fastest    O
recovery    O
from    O
the    O
anemia    O
produced    O
.    O

Anything    O
increasing    O
the    O
blood    O
flow    O
velocity    O
such    O
as    O
fever    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
or    O
hyperthyroidism    O
,    O
can    O
increase    O
the    O
amplitude    O
of    O
the    O
bruit    O
.    O

They    O
are    O
used    O
in    O
conditions    O
where    O
reduced    O
blood    O
cell    O
production    O
causes    O
anemia    B-BloodDyscrasia114053850
,    O
such    O
as    O
advanced    O
chronic    O
kidney    O
disease    O
or    O
chemotherapy    O
.    O

Medical    O
speciality    O
professional    O
organizations    O
do    O
not    O
recommend    O
the    O
use    O
of    O
ESAs    O
in    O
people    O
with    O
chronic    O
kidney    O
disease    O
(    O
CKD    O
)    O
who    O
have    O
hemoglobin    O
levels    O
greater    O
than    O
10    O
g    O
/    O
dL    O
and    O
do    O
not    O
have    O
anemia    B-BloodDyscrasia114053850
symptoms    O
.    O

The    O
most    O
common    O
adverse    O
reactions    O
(    O
≥30%    O
occurrence    O
,    O
leading    O
to    O
a    O
5%    O
treatment    O
discontinuation    O
rate    O
)    O
observed    O
with    O
sirolimus    O
in    O
clinical    O
studies    O
of    O
organ    O
rejection    O
prophylaxis    O
in    O
individuals    O
with    O
kidney    O
transplants    O
include    O
:    O
peripheral    O
edema    O
,    O
hypercholesterolemia    O
,    O
abdominal    O
pain    O
,    O
headache    O
,    O
nausea    O
,    O
diarrhea    O
,    O
pain    O
,    O
constipation    O
,    O
hypertriglyceridemia    O
,    O
hypertension    O
,    O
increased    O
creatinine    O
,    O
fever    O
,    O
urinary    O
tract    O
infection    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
arthralgia    O
,    O
and    O
thrombocytopenia    O
.    O

Common    O
adverse    O
drug    O
reactions    O
(    O
≥1%    O
of    O
patients    O
)    O
associated    O
with    O
mycophenolate    O
therapy    O
include    O
diarrhea    O
,    O
nausea    O
,    O
vomiting    O
,    O
joint    O
pain    O
;    O
infections    O
,    O
leukopenia    O
,    O
and/or    O
anemia    B-BloodDyscrasia114053850
reflect    O
the    O
immunosuppressive    O
and    O
myelosuppressive    O
nature    O
of    O
the    O
drug    O
.    O

This    O
condition    O
can    O
rapidly    O
lead    O
to    O
life    O
-    O
threatening    O
infection    O
,    O
as    O
the    O
body    O
can    O
not    O
produce    O
leukocytes    O
in    O
response    O
to    O
invading    O
bacteria    O
and    O
viruses    O
,    O
as    O
well    O
as    O
leading    O
to    O
anaemia    B-BloodDyscrasia114053850
due    O
to    O
a    O
lack    O
of    O
red    O
blood    O
cells    O
and    O
spontaneous    O
severe    O
bleeding    O
due    O
to    O
deficiency    O
of    O
platelets    O
.    O

In    O
immunocompromised    O
patients    O
,    O
B19    O
infection    O
may    O
persist    O
for    O
months    O
,    O
leading    O
to    O
chronic    O
anemia    B-BloodDyscrasia114053850
with    O
B19    O
viremia    O
due    O
to    O
chronic    O
marrow    O
suppression    O
.    O

Anemia    B-BloodDyscrasia114053850

Anemia    B-BloodDyscrasia114053850
and    O
arthritis    O
were    O
common    O
.    O

The    O
bark    O
has    O
been    O
used    O
as    O
a    O
poison    O
antidote    O
and    O
a    O
treatment    O
for    O
leprosy    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
infertility    O
,    O
gonorrhea    O
,    O
and    O
malaria    O
.    O

Sideroblastic    O
anemia    O
or    O
sideroachrestic    O
anemia    O
is    O
a    O
form    O
of    O
anemia    B-BloodDyscrasia114053850
in    O
which    O
the    O
bone    O
marrow    O
produces    O
ringed    O
sideroblasts    O
rather    O
than    O
healthy    O
red    O
blood    O
cells    O
(    O
erythrocytes    O
)    O
.    O

Anemia    B-BloodDyscrasia114053850

This    O
causes    O
a    O
deficiency    O
of    O
all    O
three    O
blood    O
cell    O
types    O
(    O
pancytopenia    O
)    O
:    O
red    O
blood    O
cells    O
(    O
anemia    B-BloodDyscrasia114053850
)    O
,    O
white    O
blood    O
cells    O
(    O
leukopenia    O
)    O
,    O
and    O
platelets    O
(    O
thrombocytopenia    O
)    O
.    O

Anemia    B-BloodDyscrasia114053850
may    O
lead    O
to    O
malaise    O
,    O
pallor    O
and    O
associated    O
symptoms    O
such    O
as    O
palpitations    O
.    O

These    O
are    O
difficult    O
to    O
distinguish    O
from    O
the    O
red    O
marrow    O
hyperplasia    O
of    O
hematopoiesis    O
,    O
as    O
can    O
occur    O
with    O
tobacco    O
smoking    O
,    O
chronically    O
anemic    B-BloodDyscrasia114053850
disease    O
states    O
like    O
sickle    O
cell    O
anemia    O
or    O
beta    B-BloodDyscrasia114053850
thalassemia    I-BloodDyscrasia114053850
,    O
medications    O
such    O
as    O
granulocyte    O
colony    O
-    O
stimulating    O
factors    O
,    O
or    O
during    O
recovery    O
from    O
chronic    O
nutritional    O
anemias    O
or    O
therapeutic    O
bone    O
marrow    O
suppression    O
.    O

Bone    O
marrow    O
examination    O
is    O
used    O
in    O
the    O
diagnosis    O
of    O
a    O
number    O
of    O
conditions    O
,    O
including    O
leukemia    O
,    O
multiple    O
myeloma    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
pancytopenia    O
.    O

It    O
is    O
recommended    O
when    O
people    O
either    O
do    O
not    O
respond    O
well    O
to    O
treatment    O
or    O
have    O
alarm    O
symptoms    O
,    O
including    O
dysphagia    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
blood    O
in    O
the    O
stool    O
(    O
detected    O
chemically    O
)    O
,    O
wheezing    O
,    O
weight    O
loss    O
,    O
or    O
voice    O
changes    O
.    O

confirmation    O
of    O
a    O
diagnosis    O
,    O
most    O
commonly    O
by    O
performing    O
a    O
biopsy    O
to    O
check    O
for    O
conditions    O
such    O
as    O
anemia    B-BloodDyscrasia114053850
,    O
bleeding    O
,    O
inflammation    O
,    O
and    O
cancers    O
of    O
the    O
digestive    O
system    O
.    O

Injectable    O
cladribine    O
suppresses    O
the    O
body    O
's    O
ability    O
to    O
make    O
new    O
blood    O
cells    O
(    O
called    O
Myelosuppression    O
)    O
;    O
data    O
from    O
HCL    O
studies    O
showed    O
that    O
about    O
70%    O
of    O
people    O
taking    O
the    O
drug    O
had    O
fewer    O
white    O
blood    O
cells    O
and    O
about    O
30%    O
developed    O
infections    O
and    O
some    O
of    O
those    O
progressed    O
to    O
septic    O
shock    O
;    O
about    O
40%    O
of    O
people    O
taking    O
the    O
drug    O
had    O
fewer    O
red    O
blood    O
cells    O
and    O
became    O
severely    O
anemic    B-BloodDyscrasia114053850
;    O
and    O
about    O
10%    O
of    O
people    O
had    O
too    O
few    O
platelets    O
.    O

As    O
the    O
name    O
implies    O
,    O
it    O
causes    O
severe    O
anemia    B-BloodDyscrasia114053850
of    O
infected    O
fish    O
.    O

As    O
the    O
name    O
implies    O
,    O
it    O
causes    O
severe    O
anemia    B-BloodDyscrasia114053850
of    O
infected    O
fish    O
.    O

Disaggregated    O
data    O
by    O
gender    O
is    O
rare    O
,    O
but    O
research    O
suggests    O
that    O
as    O
a    O
result    O
of    O
the    O
Asian    O
crisis    O
of    O
1997    O
-    O
99    O
childhood    O
anemia    B-BloodDyscrasia114053850
rose    O
by    O
50%-65%    O
,    O
and    O
maternal    O
anemia    O
by    O
15%-19%    O
in    O
Indonesia    O
,    O
while    O
maternal    O
anemia    O
increased    O
by    O
22%    O
in    O
Thailand    O
.    O

Dakota    O
was    O
n't    O
focused    O
or    O
aware    O
of    O
her    O
body    O
,    O
and    O
Colin    O
said    O
Jamie    O
had    O
no    O
energy    O
and    O
"    O
looked    O
anaemic    B-BloodDyscrasia114053850
"    O
.    O

The    O
disease    O
progresses    O
through    O
four    O
distinct    O
phases    O
;    O
an    O
initial    O
incubation    O
phase    O
of    O
between    O
a    O
few    O
days    O
up    O
to    O
three    O
months    O
with    O
little    O
or    O
no    O
symptoms    O
;    O
an    O
invasive    O
or    O
acute    O
phase    O
which    O
may    O
manifest    O
with    O
:    O
fever    O
,    O
malaise    O
,    O
abdominal    O
pain    O
,    O
gastrointestinal    O
symptoms    O
,    O
urticaria    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
jaundice    O
,    O
and    O
respiratory    O
symptoms    O
.    O

Anaemia    B-BloodDyscrasia114053850

In    O
blood    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
hypoalbuminemia    O
,    O
and    O
eosinophilia    O
may    O
be    O
observed    O
in    O
all    O
types    O
of    O
fasciolosis    O
.    O

In    O
heavy    O
infections    O
,    O
symptoms    O
can    O
include    O
abdominal    O
pain    O
,    O
chronic    O
diarrhea    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
ascites    O
,    O
toxemia    O
,    O
allergic    O
responses    O
,    O
sensitization    O
caused    O
by    O
the    O
absorption    O
of    O
the    O
worms    O
'    O
allergenic    O
metabolites    O
(    O
may    O
eventually    O
cause    O
death    O
of    O
patient    O
)    O
,    O
and    O
intestinal    O
obstruction    O
.    O

Babies    O
exposed    O
"    O
in    O
utero    O
"    O
can    O
have    O
deformities    O
,    O
delays    O
in    O
development    O
,    O
or    O
seizures    O
along    O
with    O
many    O
other    O
problems    O
such    O
as    O
rash    O
,    O
fever    O
,    O
an    O
enlarged    O
liver    O
and    O
spleen    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
jaundice    O
.    O

anemia    B-BloodDyscrasia114053850
.    O

The    O
drawing    O
shows    O
twins    O
that    O
appear    O
to    O
be    O
identical    O
,    O
but    O
one    O
is    O
pale    O
(    O
possibly    O
anemic    B-BloodDyscrasia114053850
)    O
,    O
while    O
the    O
other    O
is    O
red    O
(    O
possibly    O
polycythemic    O
)    O
.    O

It    O
is    O
said    O
to    O
be    O
suitable    O
for    O
the    O
treatment    O
of    O
physical    O
weakness    O
such    O
as    O
anemia    B-BloodDyscrasia114053850
,    O
constipation    O
,    O
dizziness    O
and    O
tinnitus    O
.    O

Adenylate    O
kinase    O
deficiency    O
in    O
the    O
erythrocyte    O
is    O
associated    O
with    O
hemolytic    O
anemia    B-BloodDyscrasia114053850
.    O

The    O
fetus    O
can    O
develop    O
reticulocytosis    O
and    O
anemia    B-BloodDyscrasia114053850
.    O

In    O
mid    O
-    O
season    O
of    O
2009    O
he    O
even    O
missed    O
a    O
few    O
races    O
due    O
to    O
chronic    O
fatigue    O
due    O
to    O
anemia    B-BloodDyscrasia114053850
,    O
having    O
started    O
the    O
season    O
strongly    O
.    O

Stoner    O
was    O
subsequently    O
diagnosed    O
with    O
anemia    B-BloodDyscrasia114053850
and    O
an    O
inflammation    O
of    O
the    O
stomach    O
lining    O
.    O

Kenneth    O
Crichton    O
,    O
the    O
son    O
of    O
Jacqueline    O
Falsworth    O
and    O
a    O
sufferer    O
of    O
the    O
medical    O
condition    O
anemia    B-BloodDyscrasia114053850
,    O
is    O
estranged    O
from    O
his    O
family    O
after    O
refusing    O
to    O
adopt    O
the    O
identity    O
of    O
Union    O
Jack    O
,    O
deeming    O
his    O
close    O
friend    O
Joey    O
Chapman    O
to    O
be    O
a    O
better    O
choice    O
.    O

Arsenic    O
was    O
recommended    O
for    O
over    O
100    O
illnesses    O
including    O
anemia    B-BloodDyscrasia114053850
,    O
diarrhea    O
,    O
hydrophobia    O
,    O
elephantiasis    O
,    O
and    O
impotence    O
.    O

In    O
the    O
final    O
phase    O
of    O
the    O
intoxication    O
,    O
the    O
exhausted    O
rodent    O
collapses    O
due    O
to    O
hemorrhagic    O
shock    O
or    O
severe    O
anemia    B-BloodDyscrasia114053850
and    O
dies    O
calmly    O
.    O

Golden    O
was    O
a    O
very    O
sickly    O
child    O
and    O
spent    O
much    O
of    O
his    O
time    O
in    O
bed    O
-    O
he    O
was    O
not    O
expected    O
to    O
live    O
past    O
his    O
teenage    O
years    O
because    O
he    O
was    O
asthmatic    O
and    O
anemic    B-BloodDyscrasia114053850
.    O

The    O
typical    O
pathology    O
of    O
infection    O
with    O
these    O
parasites    O
includes    O
anaemia    B-BloodDyscrasia114053850
and    O
enlargement    O
of    O
the    O
liver    O
and    O
spleen    O
.    O

Loss    O
of    O
blood    O
may    O
cause    O
one    O
to    O
develop    O
anemia    B-BloodDyscrasia114053850
.    O

Royal    O
jelly    O
is    O
used    O
to    O
treat    O
anaemia    B-BloodDyscrasia114053850
,    O
gastrointestinal    O
ulcers    O
,    O
arteriosclerosis    O
,    O
hypo-    O
and    O
hypertension    O
,    O
and    O
inhibition    O
of    O
sexual    O
libido    O
.    O

It    O
may    O
occur    O
in    O
situations    O
with    O
an    O
increased    O
blood    O
volume    O
,    O
from    O
excess    O
of    O
water    O
and    O
salt    O
(    O
kidney    O
pathology    O
,    O
excess    O
of    O
fluid    O
or    O
blood    O
administration    O
,    O
treatment    O
with    O
retaining    O
water    O
steroids    O
)    O
,    O
chronic    O
and    O
severe    O
anemia    B-BloodDyscrasia114053850
,    O
large    O
arteriovenous    O
fistula    O
or    O
multiple    O
small    O
arteriovenous    O
shunts    O
as    O
in    O
HHT    O
or    O
Paget    O
's    O
disease    O
of    O
bone    O
,    O
some    O
forms    O
of    O
severe    O
liver    O
or    O
kidney    O
disorders    O
,    O
hyperthyroidism    O
,    O
and    O
wet    O
beriberi    O
,    O
and    O
acutely    O
in    O
septic    O
shock    O
,    O
especially    O
caused    O
by    O
Gram    O
-    O
negative    O
bacteria    O
.    O

During    O
the    O
construction    O
of    O
the    O
Gotthard    O
Tunnel    O
in    O
Switzerland    O
(    O
1871–1881    O
)    O
,    O
a    O
large    O
number    O
of    O
miners    O
suffered    O
from    O
severe    O
anaemia    B-BloodDyscrasia114053850
of    O
unknown    O
cause    O
.    O

An    O
epidemic    O
of    O
"    O
miner    O
's    O
anaemia    B-BloodDyscrasia114053850
"    O
caused    O
by    O
"    O
Ancylostoma    O
duodenale    O
"    O
among    O
workers    O
constructing    O
the    O
Gotthard    O
Tunnel    O
contributed    O
to    O
the    O
understanding    O
of    O
ancylostomiasis    O
..    O

Hepatocellular    O
carcinoma    O
is    O
associated    O
with    O
abdominal    O
mass    O
,    O
abdominal    O
pain    O
,    O
emesis    O
,    O
anemia    B-BloodDyscrasia114053850
,    O
back    O
pain    O
,    O
jaundice    O
,    O
itching    O
,    O
weight    O
loss    O
and    O
fever    O
.    O

Anemia    B-BloodDyscrasia114053850

:    O
Adamme    O
is    O
admitted    O
to    O
the    O
hospital    O
:    O
he    O
is    O
severely    O
anaemic    B-BloodDyscrasia114053850
due    O
to    O
bleeding    O
from    O
the    O
stomach    O
and    O
must    O
have    O
several    O
transfusions    O
.    O

Acquired    O
hemochromatosis    O
is    O
common    O
in    O
patients    O
with    O
certain    O
types    O
of    O
chronic    O
anemia    B-BloodDyscrasia114053850
(    O
e.g.    O
thalassemia    O
and    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
)    O
who    O
require    O
many    O
blood    O
transfusions    O
,    O
which    O
can    O
greatly    O
increase    O
the    O
amount    O
of    O
iron    O
in    O
the    O
body    O
.    O

Trauma    B-BloodDyscrasia114053850
triad    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
death    I-BloodDyscrasia114053850
,    O
the    O
combination    O
of    O
hypothermia    O
,    O
acidosis    O
and    O
coagulopathy    O
often    O
seen    O
in    O
severe    O
trauma    O
cases    O

Damage    O
control    O
surgery    O
is    O
used    O
to    O
manage    O
severe    O
trauma    O
in    O
which    O
there    O
is    O
a    O
cycle    B-BloodDyscrasia114053850
of    O
metabolic    O
acidosis    O
,    O
hypothermia    O
,    O
and    O
hypotension    O
that    O
may    O
lead    O
to    O
death    O
,    O
if    O
not    O
corrected    O
.    O

Cholemia    B-BloodDyscrasia114053850
is    O
a    O
condition    O
caused    O
by    O
the    O
presence    O
of    O
excess    O
bile    O
in    O
the    O
blood    O
.    O

Hematopoietic    O
ulcers    O
are    O
those    O
occurring    O
with    O
sickle    O
cell    O
anemia    O
,    O
congenital    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
,    O
thrombocytopenic    O
purpura    O
,    O
macroglobulinemia    B-BloodDyscrasia114053850
,    O
and    O
cryoglobulinemia    B-BloodDyscrasia114053850
.    O

Disseminated    O
mastocytosis    B-BloodDyscrasia114053850
is    O
rarely    O
seen    O
in    O
young    O
dogs    O
and    O
cats    O
,    O
while    O
mast    O
cell    O
tumors    O
are    O
usually    O
skin    O
tumors    O
in    O
older    O
dogs    O
and    O
cats    O
.    O

The    O
presence    O
of    O
these    O
signs    O
usually    O
indicates    O
mastocytosis    B-BloodDyscrasia114053850
,    O
which    O
is    O
the    O
spread    O
of    O
mast    O
cells    O
throughout    O
the    O
body    O
.    O

mastocytosis    B-BloodDyscrasia114053850

These    O
diseases    O
include    O
atopic    O
dermatitis    O
,    O
various    O
subtypes    O
of    O
physical    O
urticaria    O
(    O
solar    O
,    O
cold    O
-    O
induced    O
,    O
local    O
heat    O
-    O
induced    O
,    O
or    O
delayed    O
pressure    O
-    O
induced    O
)    O
,    O
and    O
a    O
spectrum    O
of    O
relatively    O
less    O
prevalent    O
allergic    O
or    O
non    O
-    O
allergic    O
diseases    O
or    O
conditions    O
,    O
such    O
as    O
allergic    O
bronchopulmonary    O
aspergillosis    O
,    O
cutaneous    O
or    O
systemic    O
mastocytosis    B-BloodDyscrasia114053850
,    O
bee    O
venom    O
sensitivity    O
(    O
anaphylaxis    O
)    O
,    O
idiopathic    O
anaphylaxis    O
,    O
eosinophil    O
-    O
associated    O
gastrointestinal    O
disorder    O
,    O
bullous    O
pemphigoid    O
,    O
interstitial    O
cystitis    O
,    O
nasal    O
polyps    O
,    O
and    O
idiopathic    O
angiodema    O
,    O
.    O

The    O
tested    O
indications    O
are    O
in    O
the    O
areas    O
of    O
allergic    O
asthma    O
,    O
perennial    O
and    O
seasonal    O
allergic    O
rhinitis    O
,    O
peanut    O
allergy    O
,    O
latex    O
allergy    O
,    O
atopic    O
dermatitis    O
,    O
chronic    O
idiopathic    O
urticaria    O
(    O
also    O
called    O
chronic    O
spontaneous    O
urticaria    O
,    O
idiopathic    O
anaphylaxis    O
,    O
mastocytosis    B-BloodDyscrasia114053850
,    O
eosinophilic    O
gastroenteritis    O
,    O
nasal    O
polyposis    O
,    O
and    O
others    O
)    O
.    O

Mastocytosis    B-BloodDyscrasia114053850

Masitinib    O
is    O
being    O
studied    O
for    O
several    O
human    O
conditions    O
including    O
cancers    O
,    O
Alzheimer    O
,    O
multiple    O
sclerosis    O
,    O
mastocytosis    B-BloodDyscrasia114053850
,    O
and    O
amyotrophic    O
lateral    O
sclerosis    O
.    O

Rh    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

hexokinase    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

Other    O
perinatal    O
haematological    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850

Barr    O
virus    O
,    O
influenza    O
,    O
HIV    O
infection    O
,    O
tuberculosis    O
,    O
Lyme    O
disease    O
)    O
,    O
neuroendocrine    O
diseases    O
(    O
such    O
as    O
thyroiditis    O
,    O
Addison    O
's    O
disease    O
,    O
adrenal    O
insufficiency    O
,    O
Cushing    O
's    O
disease    O
)    O
,    O
hematologic    B-BloodDyscrasia114053850
diseases    I-BloodDyscrasia114053850
(    O
such    O
as    O
occult    O
malignancy    O
,    O
lymphoma    O
)    O
,    O
rheumatologic    O
diseases    O
(    O
such    O
as    O
fibromyalgia    O
,    O
polymyalgia    O
rheumatica    O
,    O
Sjögren    O
's    O
syndrome    O
,    O
giant    O
-    O
cell    O
arteritis    O
,    O
polymyositis    O
,    O
dermatomyositis    O
)    O
,    O
psychiatric    O
diseases    O
(    O
such    O
as    O
bipolar    O
disorder    O
,    O
schizophrenia    O
,    O
delusional    O
disorders    O
,    O
dementia    O
,    O
anorexia    O
/    O
bulimia    O
nervosa    O
)    O
,    O
neuropsychologic    O
diseases    O
(    O
such    O
as    O
obstructive    O
sleep    O
apnea    O
,    O
parkinsonism    O
,    O
multiple    O
sclerosis    O
)    O
,    O
and    O
others    O
(    O
such    O
as    O
nasal    O
obstruction    O
from    O
allergies    O
,    O
sinusitis    O
,    O
anatomic    O
obstruction    O
,    O
autoimmune    O
diseases    O
,    O
some    O
chronic    O
illness    O
,    O
alcohol    O
or    O
substance    O
abuse    O
,    O
pharmacologic    O
side    O
effects    O
,    O
heavy    O
metal    O
exposure    O
and    O
toxicity    O
,    O
marked    O
body    O
weight    O
fluctuation    O
)    O
.    O

Systemic    O
factors    O
that    O
lower    O
resistance    O
commonly    O
are    O
detectable    O
,    O
including    O
:    O
diabetes    O
,    O
obesity    O
,    O
and    O
hematologic    B-BloodDyscrasia114053850
disorder    I-BloodDyscrasia114053850
.    O

Others    O
include    O
:    O
frontal    O
fibrosing    O
alopecia    O
,    O
ulerythema    O
ophryogenes    O
,    O
acne    O
rosacea    O
,    O
telogen    O
effluvium    O
,    O
follicular    B-BloodDyscrasia114053850
mucinosis    I-BloodDyscrasia114053850
,    O
and    O
cutaneous    O
sarcoidosis    O
.    O

Mycosis    B-BloodDyscrasia114053850
fungoides    I-BloodDyscrasia114053850
,    O
also    O
known    O
as    O
Alibert-Bazin    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
or    O
granuloma    B-BloodDyscrasia114053850
fungoides    I-BloodDyscrasia114053850
,    O
is    O
the    O
most    O
common    O
form    O
of    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
.    O

"    O
Ein    O
Fall    O
von    O
Mycosis    O
fungoides    O
mit    O
Erkrankung    O
von    O
Nerven    O
und    O
mit    O
Lokalisation    O
in    O
den    O
inneren    O
Organe    O
"    O
,    O
(    O
with    O
Gustav    O
Scherber    O
)    O
in    O
Virchows    O
Archiv    O
(    O
1916    O
)    O
.    O
--    O
On    O
mycosis    B-BloodDyscrasia114053850
fungoides    I-BloodDyscrasia114053850
.    O

Pagetoid    O
reticulosis    O
(    O
also    O
known    O
as    O
"    O
acral    O
mycoses    O
fungoides    O
"    O
,    O
"    O
localized    O
epidermotropic    O
reticulosis    O
"    O
,    O
"    O
mycosis    O
fungoides    O
palmaris    O
et    O
plantaris    O
"    O
,    O
"    O
unilesional    O
mycosis    O
fungoides    O
"    O
,    O
and    O
"    O
Woringer    O
–    O
Kolopp    O
disease    O
"    O
)    O
is    O
a    O
cutaneous    O
condition    O
,    O
an    O
uncommon    O
lymphoproliferative    O
disorder    O
,    O
sometimes    O
considered    O
a    O
form    O
of    O
mycosis    B-BloodDyscrasia114053850
fungoides    I-BloodDyscrasia114053850
.    O

It    O
is    O
a    O
variant    O
of    O
mycosis    B-BloodDyscrasia114053850
fungoides    I-BloodDyscrasia114053850
.    O

Secondary    O
cutaneous    O
CD30    O
+    O
large    O
-    O
cell    O
lymphoma    O
is    O
a    O
cutaneous    O
condition    O
that    O
may    O
arise    O
in    O
cases    O
of    O
mycosis    B-BloodDyscrasia114053850
fungoides    I-BloodDyscrasia114053850
,    O
and    O
in    O
patients    O
with    O
lymphomatoid    O
papulosis    O
.    O

Extranodal    O
NK    O
/    O
T    O
-    O
cell    O
lymphoma    O
,    O
nasal    O
type    O
which    O
was    O
known    O
as    O
angiocentric    O
lymphoma    O
in    O
the    O
REAL    O
classification    O
,    O
and    O
also    O
as    O
nasal    O
-    O
type    O
NK    O
lymphoma    O
,    O
NK    O
/    O
T    O
-    O
cell    O
lymphoma    O
,    O
and    O
polymorphic    O
/    O
malignant    O
midline    O
reticulosis    O
is    O
a    O
cutaneous    O
condition    O
which    O
in    O
Korea    O
is    O
reported    O
to    O
be    O
the    O
most    O
common    O
form    O
of    O
cutaneous    O
lymphoma    O
after    O
mycosis    B-BloodDyscrasia114053850
fungoides    I-BloodDyscrasia114053850
.    O

No    B-BloodDyscrasia114053850
reflow    I-BloodDyscrasia114053850
phenomenon    I-BloodDyscrasia114053850
is    O
the    O
failure    O
of    O
blood    O
to    O
reperfuse    O
an    O
ischemic    O
area    O
after    O
the    O
physical    O
obstruction    O
has    O
been    O
removed    O
or    O
bypassed    O
.    O

Heterozygous    O
for    O
factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
mutation    O

To    O
rule    O
out    O
other    O
causes    O
for    O
hypercoagulation    O
,    O
it    O
may    O
be    O
appropriate    O
to    O
check    O
the    O
antithrombin    O
,    O
protein    O
C    O
,    O
protein    O
S    O
,    O
factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
,    O
and    O
prothrombin    O
G20210A.    O

A    O
point    O
mutation    O
in    O
the    O
gene    O
encoding    O
Factor    O
V    O
can    O
lead    O
to    O
a    O
hypercoagulability    O
disorder    O
called    O
Factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
.    O

Thrombophilia    O
,    O
a    O
tendency    O
to    O
develop    O
blood    O
clots    O
due    O
to    O
abnormalities    O
in    O
coagulation    O
,    O
e.g.    O
factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
,    O
deficiency    O
of    O
protein    O
C    O
,    O
protein    O
S    O
or    O
antithrombin    O
,    O
or    O
related    O
problems    O

This    O
is    O
important    O
in    O
those    O
predisposed    O
to    O
blood    O
clots    O
(    O
e.g.    O
,    O
Factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
)    O
but    O
also    O
for    O
thrombus    O
formation    O
when    O
an    O
atherosclerotic    O
plaque    O
rupture    O
that    O
would    O
,    O
otherwise    O
,    O
lead    O
to    O
myocardial    O
infarction    O
.    O

Among    O
researchers    O
using    O
the    O
term    O
,    O
it    O
has    O
been    O
described    O
as    O
a    O
coagulation    O
disorder    O
that    O
can    O
present    O
in    O
conjunction    O
with    O
protein    B-BloodDyscrasia114053850
S    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
and    O
Factor    B-BloodDyscrasia114053850
V    I-BloodDyscrasia114053850
Leiden    I-BloodDyscrasia114053850
.    O

The    O
importance    O
of    O
complement    O
regulation    O
for    O
good    O
health    O
is    O
highlighted    O
by    O
recent    O
work    O
that    O
seems    O
to    O
imply    O
that    O
individuals    O
carrying    O
point    O
mutations    O
or    O
single    O
nucleotide    O
polymorphisms    O
in    O
their    O
genes    O
for    O
factor    O
H    O
may    O
be    O
more    O
susceptible    O
to    O
diseases    O
including    O
atypical    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
dense    O
deposit    O
diseases    O
(    O
or    O
membranoproliferative    O
glomrulonephritis    O
type    O
2    O
)    O
and    O
-    O
most    O
notably    O
because    O
of    O
its    O
prevalence    O
in    O
the    O
elderly    O
-    O
age    O
-    O
related    O
macular    O
degeneration    O
.    O

The    O
absence    O
of    O
regulatory    O
proteins    O
,    O
resulting    O
in    O
excessive    O
C3    O
activation    O
and    O
C3b    O
formation    O
,    O
is    O
associated    O
with    O
diseases    O
such    O
as    O
atypical    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
aHUS    O
)    O
,    O
hemolytic    O
disorders    O
,    O
and    O
certain    O
autoimmune    O
disorders    O
.    O

cold    B-BloodDyscrasia114053850
agglutinin    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

The    O
classical    O
laboratory    O
finding    O
is    O
polyclonal    O
hypergammaglobulinemia    O
,    O
and    O
other    O
immunoglobulin    O
derangements    O
are    O
also    O
seen    O
,    O
including    O
hemolytic    O
anemia    O
with    O
cold    B-BloodDyscrasia114053850
agglutinins    I-BloodDyscrasia114053850
,    O
circulating    O
immune    O
complexes    O
,    O
anti    O
-    O
smooth    O
muscle    O
antibodies    O
,    O
and    O
positive    O
rheumatoid    O
factor    O
.    O

Cold    B-BloodDyscrasia114053850
agglutinin    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

In    O
May    O
2017    O
,    O
the    O
company    O
announced    O
it    O
would    O
acquire    O
True    O
North    O
Therapeutics    O
for    O
$    O
825    O
million    O
,    O
strengthening    O
Bioverativ    O
's    O
pipeline    O
with    O
the    O
acquisition    O
of    O
TNT009    O
–    O
a    O
treatment    O
for    O
cold    B-BloodDyscrasia114053850
agglutinin    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

Mutations    O
in    O
this    O
gene    O
cause    O
congenital    B-BloodDyscrasia114053850
dyserythropoietic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
type    I-BloodDyscrasia114053850
I    I-BloodDyscrasia114053850
,    O
a    O
disease    O
resulting    O
in    O
morphological    O
and    O
functional    O
abnormalities    O
of    O
erythropoiesis    O
.    O

Elliptocytosis    B-BloodDyscrasia114053850
(    O
congenital    O
)    O

Southeast    B-BloodDyscrasia114053850
Asian    I-BloodDyscrasia114053850
ovalocytosis    I-BloodDyscrasia114053850
is    O
a    O
form    O
of    O
hereditary    B-BloodDyscrasia114053850
elliptocytosis    I-BloodDyscrasia114053850
common    O
in    O
some    O
communities    O
in    O
Malaysia    O
and    O
Papua    O
New    O
Guinea    O
,    O
as    O
it    O
confers    O
some    O
resistance    O
to    O
cerebral    O
Falciparum    O
Malaria    O
.    O

Hereditary    B-BloodDyscrasia114053850
elliptocytosis    I-BloodDyscrasia114053850

The    O
contiguous    O
gene    O
deletion    O
syndrome    O
is    O
characterised    O
by    O
Alport    O
syndrome    O
(    O
A    O
)    O
,    O
intellectual    O
disability    O
(    O
M    O
)    O
,    O
midface    O
hypoplasia    O
(    O
M    O
)    O
,    O
and    O
elliptocytosis    B-BloodDyscrasia114053850
(    O
E    O
)    O
,    O
as    O
well    O
as    O
generalized    O
hypoplasia    O
and    O
cardiac    O
abnormalities    O
.    O

It    O
used    O
,    O
often    O
in    O
combination    O
with    O
other    O
cytotoxic    O
agents    O
,    O
to    O
treat    O
various    O
kinds    O
of    O
histiocytosis    O
,    O
including    O
Erdheim–Chester    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
Langerhans    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
,    O

In    O
Erdheim-Chester    B-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
,    O
cells    O
of    O
the    O
immune    O
system    O
called    O
histiocytes    O
proliferate    O
at    O
an    O
abnormal    O
rate    O
causing    O
a    O
plethora    O
of    O
symptoms    O
and    O
,    O
in    O
more    O
severe    O
cases    O
,    O
death    O
.    O

Erdheim–Chester    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
a    O
rare    O
illness    O
also    O
known    O
as    O
polyostotic    O
sclerosing    O
histiocytosis    O

Sinus    B-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
with    O
massive    O
lymphadenopathy    O

Rahal    O
died    O
on    O
June    O
11    O
,    O
2011    O
from    O
a    O
rare    O
disorder    O
called    O
Rosai-Dorfman    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

Excludes    O
:    O
ornithinaemia    B-BloodDyscrasia114053850
(    O
E72.4    O
)    O

This    O
is    O
in    O
contrast    O
to    O
primarily    O
unconjugated    O
hyperbilirubinemia    O
which    O
is    O
the    O
water    O
-    O
insoluble    O
form    O
that    O
is    O
bound    O
to    O
serum    O
albumin    O
;    O
the    O
liver    O
has    O
not    O
had    O
a    O
chance    O
to    O
conjugate    O
the    O
bilirubin    O
yet    O
and    O
can    O
be    O
caused    O
either    O
because    O
too    O
much    O
unconjugated    O
bilirubin    O
is    O
made    O
(    O
such    O
as    O
in    O
massive    O
hemolysis    O
or    O
ineffective    B-BloodDyscrasia114053850
erythropoiesis    I-BloodDyscrasia114053850
)    O
or    O
because    O
too    O
little    O
is    O
conjugated    O
(    O
Gilbert    O
's    O
disease    O
or    O
Crigler    O
-    O
Najjar    O
syndrome    O
)    O
.    O

Paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
haemoglobinuria    I-BloodDyscrasia114053850
(    O
Marchiafava    O
-    O
Micheli    O
)    O

Particular    O
blood    O
disorders    O
,    O
especially    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
and    O
paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850

Fluorescein    O
-    O
labeled    O
proaerolysin    O
(    O
FLAER    O
)    O
is    O
used    O
in    O
a    O
flow    O
cytometric    O
assay    O
to    O
diagnose    O
paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850
(    O
PNH    O
)    O
.    O

Paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850

#    O
Blood    O
tests    O
for    O
paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850

Many    O
patients    O
with    O
aplastic    O
anemia    O
also    O
have    O
clones    O
of    O
cells    O
characteristic    O
of    O
the    O
rare    O
disease    O
paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850
(    O
PNH    O
,    O
anemia    O
with    O
thrombopenia    O
and/or    O
thrombosis    O
)    O
,    O
sometimes    O
referred    O
to    O
as    O
AA    O
/    O
PNH    O
.    O

Mutations    O
affecting    O
GPI    O
that    O
reduce    O
expression    O
of    O
CD59    O
and    O
decay    O
-    O
accelerating    O
factor    O
on    O
red    O
blood    O
cells    O
result    O
in    O
paroxysmal    B-BloodDyscrasia114053850
nocturnal    I-BloodDyscrasia114053850
hemoglobinuria    I-BloodDyscrasia114053850
.    O

It    O
is    O
deficient    O
or    O
defective    O
in    O
von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
is    O
involved    O
in    O
a    O
large    O
number    O
of    O
other    O
diseases    O
,    O
including    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
Heyde    O
's    O
syndrome    O
,    O
and    O
possibly    O
hemolytic-uremic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

In    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
(    O
TTP    O
)    O
and    O
hemolytic    B-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
HUS    O
)    O
,    O
ADAMTS13    O
either    O
is    O
deficient    O
or    O
has    O
been    O
inhibited    O
by    O
antibodies    O
directed    O
at    O
the    O
enzyme    O
.    O

Non    O
-    O
infectious    O
diseases    O
that    O
can    O
be    O
confused    O
with    O
MVD    O
are    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
hemolytic    B-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
snake    O
envenomation    O
,    O
clotting    O
factor    O
deficiencies    O
/    O
platelet    O
disorders    O
,    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
hereditary    O
hemorrhagic    O
telangiectasia    O
,    O
Kawasaki    O
disease    O
,    O
and    O
even    O
warfarin    O
intoxication    O
.    O

Thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
a    O
blood    O
disorder    O

Non    O
-    O
infectious    O
diseases    O
that    O
may    O
result    O
in    O
symptoms    O
similar    O
to    O
those    O
of    O
EVD    O
include    O
acute    B-BloodDyscrasia114053850
promyelocytic    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
hemolytic    B-BloodDyscrasia114053850
uremic    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
snake    O
envenomation    O
,    O
clotting    O
factor    O
deficiencies    O
/    O
platelet    O
disorders    O
,    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
,    O
hereditary    O
hemorrhagic    O
telangiectasia    O
,    O
Kawasaki    O
disease    O
,    O
and    O
warfarin    O
poisoning    O
.    O

Thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850

Platelet    O
transfusion    O
is    O
contraindicated    O
in    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
(    O
TTP    O
)    O
,    O
as    O
it    O
fuels    O
the    O
coagulopathy    B-BloodDyscrasia114053850
.    O

However    O
,    O
because    O
of    O
its    O
rare    O
but    O
serious    O
side    O
effects    O
of    O
neutropenia    O
and    O
thrombotic    B-BloodDyscrasia114053850
thrombocytopenic    I-BloodDyscrasia114053850
purpura    I-BloodDyscrasia114053850
it    O
was    O
primarily    O
used    O
in    O
patients    O
in    O
whom    O
aspirin    O
was    O
not    O
tolerated    O
,    O
or    O
in    O
whom    O
dual    O
antiplatelet    O
therapy    O
was    O
desirable    O
.    O

:*    O
Platelet    B-BloodDyscrasia114053850
dysfunction    I-BloodDyscrasia114053850
or    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

First    O
line    O
treatment    O
for    O
aplastic    O
anemia    O
consists    O
of    O
immunosuppressive    O
drugs    O
,    O
typically    O
either    O
anti    O
-    O
lymphocyte    O
globulin    O
or    O
anti-thymocyte    B-BloodDyscrasia114053850
globulin    I-BloodDyscrasia114053850
,    O
combined    O
with    O
corticosteroids    O
and    O
ciclosporin    O
.    O

Medical    O
therapy    O
of    O
aplastic    O
anemia    O
often    O
includes    O
a    O
course    O
of    O
antithymocyte    B-BloodDyscrasia114053850
globulin    I-BloodDyscrasia114053850
(    O
ATG    O
)    O
and    O
several    O
months    O
of    O
treatment    O
with    O
ciclosporin    O
to    O
modulate    O
the    O
immune    O
system    O
.    O

A    O
thrombohemorrhagic    B-BloodDyscrasia114053850
event    I-BloodDyscrasia114053850
is    O
a    O
process    O
that    O
involves    O
either    O
a    O
blood    O
clot    O
or    O
bleeding    O
,    O
such    O
as    O
a    O
heart    O
attack    O
or    O
stroke    O
.    O

Ruptured    B-BloodDyscrasia114053850
spleen    I-BloodDyscrasia114053850

Ruptured    B-BloodDyscrasia114053850
spleen    I-BloodDyscrasia114053850

Early    O
deaths    O
occur    O
within    O
minutes    O
to    O
hours    O
and    O
often    O
are    O
due    O
to    O
hemorrhages    O
in    O
the    O
outer    O
meningeal    O
layer    O
of    O
the    O
brain    O
,    O
torn    O
arteries    O
,    O
blood    O
around    O
the    O
lungs    O
,    O
air    O
around    O
the    O
lungs    O
,    O
ruptured    B-BloodDyscrasia114053850
spleen    I-BloodDyscrasia114053850
,    O
liver    O
laceration    O
,    O
or    O
pelvic    O
fracture    O
.    O

However    O
,    O
as    O
he    O
jumped    O
towards    O
the    O
table    O
,    O
the    O
corner    O
of    O
the    O
table    O
struck    O
his    O
abdomen    O
,    O
resulting    O
in    O
a    O
splenic    B-BloodDyscrasia114053850
rupture    I-BloodDyscrasia114053850
from    O
which    O
he    O
lost    O
a    O
significant    O
amount    O
of    O
blood    O
.    O

internal    B-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
caused    O
by    O
a    O
fractured    O
pelvis    O
and    O
an    O
ruptured    B-BloodDyscrasia114053850
spleen    I-BloodDyscrasia114053850
.    O

Grant    O
batters    O
Phil    O
in    O
revenge    O
,    O
leaving    O
him    O
with    O
a    O
ruptured    B-BloodDyscrasia114053850
spleen    I-BloodDyscrasia114053850
,    O
and    O
bullies    O
Sharon    O
until    O
she    O
flees    O
to    O
the    O
United    O
States    O
.    O

There    O
is    O
evidence    O
tying    O
it    O
to    O
Greenberg    O
dysplasia    O
and    O
Pelger-Huet    B-BloodDyscrasia114053850
anomaly    I-BloodDyscrasia114053850
.    O

Pelger–Huet    B-BloodDyscrasia114053850
anomaly    I-BloodDyscrasia114053850

Other    O
differential    O
diagnostic    O
considerations    O
include    O
interstitial    O
lung    O
disease    O
related    O
to    O
mixed    O
connective    O
tissue    O
disease    O
,    O
advanced    O
sarcoidosis    O
,    O
chronic    O
hypersensitivity    O
pneumonitis    O
,    O
pulmonary    O
Langerhan’s    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
and    O
radiation    O
-    O
induced    O
lung    O
injury    O
.    O

Examples    O
of    O
ILD    O
of    O
known    O
cause    O
include    O
hypersensitivity    O
pneumonitis    O
,    O
pulmonary    O
Langerhan’s    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
,    O
asbestosis    O
,    O
and    O
collagen    O
vascular    O
disease    O
.    O

BAL    O
may    O
reveal    O
alternative    O
specific    O
diagnoses    O
:    O
malignancy    O
,    O
infections    O
,    O
eosinophilic    O
pneumonia    O
,    O
histiocytosis    B-BloodDyscrasia114053850
X    I-BloodDyscrasia114053850
,    O
or    O
alveolar    O
proteinosis    O
.    O

It    O
used    O
,    O
often    O
in    O
combination    O
with    O
other    O
cytotoxic    O
agents    O
,    O
to    O
treat    O
various    O
kinds    O
of    O
histiocytosis    O
,    O
including    O
Erdheim–Chester    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
and    O
Langerhans    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
,    O

CD1a    O
,    O
in    O
particular    O
,    O
is    O
a    O
specific    O
marker    O
for    O
Langerhans    O
cells    O
,    O
and    O
can    O
therefore    O
also    O
be    O
used    O
in    O
the    O
diagnosis    O
of    O
Langerhans    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
.    O

Pulmonary    O
Langerhans'    B-BloodDyscrasia114053850
cell    I-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850

It    O
has    O
been    O
associated    O
with    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
and    O
shown    O
to    O
respond    O
to    O
iron    O
supplementation    O
,    O

According    O
to    O
WHO    O
,    O
São    O
Tomé    O
and    O
Príncipe    O
is    O
also    O
home    O
to    O
the    O
largest    O
documented    O
amount    O
of    O
iron-deficiency    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
amongst    O
any    O
country    O
's    O
population    O
.    O

Iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
a    O
type    O
of    O
anemia    O
of    O
lack    O
of    O
iron    O

Moreover    O
,    O
the    O
female    O
DALYs    O
to    O
male    O
DALYs    O
ratio    O
for    O
malnutrition    O
-    O
related    O
diseases    O
such    O
as    O
Iron-Deficiency    B-BloodDyscrasia114053850
Anemia    I-BloodDyscrasia114053850
are    O
often    O
close    O
to    O
1.5    O
,    O
suggesting    O
that    O
poor    O
nutrition    O
impacts    O
women    O
at    O
a    O
much    O
higher    O
level    O
than    O
men    O
.    O

Clinically    O
,    O
IPH    O
manifests    O
as    O
a    O
triad    O
of    O
haemoptysis    O
,    O
diffuse    O
parenchymal    O
infiltrates    O
on    O
chest    O
radiographs    O
,    O
and    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850
.    O

Iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850
secondary    O
to    O
blood    O
loss    O
(    O
chronic    O
)    O

Other    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850
,    O
unspecified    O

If    O
the    O
bleeding    O
is    O
repeated    O
and    O
heavy    O
,    O
it    O
can    O
cause    O
significant    O
iron-deficiency    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
.    O

The    O
removal    O
of    O
naturally    O
occurring    O
nutrients    O
that    O
occurs    O
in    O
grain    O
processing    O
led    O
to    O
a    O
number    O
of    O
diseases    O
caused    O
by    O
nutritional    O
deficiency    O
,    O
including    O
beriberi    O
,    O
pellagra    O
,    O
neural    O
tube    O
defect    O
,    O
and    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
.    O

Hypoferremia    O
–    O
impairment    O
in    O
biological    O
processes    O
needing    O
iron    O
resulting    O
in    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

Complications    O
may    O
include    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
volvulus    O
,    O
or    O
bowel    O
obstruction    O
.    O

The    O
minor    O
ones    O
were    O
keloid    O
scarring    O
,    O
burns    O
,    O
and    O
bullae    O
;    O
the    O
serious    O
ones    O
were    O
acquired    O
hemophilia    O
A    O
,    O
stroke    O
following    O
cupping    O
on    O
the    O
back    O
and    O
neck    O
,    O
factitious    O
panniculitis    O
,    O
reversible    O
cardiac    O
hypertrophy    O
,    O
and    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
.    O

Ancylostomiasis    O
is    O
caused    O
when    O
hookworms    O
,    O
present    O
in    O
large    O
numbers    O
,    O
produce    O
an    O
iron    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
by    O
sucking    O
blood    O
from    O
the    O
host    O
's    O
intestinal    O
walls    O
.    O

They    O
appear    O
grey    O
-    O
red    O
with    O
alternating    O
light    O
and    O
dark    O
lines    O
(    O
known    O
as    O
lines    B-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
Zahn    I-BloodDyscrasia114053850
)    O
which    O
represent    O
bands    O
of    O
fibrin    O
(    O
lighter    O
)    O
with    O
entrapped    O
white    O
blood    O
cells    O
and    O
red    O
blood    O
cells    O
(    O
darker    O
)    O
.    O

Sézary    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

In    O
pathology    O
,    O
cerebriform    O
nuclei    O
refers    O
to    O
convoluted    O
(    O
"    O
brain    O
-    O
like    O
"    O
)    O
cell    O
nuclei    O
,    O
such    O
as    O
the    O
nuclei    O
seen    O
in    O
T    O
-    O
cells    O
in    O
T    O
-    O
cell    O
prolymphocytic    O
leukemia    O
or    O
Sézary's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

The    O
average    O
age    O
of    O
onset    O
is    O
between    O
45    O
and    O
55    O
years    O
of    O
age    O
for    O
patients    O
with    O
patch    O
and    O
plaque    O
disease    O
only    O
,    O
but    O
is    O
over    O
60    O
for    O
patients    O
who    O
present    O
with    O
tumours    O
,    O
erythroderma    O
(    O
red    O
skin    O
)    O
or    O
a    O
leukemic    O
form    O
(    O
the    O
Sézary    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
)    O
.    O

Sézary's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Apart    O
from    O
normal    O
variation    O
(    O
with    O
a    O
genetic    O
component    O
)    O
,    O
tumor    B-BloodDyscrasia114053850
lysis    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
produces    O
extreme    O
levels    O
of    O
uric    O
acid    O
,    O
mainly    O
leading    O
to    O
renal    O
failure    O
.    O

This    O
rapid    O
response    O
to    O
chemotherapy    O
can    O
be    O
hazardous    O
to    O
the    O
patient    O
,    O
as    O
a    O
phenomenon    O
called    O
"    O
tumor    B-BloodDyscrasia114053850
lysis    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
"    O
could    O
occur    O
.    O

Tumor    B-BloodDyscrasia114053850
lysis    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
TLS    B-BloodDyscrasia114053850
)    O
is    O
a    O
group    O
of    O
metabolic    O
abnormalities    O
that    O
can    O
occur    O
as    O
a    O
complication    O
during    O
the    O
treatment    O
of    O
cancer    O
,    O
where    O
large    O
amounts    O
of    O
tumor    O
cells    O
are    O
killed    O
off    O
(    O
lysed    O
)    O
at    O
the    O
same    O
time    O
by    O
the    O
treatment    O
,    O
releasing    O
their    O
contents    O
into    O
the    O
bloodstream    O
.    O

Major    O
side    O
effects    O
include    O
tumor    B-BloodDyscrasia114053850
lysis    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
severe    O
neutropenia    O
.    O

Persons    O
with    O
short    O
bowel    O
syndrome    O
may    O
have    O
complications    O
caused    O
by    O
malabsorption    O
of    O
vitamins    O
and    O
minerals    O
,    O
such    O
as    O
deficiencies    O
in    O
vitamins    O
A    O
,    O
D    O
,    O
E    O
,    O
K    O
,    O
B9    B-BloodDyscrasia114053850
(folic    I-BloodDyscrasia114053850
acid)    I-BloodDyscrasia114053850
,    O
and    O
B12    B-BloodDyscrasia114053850
,    O
calcium    O
,    O
magnesium    O
,    O
iron    B-BloodDyscrasia114053850
,    O
and    O
zinc    O
.    O

Folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
:    O

Folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    B-BloodDyscrasia114053850

Folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850
,    O
unspecified    O

The    O
"    O
FIGLU    O
"    O
test    O
is    O
used    O
to    O
identify    O
deficiency    O
of    O
vitamin    O
B12    O
or    O
folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
or    O
liver    O
disease    O
.    O

It    O
is    O
also    O
used    O
in    O
combination    O
with    O
5-fluorouracil    O
to    O
treat    O
colorectal    O
cancer    O
,    O
may    O
be    O
used    O
to    O
treat    O
folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
that    O
results    O
in    O
anemia    B-BloodDyscrasia114053850
,    O
and    O
methanol    O
poisoning    O
.    O

Treatment    O
is    O
with    O
reduced    O
forms    O
of    O
folic    O
acid    O
.    O
Because    O
tetrahydrofolate    O
,    O
the    O
product    O
of    O
this    O
reaction    O
,    O
is    O
the    O
active    O
form    O
of    O
folate    O
in    O
humans    O
,    O
inhibition    O
of    O
DHFR    O
can    O
cause    O
functional    O
folate    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

Histologic    O
findings    O
include    O
peribulbar    O
lymphocytic    B-BloodDyscrasia114053850
infiltrate    I-BloodDyscrasia114053850
(    O
"    O
swarm    O
of    O
bees    O
"    O
)    O
.    O

It    O
has    O
been    O
suggested    O
that    O
it    O
is    O
equivalent    O
to    O
Jessner    B-BloodDyscrasia114053850
lymphocytic    I-BloodDyscrasia114053850
infiltrate    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
skin    I-BloodDyscrasia114053850
.    O

In    O
medicine    O
,    O
it    O
is    O
synonymous    O
with    O
left    B-BloodDyscrasia114053850
shift    I-BloodDyscrasia114053850

Screening    O
for    O
protein    B-BloodDyscrasia114053850
C    I-BloodDyscrasia114053850
,    O
protein    B-BloodDyscrasia114053850
S    I-BloodDyscrasia114053850
,    O
or    O
antithrombin    O
III    O
deficiency    O
is    O
sometimes    O
recommended    O
but    O
these    O
are    O
more    O
usually    O
responsible    O
for    O
venous    O
thrombosis    O
than    O
arterial    O
problems    O
.    O

Protein    B-BloodDyscrasia114053850
C    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
a    O
rare    O
genetic    O
disorder    O
increasing    O
the    O
likelihood    O
of    O
thrombotic    O
disease    O

Protein    B-BloodDyscrasia114053850
C    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

It    O
is    O
distinguished    O
from    O
1    O
)    O
eosinophilia    O
which    O
is    O
an    O
elevation    O
in    O
an    O
individual    O
's    O
blood    O
eosinophil    O
count    O
above    O
normal    O
levels    O
of    O
to    O
but    O
below    O
the    O
hypereosinophilia    O
cutoff    O
level    O
and    O
2    O
)    O
the    O
hypereosinophilic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
which    O
is    O
a    O
sustained    O
elevation    O
in    O
an    O
individual    O
's    O
blood    O
eosinophil    O
count    O
above    O
normal    O
that    O
is    O
associated    O
with    O
clear    O
evidence    O
of    O
eosinophil    O
-    O
based    O
tissue    O
injury    O
.    O

However    O
,    O
when    O
the    O
blood    O
eosinophil    O
count    O
is    O
persistently    O
greater    O
than    O
1.5    O
×    O
109    O
/L    O
,    O
for    O
a    O
period    O
of    O
more    O
than    O
six    O
months    O
,    O
damage    O
to    O
end    O
organs    O
such    O
as    O
the    O
heart    O
,    O
lungs    O
,    O
skin    O
,    O
joints    O
and    O
nervous    O
system    O
can    O
be    O
demonstrated    O
,    O
and    O
in    O
the    O
absence    O
of    O
any    O
clonal    O
or    O
reactive    O
cause    O
,    O
the    O
term    O
idiopathic    O
hypereosinophilic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
HES    O
)    O
is    O
used    O
.    O

It    O
can    O
arise    O
de    O
novo    O
or    O
may    O
develop    O
in    O
patients    O
having    O
the    O
chronic    O
form    O
of    O
a    O
hypereosinophilic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Patients    O
with    O
acute    O
eosinophilic    O
leukemia    O
have    O
a    O
propensity    O
for    O
developing    O
bronchospasm    O
and    O
heart    O
failure    O
from    O
endomyocardial    B-BloodDyscrasia114053850
fibrosis    I-BloodDyscrasia114053850
.    O

This    O
happens    O
in    O
hematologic    O
disorders    O
like    O
chronic    B-BloodDyscrasia114053850
myelogeneous    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
promyelocytic    B-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
and    O
also    O
the    O
hypereosinophilic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Nutritional    B-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850
,    O
unspecified    O

Congenital    B-BloodDyscrasia114053850
dyserythropoietic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
type    I-BloodDyscrasia114053850
IV    I-BloodDyscrasia114053850
(    O
CDA    O
IV    O
)    O
has    O
been    O
described    O
with    O
typical    O
morphologic    O
features    O
of    O
CDA    O
II    O
but    O
a    O
negative    O
acidified    O
-    O
serum    O
test    O
.    O

Leukemoid    B-BloodDyscrasia114053850
reaction    I-BloodDyscrasia114053850

leukemoid    B-BloodDyscrasia114053850
reaction    I-BloodDyscrasia114053850

related    O
PYD    O
-    O
containing    O
proteins    O
,    O
cryopyrin    O
/    O
CIAS-1    O
and    O
pyrin    O
/    O
MEFV    O
,    O
have    O
been    O
linked    O
to    O
Muckle-Wells    B-BloodDyscrasia114053850
Syndrome    I-BloodDyscrasia114053850
and    O
familial    O
Mediterranean    O
fever    O
,    O
respectively    O
.    O

Muckle–Wells    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

The    O
currently    O
recognized    O
features    O
of    O
HHS    O
are    O
cerebellar    O
hypoplasia    O
,    O
immunodeficiency    O
,    O
progressive    O
bone    B-BloodDyscrasia114053850
marrow    I-BloodDyscrasia114053850
failure    I-BloodDyscrasia114053850
,    O
and    O
intrauterine    O
growth    O
retardation    O
.    O

Thirteen    O
wants    O
to    O
turn    O
to    O
the    O
internet    O
theories    O
but    O
Foreman    O
thinks    O
Vince    O
has    O
light-chain    B-BloodDyscrasia114053850
deposition    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
LCDD    O
)    O
,    O
which    O
can    O
be    O
treated    O
with    O
chemotherapy    O
.    O

HELLP    O
syndrome    O
leads    O
to    O
a    O
variant    O
form    O
of    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
,    O
leading    O
to    O
paradoxical    O
bleeding    O
,    O
which    O
can    O
make    O
emergency    O
surgery    O
a    O
challenge    O
.    O

Complications    O
may    O
include    O
seizures    O
,    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulopathy    I-BloodDyscrasia114053850
,    O
mesenteric    O
artery    O
occlusion    O
,    O
or    O
rhabdomyolysis    O
.    O

The    O
acquired    O
form    O
of    O
FXII    O
deficiency    O
is    O
seen    O
in    O
patients    O
with    O
the    O
nephrotic    O
syndrome    O
,    O
liver    O
disease    O
,    O
sepsis    O
and    O
shock    O
,    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
,    O
and    O
other    O
diseases    O
.    O

Release    O
of    O
a    O
large    O
amount    O
of    O
histamine    O
at    O
one    O
time    O
can    O
result    O
in    O
ulceration    O
of    O
the    O
stomach    O
and    O
duodenum    O
(    O
present    O
in    O
up    O
to    O
25    O
percent    O
of    O
cases    O
)    O
or    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
.    O

Acute    O
severe    O
hemolysis    O
results    O
,    O
with    O
multi    O
-    O
organ    O
failure    O
,    O
including    O
DIC    B-BloodDyscrasia114053850
and    O
renal    O
failure    O
.    O

Disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
of    O
fetus    O
and    O
newborn    O

Disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
(    O
defibrination    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
)    O

Diffuse    O
or    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
(    O
DIC    O
)    O

Instead    O
,    O
death    O
occurs    O
due    O
to    O
multiple    O
organ    O
dysfunction    O
syndrome    O
(    O
MODS    O
)    O
due    O
to    O
fluid    O
redistribution    O
,    O
hypotension    O
,    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
,    O
and    O
focal    O
tissue    O
necroses    O
.    O

Treatment    O
is    O
primarily    O
supportive    O
in    O
nature    O
and    O
includes    O
minimizing    O
invasive    O
procedures    O
,    O
balancing    O
fluids    O
and    O
electrolytes    O
to    O
counter    O
dehydration    O
,    O
administration    O
of    O
anticoagulants    O
early    O
in    O
infection    O
to    O
prevent    O
or    O
control    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
,    O
administration    O
of    O
procoagulants    O
late    O
in    O
infection    O
to    O
control    O
hemorrhaging    O
,    O
maintaining    O
oxygen    O
levels    O
,    O
pain    O
management    O
,    O
and    O
administration    O
of    O
antibiotics    O
or    O
antimycotics    O
to    O
treat    O
secondary    O
infections    O
.    O

When    O
blood    O
begins    O
to    O
appear    O
from    O
everywhere    O
,    O
Meredith    O
diagnoses    O
herself    O
in    O
as    O
being    O
in    O
DIC    B-BloodDyscrasia114053850
.    O

Sicarius    O
bite    O
treatment    O
should    O
be    O
directed    O
,    O
as    O
with    O
all    O
cytotoxic    O
bites    O
,    O
at    O
prevention    O
of    O
secondary    O
infection    O
and    O
combating    O
Disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
(    O
DIC    O
)    O
if    O
it    O
develops    O
.    O

Dysregulated    O
intravascular    O
immune    O
response    O
or    O
pathogen    O
evasion    O
can    O
create    O
conditions    O
like    O
thrombosis    O
,    O
sepsis    O
,    O
or    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
.    O

The    O
dysfunction    B-BloodDyscrasia114053850
in    I-BloodDyscrasia114053850
bleeding    I-BloodDyscrasia114053850
and    I-BloodDyscrasia114053850
clotting    I-BloodDyscrasia114053850
commonly    O
seen    O
in    O
EVD    O
has    O
been    O
attributed    O
to    O
increased    O
activation    O
of    O
the    O
extrinsic    O
pathway    O
of    O
the    O
coagulation    O
cascade    O
due    O
to    O
excessive    O
tissue    O
factor    O
production    O
by    O
macrophages    O
and    O
monocytes    O
.    O

Possible    O
non    O
-    O
specific    O
laboratory    O
indicators    O
of    O
EVD    O
include    O
a    O
low    O
platelet    O
count    O
;    O
an    O
initially    O
decreased    O
white    O
blood    O
cell    O
count    O
followed    O
by    O
an    O
increased    O
white    O
blood    O
cell    O
count    O
;    O
elevated    O
levels    O
of    O
the    O
liver    O
enzymes    O
alanine    O
aminotransferase    O
(    O
ALT    O
)    O
and    O
aspartate    O
aminotransferase    O
(    O
AST    O
)    O
;    O
and    O
abnormalities    O
in    O
blood    O
clotting    O
often    O
consistent    O
with    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
(    O
DIC    O
)    O
such    O
as    O
a    O
prolonged    O
prothrombin    O
time    O
,    O
partial    O
thromboplastin    O
time    O
,    O
and    O
bleeding    O
time    O
.    O

Other    O
regulators    O
of    O
coagulation    O
have    O
also    O
been    O
tried    O
including    O
heparin    O
in    O
an    O
effort    O
to    O
prevent    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
and    O
clotting    O
factors    O
to    O
decrease    O
bleeding    O
.    O

Fibrin    O
and    O
fibrinogen    O
degradation    O
product    O
(    O
FDP    O
)    O
testing    O
is    O
commonly    O
used    O
to    O
diagnose    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
.    O

Disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850

People    O
with    O
penetrating    O
head    O
trauma    O
may    O
have    O
complications    O
such    O
as    O
acute    O
respiratory    O
distress    O
syndrome    O
,    O
disseminated    B-BloodDyscrasia114053850
intravascular    I-BloodDyscrasia114053850
coagulation    I-BloodDyscrasia114053850
,    O
and    O
neurogenic    O
pulmonary    O
edema    O
.    O

Because    O
intrinsic    O
factor    O
is    O
crucial    O
for    O
the    O
normal    O
absorption    O
of    O
B12    O
,    O
its    O
lack    O
in    O
the    O
presence    O
of    O
pernicious    O
anemia    O
causes    O
a    O
vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

Vitamin    O
B12    O
is    O
used    O
to    O
treat    O
vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
cyanide    O
poisoning    O
,    O
and    O
hereditary    O
deficiency    O
of    O
transcobalamin    O
II    O
.    O

This    O
functionality    O
is    O
lost    O
in    O
vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
and    O
can    O
be    O
measured    O
clinically    O
as    O
an    O
increased    O
methylmalonic    O
acid    O
(    O
MMA    O
)    O
level    O
.    O

This    O
functionality    O
is    O
lost    O
in    O
vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
resulting    O
in    O
an    O
increased    O
homocysteine    O
level    O
and    O
the    O
trapping    O
of    O
folate    O
as    O
5-methyl    O
-    O
tetrahydrofolate    O
,    O
from    O
which    O
THF    O
(    O
the    O
active    O
form    O
of    O
folate    O
)    O
can    O
not    O
be    O
recovered    O
.    O

The    O
human    O
physiology    O
of    O
vitamin    O
B12    O
is    O
complex    O
,    O
and    O
therefore    O
is    O
prone    O
to    O
mishaps    O
leading    O
to    O
vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

Problems    O
with    O
any    O
one    O
of    O
these    O
organs    O
makes    O
a    O
vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
possible    O
.    O

Thus    O
,    O
elevated    O
blood    O
levels    O
of    O
homocysteine    O
and    O
MMA    O
may    O
both    O
be    O
indicators    O
of    O
Vitamin    B-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
.    O

Vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

Also    O
this    O
type    O
of    O
urinary    O
diversion    O
causes    O
immediate    O
metabolic    O
changes    O
that    O
can    O
give    O
a    O
wide    O
range    O
of    O
symptoms    O
from    O
diarrhea    O
,    O
vitamin    B-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
electrolyte    O
abnormalities    O
,    O
hepatic    O
metabolism    O
,    O
and    O
possible    O
bone    O
health    O
deterioration    O
.    O

Maternal    B-BloodDyscrasia114053850
vitamin    I-BloodDyscrasia114053850
B12    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850

Pseudothrombocytopenia    B-BloodDyscrasia114053850

Hyperviscosity    O
occurs    O
from    O
pathologic    O
changes    O
of    O
either    O
cellular    O
or    O
protein    O
fractions    O
of    O
the    O
blood    O
such    O
as    O
is    O
found    O
in    O
polycythemias    O
,    O
multiple    O
myeloma    O
(    O
particularly    O
IgA    O
and    O
IgG3    O
)    O
,    O
leukemia    O
,    O
monoclonal    B-BloodDyscrasia114053850
gammopathies    I-BloodDyscrasia114053850
such    O
as    O
Waldenström    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850
,    O
sickle    O
cell    O
anemia    O
,    O
and    O
sepsis    O
.    O

Waldenström    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850

Lymphoplasmacytic    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850

Others    O
may    O
make    O
blood    O
too    O
viscous    O
to    O
flow    O
smoothly    O
(    O
usually    O
with    O
IgM    O
pentamer    O
macroglobulins    O
)    O
,    O
a    O
phenomenon    O
known    O
as    O
Waldenström    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850
.    O

Waldenström    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850

Elevated    O
levels    O
of    O
macroglobulins    O
(    O
macroglobulinemia    B-BloodDyscrasia114053850
)    O
may    O
cause    O
manifestations    O
of    O
excess    O
blood    O
viscosity    O
(    O
as    O
is    O
the    O
case    O
for    O
IgM    O
antibodies    O
in    O
Waldenström    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850
)    O
and/or    O
precipitate    O
within    O
blood    O
vessels    O
when    O
temperature    O
drops    O
(    O
as    O
in    O
cryoglobulinaemia    B-BloodDyscrasia114053850
)    O
.    O

Waldenström's    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850
,    O
a    O
rare    O
form    O
of    O
blood    O
cancer    O

He    O
was    O
directing    O
a    O
catalogue    O
raisonné    O
on    O
Albert    O
Gleizes    O
when    O
he    O
was    O
diagnosed    O
with    O
Waldenström's    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850
,    O
a    O
cancer    O
of    O
the    O
lymphatic    O
system    O
.    O

On    O
August    O
11    O
,    O
2007    O
,    O
Kirsch    O
announced    O
on    O
his    O
personal    O
Web    O
site    O
that    O
he    O
had    O
been    O
diagnosed    O
with    O
Waldenstrom's    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850
,    O
a    O
rare    O
blood    O
cancer    O
.    O

disorders    O
of    O
exocrine    O
pancreatic    O
function    O
,    O
such    O
as    O
chronic    O
pancreatitis    O
,    O
cystic    O
fibrosis    O
and    O
Shwachman–Diamond    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
these    O
are    O
characterized    O
by    O
deficiency    O
of    O
pancreatic    O
digestive    O
enzymes    O
)    O

Shwachman–Bodian–Diamond    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Alternatively    O
,    O
his    O
wives    O
'    O
pattern    O
of    O
pregnancies    O
and    O
his    O
mental    O
deterioration    O
have    O
led    O
some    O
to    O
suggest    O
that    O
the    O
king    O
may    O
have    O
been    O
Kell    O
positive    O
and    O
suffered    O
from    O
McLeod    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

McLeod    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
or    O
McLeod    B-BloodDyscrasia114053850
phenomenon    I-BloodDyscrasia114053850
;    O
)    O
is    O
an    O
X    O
-    O
linked    O
recessive    O
genetic    O
disorder    O
that    O
may    O
affect    O
the    O
blood    O
,    O
brain    O
,    O
peripheral    O
nerves    O
,    O
muscle    O
,    O
and    O
heart    O
.    O

X-linked    B-BloodDyscrasia114053850
agammaglobulinemia    I-BloodDyscrasia114053850
or    O
Bruton    O
's    O
Disease    O

Some    O
immune    O
deficiencies    O
,    O
such    O
as    O
X-linked    B-BloodDyscrasia114053850
agammaglobulinemia    I-BloodDyscrasia114053850
and    O
hypogammaglobulinemia    O
,    O
result    O
in    O
partial    O
or    O
complete    O
lack    O
of    O
antibodies    O
.    O

Serology    O
blood    O
tests    O
help    O
to    O
diagnose    O
patients    O
with    O
certain    O
immune    O
deficiencies    O
associated    O
with    O
the    O
lack    O
of    O
antibodies    O
,    O
such    O
as    O
X-linked    B-BloodDyscrasia114053850
agammaglobulinemia    I-BloodDyscrasia114053850
.    O

TAR    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

TAR    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

In    O
case    O
of    O
an    O
inherited    O
condition    O
,    O
several    O
syndromes    O
are    O
known    O
for    O
an    O
association    O
with    O
radial    O
dysplasia    O
,    O
such    O
as    O
the    O
cardiovascular    O
Holt    O
-    O
Oram    O
syndrome    O
,    O
the    O
gastrointestinal    O
VATER    O
syndrome    O
and    O
the    O
hematologic    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
and    O
TAR    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

The    O
rarest    O
is    O
congenital    O
erythropoietic    O
porphyria    O
(    O
C.E.P.    O
)    O
,    O
otherwise    O
known    O
as    O
Gunther's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

Gunther's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
ILDS    O
(    O
ILDS    O
E80.020    O
)    O

But    O
,    O
in    O
patients    O
with    O
severe    O
endogenous    O
or    O
exogenous    O
hypertriglyceridemia    O
and    O
in    O
patients    O
with    O
high    O
plasma    O
protein    O
concentration    O
(    O
usually    O
due    O
to    O
paraproteinemia    B-BloodDyscrasia114053850
)    O
,    O
water    O
portion    O
of    O
plasma    O
is    O
replaced    O
with    O
either    O
lipid    O
or    O
protein    O
causing    O
falsely    O
low    O
electrolyte    O
value    O
(    O
pseudohyponatremia    O
)    O
.    O

"    O
Plasma    O
cell    O
dyscrasia    O
"    O
is    O
sometimes    O
considered    O
synonymous    O
with    O
paraproteinemia    B-BloodDyscrasia114053850
or    O
monoclonal    B-BloodDyscrasia114053850
gammopathy    I-BloodDyscrasia114053850
.    O

Hyperviscosity    O
occurs    O
from    O
pathologic    O
changes    O
of    O
either    O
cellular    O
or    O
protein    O
fractions    O
of    O
the    O
blood    O
such    O
as    O
is    O
found    O
in    O
polycythemias    O
,    O
multiple    O
myeloma    O
(    O
particularly    O
IgA    O
and    O
IgG3    O
)    O
,    O
leukemia    O
,    O
monoclonal    B-BloodDyscrasia114053850
gammopathies    I-BloodDyscrasia114053850
such    O
as    O
Waldenström    B-BloodDyscrasia114053850
macroglobulinemia    I-BloodDyscrasia114053850
,    O
sickle    O
cell    O
anemia    O
,    O
and    O
sepsis    O
.    O

Paraproteinemia    B-BloodDyscrasia114053850
,    O
also    O
known    O
as    O
monoclonal    B-BloodDyscrasia114053850
gammopathy    I-BloodDyscrasia114053850
,    O
is    O
the    O
presence    O
of    O
excessive    O
amounts    O
of    O
paraprotein    O
or    O
single    O
monoclonal    O
gammaglobulin    O
in    O
the    O
blood    O
.    O

He    O
is    O
credited    O
with    O
coining    O
the    O
phrase    O
"    O
HIV    O
equal    O
"    O
as    O
opposed    O
to    O
"    O
HIV-negative    B-BloodDyscrasia114053850
"    O
or    O
"    O
HIV    O
-    O
positive    O
"    O
.    O

Venom-induced    B-BloodDyscrasia114053850
consumption    I-BloodDyscrasia114053850
coagulopathy    I-BloodDyscrasia114053850
(    O
VICC    O
)    O
is    O
a    O
medical    O
condition    O
caused    O
by    O
the    O
effects    O
of    O
some    O
snake    O
venoms    O
on    O
hemostasis    O
.    O

Stomatocytosis    B-BloodDyscrasia114053850

Giant    O
platelet    O
disorder    O
occurs    O
for    O
inherited    O
diseases    O
like    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
gray    B-BloodDyscrasia114053850
platelet    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
May-Hegglin    B-BloodDyscrasia114053850
anomaly    I-BloodDyscrasia114053850
.    O

Characterized    O
by    O
abnormal    O
neutrophil    O
inclusions    O
:    O
May-Hegglin    B-BloodDyscrasia114053850
anomaly    I-BloodDyscrasia114053850
,    O
Sebastian    O
syndrome    O

Inherited    O
medical    O
problems    O
that    O
a    O
Bernese    O
Mountain    O
Dog    O
may    O
face    O
include    O
malignant    B-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
,    O
hypomyelinogenesis    O
,    O
progressive    O
retinal    O
atrophy    O
,    O
and    O
possibly    O
cataracts    O
and    O
hypoadrenocorticism    O
.    O

Hemangiosarcoma    O
,    O
fibrosarcoma    O
,    O
osteosarcoma    O
,    O
and    O
malignant    B-BloodDyscrasia114053850
histiocytosis    I-BloodDyscrasia114053850
are    O
particularly    O
devastating    O
,    O
and    O
occur    O
at    O
higher    O
rates    O
in    O
them    O
than    O
in    O
many    O
other    O
breeds    O
.    O

Hereditary    B-BloodDyscrasia114053850
spherocytosis    I-BloodDyscrasia114053850
,    O
a    O
genetic    O
disorder    O
marked    O
by    O
hemolytic    O
anemia    O

Hereditary    B-BloodDyscrasia114053850
spherocytosis    I-BloodDyscrasia114053850

Minkowski-Chauffard    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Spleens    O
are    O
also    O
removed    O
for    O
therapeutic    O
purposes    O
in    O
conditions    O
like    O
hereditary    B-BloodDyscrasia114053850
spherocytosis    I-BloodDyscrasia114053850
,    O
trauma    O
to    O
the    O
spleen    O
,    O
and    O
autosplenectomy    O
caused    O
by    O
sickle    O
cell    O
anemia    O
.    O

After    O
clinical    O
training    O
,    O
Agre    O
joined    O
Vann    O
Bennett    O
’s    O
lab    O
in    O
the    O
Cell    O
Biology    O
Department    O
at    O
Johns    O
Hopkins    O
where    O
he    O
studied    O
red    O
cell    O
membranes    O
and    O
identified    O
spectrin    O
deficiency    O
as    O
a    O
common    O
cause    O
of    O
hereditary    B-BloodDyscrasia114053850
spherocytosis    I-BloodDyscrasia114053850
,    O
a    O
hemolytic    O
anemia    O
with    O
fragile    O
,    O
spherically    O
shaped    O
red    O
cells    O
.    O

Kostmann's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

Intrinsic    O
disorders    O
-    O
Fanconi    O
's    O
,    O
Kostmann's    B-BloodDyscrasia114053850
,    O
cyclic    O
neutropenia    O
,    O
Chédiak    O

Women    O
with    O
antiphospholipid    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
should    O
have    O
an    O
additional    O
low    O
-    O
dose    O
prophylactic    O
treatment    O
of    O
aspirin    O
.    O

Antiphospholipid    B-BloodDyscrasia114053850
antibodies    I-BloodDyscrasia114053850

Antiphospholipid    B-BloodDyscrasia114053850
antibody    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

He    O
says    O
it    O
is    O
primary    B-BloodDyscrasia114053850
antiphospholipid    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
tells    O
him    O
to    O
start    O
Jack    O
on    O
heparin    O
and    O
IV    O
immunoglobulin    O
.    O

The    O
activity    O
of    O
anti    O
-    O
cardiolipin    O
antibodies    O
in    O
autoimmune    O
antiphospholipid    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
requires    O
apolipoprotein    O
H.    O
The    O
subset    O
of    O
antibodies    O
that    O
bind    O
Apo    O
-    O
H    O
and    O
alter    O
its    O
activity    O
are    O
considered    O
different    O
from    O

Problems    O
such    O
as    O
a    O
mutation    O
in    O
this    O
protein    O
would    O
lead    O
to    O
Antiphospholipid    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
which    O
often    O
leads    O
to    O
pregnancy    O
complications    O
.    O

Other    O
less    O
common    O
causes    O
include    O
hypercoagulable    O
state    O
,    O
cancer    O
,    O
renal    O
transplantation    O
,    O
behcet    O
syndrome    O
,    O
antiphospholipid    B-BloodDyscrasia114053850
antibody    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
or    O
blunt    O
trauma    O
to    O
the    O
back    O
or    O
abdomen    O
.    O

Other    O
less    O
common    O
causes    O
include    O
hypercoagulable    O
state    O
,    O
invasion    O
by    O
renal    O
cell    O
cancer    O
,    O
renal    O
transplantation    O
,    O
behcet    O
syndrome    O
,    O
antiphospholipid    B-BloodDyscrasia114053850
antibody    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
or    O
blunt    O
trauma    O
to    O
the    O
back    O
or    O
abdomen    O
.    O

|    O
Anti-phospholipid    B-BloodDyscrasia114053850
IgG    O

Anti-phospholipid    B-BloodDyscrasia114053850
antibody    I-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
an    O
autoimmune    O
condition    O
that    O
may    O
be    O
seen    O
in    O
systemic    O
lupus    O
erythematosus    O

It    O
is    O
used    O
to    O
provide    O
passive    O
immune    O
binding    O
of    O
antigen    O
,    O
preventing    O
a    O
maternal    O
active    O
immune    O
response    O
which    O
could    O
potentially    O
result    O
in    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
.    O

The    O
discovery    O
of    O
these    O
antibodies    O
led    O
to    O
the    O
development    O
of    O
immune    O
globulin    O
based    O
products    O
to    O
prevent    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
(    O
HDN    O
)    O
.    O

In    O
1908    O
he    O
was    O
the    O
first    O
physician    O
to    O
give    O
a    O
comprehensive    O
description    O
of    O
familial    B-BloodDyscrasia114053850
icterus    I-BloodDyscrasia114053850
gravis    I-BloodDyscrasia114053850
neonatorum    I-BloodDyscrasia114053850
.    O

In    O
the    O
case    O
of    O
an    O
Rh    O
-    O
incompatible    O
mother    O
and    O
child    O
,    O
consequential    O
blood    O
mixing    O
may    O
sensitize    O
an    O
Rh-    O
mother    O
to    O
the    O
Rh    O
antigen    O
on    O
the    O
blood    O
cells    O
of    O
the    O
Rh+    O
child    O
,    O
putting    O
the    O
remainder    O
of    O
the    O
pregnancy    O
,    O
and    O
any    O
subsequent    O
pregnancies    O
,    O
at    O
risk    O
for    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
.    O

Hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
,    O
also    O
known    O
as    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
fetus    I-BloodDyscrasia114053850
and    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
,    O
HDN    B-BloodDyscrasia114053850
,    O
HDFN    B-BloodDyscrasia114053850
,    O
or    O
erythroblastosis    B-BloodDyscrasia114053850
fetalis    I-BloodDyscrasia114053850
,    O
is    O
an    O
alloimmune    O
condition    O
that    O
develops    O
in    O
a    O
fetus    O
,    O
when    O
the    O
IgG    O
molecules    O
(    O
one    O
of    O
the    O
five    O
main    O
types    O
of    O
antibodies    O
)    O
produced    O
by    O
the    O
mother    O
pass    O
through    O
the    O
placenta    O
.    O

Anti    O
-    O
S    O
and    O
anti    O
-    O
s    O
can    O
cause    O
hemolytic    O
transfusion    O
reactions    O
and    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
.    O

These    O
individuals    O
have    O
a    O
very    O
strong    O
anti    O
-    O
PP1Pk    O
which    O
can    O
be    O
associated    O
with    O
delayed    O
hemolytic    O
transfusion    O
reactions    O
and    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
fetus    I-BloodDyscrasia114053850
and    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
(    O
HDFN    O
)    O
.    O

The    O
antibodies    O
are    O
capable    O
of    O
causing    O
hemolytic    O
transfusion    O
reactions    O
and    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
fetus    I-BloodDyscrasia114053850
and    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
(    O
if    O
IgG    O
isotype    O
and    O
therefore    O
capable    O
of    O
crossing    O
the    O
placenta    O
)    O
.    O

Though    O
present    O
in    O
the    O
fetus    O
,    O
it    O
is    O
seldom    O
the    O
cause    O
of    O
erythroblastosis    B-BloodDyscrasia114053850
fetalis    I-BloodDyscrasia114053850
or    O
of    O
transfusion    O
reactions    O
.    O

Lewis    O
antibodies    O
are    O
not    O
a    O
cause    O
of    O
hemolytic    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
the    I-BloodDyscrasia114053850
fetus    I-BloodDyscrasia114053850
and    I-BloodDyscrasia114053850
newborn    I-BloodDyscrasia114053850
(    O
HDFN    O
)    O
,    O
as    O
stated    O
below    O
.    O

Reduced    O
or    O
absent    O
aggregation    O
in    O
response    O
to    O
ristocetin    O
can    O
be    O
caused    O
by    O
a    O
lack    O
of    O
or    O
reduction    O
of    O
vWF    O
,    O
as    O
seen    O
in    O
von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
vWD    O
)    O
,    O
or    O
absence    O
or    O
reduction    O
in    O
numbers    O
of    O
GP1b    O
receptors    O
,    O
as    O
in    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
BSS    O
)    O
.    O

It    O
is    O
similar    O
to    O
the    O
ristocetin    O
cofactor    O
assay    O
but    O
has    O
the    O
added    O
benefit    O
in    O
that    O
it    O
helps    O
in    O
the    O
diagnosis    O
of    O
type    O
2B    O
/    O
pseudo    O
von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
vWD    O
)    O
and    O
Bernard-Soulier    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
because    O
it    O
uses    O
patient    O
's    O
live    O
endogenous    O
platelets    O
,    O
whereas    O
ristocetin    O
cofactor    O
assay    O
tests    O
the    O
function    O
of    O
only    O
the    O
vWF    O
and    O
not    O
the    O
platelets    O
.    O

hip    O
dysplasia    O
,    O
cancer    O
,    O
progressive    O
retinal    O
atrophy    O
(    O
PRA    O
)    O
,    O
epilepsy    O
,    O
entropion    O
,    O
hypothyroidism    O
,    O
hyperosteodystrophy    O
,    O
gastric    O
dilatation    O
volvulus    O
(    O
bloat    O
)    O
,    O
osteosarcoma    O
,    O
Von    B-BloodDyscrasia114053850
Willebrand's    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
patent    O
ductus    O
arteriosus    O
,    O
canine    O
Leukocyte    O
adhesion    O
deficiency    O
(    O
CLAD    O
)    O
and    O
celiac    O
disease    O
.    O

von    B-BloodDyscrasia114053850
Willebrands    I-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
(    O
vWD    O
)    O
–    O
a    O
failure    O
of    O
the    O
blood    O
to    O
clot    O
over    O
a    O
wound    O
,    O
which    O
in    O
extreme    O
cases    O
,    O
the    O
dog    O
can    O
bleed    O
to    O
death    O
with    O
only    O
a    O
small    O
wound    O
,    O
if    O
unattended    O
.    O

Von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850

von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
vWD    O
)    O
(    O
Bleeding    O
disorder    O
)    O

#    O
von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850

An    O
autopsy    O
at    O
the    O
time    O
of    O
her    O
death    O
concluded    O
she    O
died    O
from    O
an    O
intra    O
-    O
cerebral    O
haemorrhage    O
secondary    O
to    O
the    O
blood    O
coagulation    O
disorder    O
Von    B-BloodDyscrasia114053850
Willebrand's    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
based    O
on    O
blood    O
in    O
her    O
cerebrospinal    O
fluid    O
and    O
reports    O
that    O
she    O
had    O
been    O
suffering    O
severe    O
,    O
persistent    O
headaches    O
in    O
the    O
weeks    O
leading    O
up    O
to    O
her    O
death    O
.    O

Haematology    O
:    O
high    O
-    O
purity    O
coagulation    O
factor    O
concentrates    O
for    O
patients    O
with    O
bleeding    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850
Haemophilia    O
A    O
,    O
B    O
and    O
von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
Disease    I-BloodDyscrasia114053850
.    O

Von    B-BloodDyscrasia114053850
Willebrand    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

A    O
gain    O
-    O
of    O
-    O
function    O
mutation    O
causes    O
platelet    O
-    O
type    O
von    B-BloodDyscrasia114053850
Willebrand's    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

Peginesatide    B-BloodDyscrasia114053850
(    O
Omontys    O
)    O
–    O
once    O
-    O
monthly    O
medication    O
to    O
treat    O
anemia    O
associated    O
with    O
chronic    O
kidney    O
disease    O
in    O
adult    O
patients    O
on    O
dialysis    O
(    O
Affymax    O
/    O
Takeda    O
Pharmaceuticals    O
,    O
2012    O
)    O

For    O
example    O
,    O
most    O
if    O
not    O
all    O
research    O
on    O
the    O
endothelium    O
ECV-304    O
or    O
the    O
megakaryocyte    O
DAMI    O
cell    O
lines    O
has    O
in    O
reality    O
been    O
conducted    O
on    O
bladder    O
carcinoma    O
and    O
erythroleukemia    B-BloodDyscrasia114053850
cells    O
,    O
respectively    O
.    O

In    O
general    O
,    O
the    O
defects    O
in    O
the    O
erythropoietin    O
receptor    O
may    O
produce    O
erythroleukemia    B-BloodDyscrasia114053850
and    O
familial    O
erythrocytosis    O
.    O

Defects    O
in    O
the    O
erythropoietin    O
receptor    O
may    O
produce    O
erythroleukemia    B-BloodDyscrasia114053850
and    O
familial    O
erythrocytosis    O
.    O

Erythroleukemia    B-BloodDyscrasia114053850

Common    B-BloodDyscrasia114053850
variable    I-BloodDyscrasia114053850
immunodeficiency    I-BloodDyscrasia114053850
CVID    O
)    O

Common    B-BloodDyscrasia114053850
variable    I-BloodDyscrasia114053850
immunodeficiency    I-BloodDyscrasia114053850

Mutation    O
of    O
the    O
NFKB2    O
gene    O
has    O
been    O
linked    O
to    O
Common    B-BloodDyscrasia114053850
variable    I-BloodDyscrasia114053850
immunodeficiency    I-BloodDyscrasia114053850
(    O
CVID    O
)    O
as    O
the    O
cause    O
of    O
the    O
disease    O
.    O

Inherited    O
immune    O
deficiency    O
-    O
severe    O
combined    O
immunodeficiency    O
,    O
common    B-BloodDyscrasia114053850
variable    I-BloodDyscrasia114053850
immune    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
ataxia    O
-    O
telangiectasia    O
,    O
Wiskott-Aldrich    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
immunodeficiency    O
with    O
short    O
-    O
limbed    O
dwarfism    O
,    O
immunodeficiency    O
with    O
thymoma    O
,    O
purine    O
nucleoside    O
phosphorylase    O
deficiency    O
,    O
genetic    O
polymorphism    O

Evans    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
is    O
an    O
autoimmune    O
disease    O
in    O
which    O
an    O
individual    O
's    O
antibodies    O
attack    O
their    O
own    O
red    O
blood    O
cells    O
and    O
platelets    O
.    O

Evans'    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Hereditary    B-BloodDyscrasia114053850
persistence    I-BloodDyscrasia114053850
of    I-BloodDyscrasia114053850
fetal    I-BloodDyscrasia114053850
haemoglobin    I-BloodDyscrasia114053850
(    O
HPFH    O
)    O

Congenital    O
/    O
inherited    O
causes    O
include    O
congenital    B-BloodDyscrasia114053850
dyserythropoietic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
thalassemia    O
,    O
pyruvate    B-BloodDyscrasia114053850
kinase    I-BloodDyscrasia114053850
deficiency    I-BloodDyscrasia114053850
,    O
hereditary    O
pyropoikilocytosis    O
,    O
and    O
abetalipoproteinemia    O
.    O

Congenital    B-BloodDyscrasia114053850
dyserythropoietic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

Congenital    B-BloodDyscrasia114053850
dyserythropoietic    I-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Cytokine    O
storms    O
can    O
occur    O
in    O
a    O
number    O
of    O
infectious    O
and    O
non    O
-    O
infectious    O
diseases    O
including    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
GVHD    O
)    O
,    O
acute    O
respiratory    O
distress    O
syndrome    O
(    O
ARDS    O
)    O
,    O
sepsis    O
,    O
Ebola    O
,    O
avian    O
influenza    O
,    O
smallpox    O
,    O
and    O
systemic    O
inflammatory    O
response    O
syndrome    O
(    O
SIRS    O
)    O
.    O

The    O
first    O
reference    O
to    O
the    O
term    O
"    O
cytokine    O
storm    O
"    O
in    O
the    O
published    O
medical    O
literature    O
appears    O
to    O
be    O
by    O
Ferrara    O
et    O
al    O
.    O
in    O
1993    O
in    O
a    O
discussion    O
of    O
graft    B-BloodDyscrasia114053850
vs.    I-BloodDyscrasia114053850
host    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
;    O
a    O
condition    O
in    O
which    O
the    O
role    O
of    O
excessive    O
and    O
self    O
-    O
perpetuating    O
cytokine    O
release    O
had    O
already    O
been    O
under    O
discussion    O
for    O
many    O
years    O
.    O

Chronic    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
GVHD    O
)    O

It    O
is    O
rarely    O
used    O
in    O
humans    O
,    O
and    O
requires    O
histocompatible    O
(    O
matched    O
)    O
donors    O
,    O
which    O
are    O
often    O
difficult    O
to    O
find    O
,    O
and    O
carries    O
severe    O
risks    O
of    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

On    O
the    O
afternoon    O
of    O
September    O
8    O
,    O
2010    O
,    O
Cronin    O
died    O
at    O
the    O
Brigham    O
and    O
Women    O
's    O
Hospital    O
after    O
suffering    O
a    O
stroke    O
secondary    O
to    O
his    O
leukemia    O
due    O
to    O
complications    O
from    O
medicine    O
he    O
was    O
taking    O
to    O
offset    O
GVHD    B-BloodDyscrasia114053850
(graft-versus-host    I-BloodDyscrasia114053850
disease)    I-BloodDyscrasia114053850
,    O
which    O
he    O
had    O
been    O
struggling    O
with    O
since    O
the    O
transplant    O
.    O

On    O
January    O
22    O
,    O
2016    O
,    O
very    O
encouraging    O
results    O
of    O
a    O
Phase2    O
clinical    O
trial    O
on    O
241    O
children    O
with    O
acute    O
Graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
were    O
reported    O
,    O
see    O
Graft    O
vs    O
Host    O
Disease    O
,    O
later    O
.    O

In    O
January    O
2016    O
,    O
results    O
of    O
a    O
Phase2    O
clinical    O
trial    O
on    O
241    O
children    O
with    O
acute    O
Graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
that    O
was    O
not    O
responsive    O
to    O
steroids    O
,    O
were    O
announced    O
.    O

There    O
is    O
a    O
risk    O
of    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
(    O
GVHD    O
)    O
,    O
however    O
,    O
whereby    O
mature    O
lymphocytes    O
entering    O
with    O
marrow    O
recognize    O
the    O
new    O
host    O
tissues    O
as    O
foreign    O
and    O
destroy    O
them    O
.    O

Graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

The    O
experimental    O
use    O
of    O
everolimus    O
in    O
refractory    O
chronic    B-BloodDyscrasia114053850
graft-versus-host    I-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
was    O
reported    O
in    O
2012    O
.    O

In    O
the    O
United    O
States    O
it    O
is    O
frequently    O
given    O
at    O
the    O
time    O
of    O
the    O
transplant    O
to    O
prevent    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
although    O
many    O
European    O
centers    O
prefer    O
to    O
reserve    O
its    O
use    O
for    O
the    O
treatment    O
of    O
steroid    O
-    O
resistant    O
acute    O
rejection    O
,    O
as    O
European    O
centres    O
generally    O
serve    O
more    O
homogeneous    O
populations    O
and    O
rejection    O
tends    O
to    O
be    O
less    O
of    O
a    O
problem    O
.    O

They    O
are    O
also    O
administered    O
as    O
post    O
-    O
transplantory    O
immunosuppressants    O
to    O
prevent    O
the    O
acute    O
transplant    O
rejection    O
and    O
the    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
.    O

However    O
,    O
besides    O
the    O
risk    O
of    O
graft    O
failure    O
,    O
there    O
is    O
also    O
a    O
risk    O
that    O
the    O
newly    O
created    O
white    O
blood    O
cells    O
may    O
attack    O
the    O
rest    O
of    O
the    O
body    O
(    O
"    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
"    O
)    O
.    O

A    O
2009    O
retrospective    O
study    O
of    O
alemtuzumab    O
(    O
10    O
mg    O
IV    O
weekly    O
)    O
in    O
20    O
patients    O
(    O
no    O
controls    O
)    O
with    O
severe    O
steroid    O
-    O
resistant    O
acute    O
intestinal    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
after    O
allogeneic    O
hematopoietic    O
stem    O
cell    O
transplantation    O
(    O
HSCT    O
)    O
demonstrated    O
improvement    O
.    O

Graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

The    O
depletion    O
of    O
T    O
-    O
cells    O
in    O
the    O
donor    O
tissue    O
and    O
a    O
close    O
HLA    O
match    O
will    O
reduce    O
the    O
chances    O
of    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
occurring    O
.    O

Photopheresis    O
–    O
used    O
to    O
treat    O
graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
cutaneous    B-BloodDyscrasia114053850
T-cell    I-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
and    O
rejection    O
in    O
heart    O
transplantation    O
.    O

Graft-versus-host    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850

It    O
is    O
important    O
to    O
consider    O
May    O
-    O
Thurner    O
syndrome    O
in    O
patients    O
who    O
have    O
no    O
other    O
obvious    O
reason    O
for    O
hypercoagulability    B-BloodDyscrasia114053850
and    O
who    O
present    O
with    O
left    O
lower    O
extremity    O
thrombosis    O
.    O

Hypercoagulability    B-BloodDyscrasia114053850

A    O
significant    O
fraction    O
of    O
people    O
presenting    O
with    O
this    O
condition    O
have    O
an    O
underlying    O
hypercoagulable    B-BloodDyscrasia114053850
state    O
.    O

Anticoagulant    O
prophylaxis    O
is    O
recommended    O
to    O
be    O
administered    O
only    O
to    O
selected    O
subgroups    O
of    O
women    O
such    O
as    O
those    O
with    O
other    O
risk    O
factors    O
of    O
hypercoagulability    B-BloodDyscrasia114053850
or    O
those    O
who    O
do    O
develop    O
early    O
OHSS    O
.    O

Rudolf    O
Virchow    O
,    O
was    O
the    O
first    O
to    O
describe    O
the    O
physiological    O
mechanism    O
behind    O
venous    O
thrombosis    O
(    O
blood    O
clots    O
)    O
using    O
three    O
related    O
factors    O
,    O
known    O
as    O
Virchow    O
's    O
Triad    O
;    O
damage    O
to    O
the    O
blood    O
vessel    O
(    O
endothelial    O
damage    O
)    O
,    O
decrease    O
in    O
blood    O
flow    O
(    O
stasis    O
)    O
and    O
increased    O
coagulability    O
of    O
the    O
blood    O
(    O
thrombophilia    B-BloodDyscrasia114053850
or    O
hypercoagulability    O
)    O
.    O

Identifying    O
a    O
source    O
of    O
infection    O
is    O
crucial    O
;    O
it    O
is    O
common    O
practice    O
to    O
screen    O
for    O
various    O
forms    O
of    O
thrombophilia    B-BloodDyscrasia114053850
(    O
a    O
propensity    O
to    O
form    O
blood    O
clots    O
)    O
.    O

Hypercoagulation    B-BloodDyscrasia114053850

Thrombophilia    B-BloodDyscrasia114053850

The    O
formation    O
of    O
these    O
networks    O
leads    O
to    O
a    O
microangiopathic    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
:    O
the    O
mesh    O
causes    O
destruction    O
of    O
red    O
blood    O
cells    O
as    O
if    O
they    O
were    O
being    O
forced    O
through    O
a    O
strainer    O
.    O

This    O
leads    O
to    O
decreased    O
breakdown    O
of    O
the    O
ultra    O
-    O
large    O
multimers    O
of    O
vWF    O
and    O
microangiopathic    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
with    O
deposition    O
of    O
fibrin    O
and    O
platelets    O
in    O
small    O
vessels    O
,    O
and    O
capillary    O
necrosis    O
.    O

Microangiopathic    B-BloodDyscrasia114053850
hemolytic    I-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

#    O
Today    O
's    O
Ashkenazi    O
Jews    O
suffer    O
from    O
a    O
number    O
of    O
congenital    O
diseases    O
and    O
mutations    O
at    O
higher    O
rates    O
than    O
most    O
other    O
ethnic    O
groups    O
;    O
these    O
include    O
Tay    O
-    O
Sachs    O
,    O
Gaucher's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
Bloom    O
's    O
syndrome    O
,    O
and    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
and    O
mutations    O
at    O
BRCA1    O
and    O
BRCA2    O
.    O

Bone    O
marrow    O
failure    O
is    O
associated    O
with    O
three    O
types    O
of    O
diseases    O
,    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
(    O
FA    O
)    O
,    O
dyskeratosis    O
congenita    O
,    O
and    O
aplastic    O
anemia    O
.    O

In    O
case    O
of    O
an    O
inherited    O
condition    O
,    O
several    O
syndromes    O
are    O
known    O
for    O
an    O
association    O
with    O
radial    O
dysplasia    O
,    O
such    O
as    O
the    O
cardiovascular    O
Holt    O
-    O
Oram    O
syndrome    O
,    O
the    O
gastrointestinal    O
VATER    O
syndrome    O
and    O
the    O
hematologic    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
and    O
TAR    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Fanconi    B-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850
(    O
FA    B-BloodDyscrasia114053850
)    O
is    O
a    O
rare    O
genetic    O
disease    O
resulting    O
in    O
impaired    O
response    O
to    O
DNA    O
damage    O
.    O

Fanconi's    B-BloodDyscrasia114053850
anaemia    I-BloodDyscrasia114053850

Diamond    O
syndrome    O
,    O
in    O
which    O
the    O
bone    O
marrow    O
defect    O
results    O
primarily    O
in    O
neutropenia    O
,    O
and    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
where    O
all    O
cell    O
lines    O
are    O
affected    O
resulting    O
in    O
pancytopenia    O
.    O

Studies    O
in    O
"    O
Xenopus    O
"    O
egg    O
extracts    O
have    O
also    O
yielded    O
critical    O
insights    O
into    O
the    O
mechanism    O
of    O
action    O
of    O
human    O
disease    O
genes    O
associated    O
with    O
genetic    O
instability    O
and    O
elevated    O
cancer    O
risk    O
,    O
such    O
as    O
ataxia    O
telangiectasia    O
,    O
"    O
BRCA1    O
"    O
inherited    O
breast    O
and    O
ovarian    O
cancer    O
,    O
"    O
Nbs1    O
"    O
Nijmegen    O
breakage    O
syndrome    O
,    O
"    O
RecQL4    O
"    O
Rothmund    O
-    O
Thomson    O
syndrome    O
,    O
"    O
c    O
-    O
Myc    O
"    O
oncogene    O
and    O
FANC    O
proteins    O
(    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
)    O
.    O

BRCA2    O
"    O
mutations    O
produces    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
.    O

Tommy    O
suffers    O
from    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
,    O
a    O
rare    O
genetic    O
blood    O
disorder    O
with    O
no    O
cure    O
.    O

Mutations    O
in    O
the    O
gene    O
are    O
associated    O
with    O
the    O
disease    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
.    O

Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850

The    O
book    O
tells    O
the    O
story    O
of    O
her    O
family    O
's    O
pioneering    O
use    O
of    O
in    O
vitro    O
fertilization    O
and    O
Preimplantation    O
genetic    O
diagnosis    O
to    O
try    O
to    O
save    O
the    O
life    O
of    O
her    O
son    O
,    O
Henry    O
Strongin    O
Goldberg    O
,    O
who    O
was    O
born    O
with    O
the    O
genetic    O
disease    O
Fanconi    B-BloodDyscrasia114053850
anemia    I-BloodDyscrasia114053850
.    O

John    O
Ebersole    O
,    O
72    O
,    O
American    O
educator    O
,    O
President    O
of    O
Excelsior    O
College    O
(    O
2006–2016    O
)    O
,    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Mark    O
died    O
on    O
May    O
25    O
,    O
2015    O
in    O
Manhattan    O
,    O
aged    O
75    O
,    O
of    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
a    O
blood    O
illness    O
caused    O
by    O
bone    O
marrow    O
failure    O
.    O

Infertility    O
was    O
a    O
major    O
long    O
-    O
term    O
side    O
effect    O
,    O
and    O
even    O
more    O
seriously    O
,    O
the    O
risk    O
of    O
developing    O
treatment    O
-    O
related    O
myelodysplasia    B-BloodDyscrasia114053850
or    O
acute    O
leukemia    O
was    O
increased    O
up    O
to    O
14-fold    O
in    O
patients    O
who    O
received    O
MOPP    O
.    O

He    O
died    O
after    O
a    O
several    O
-    O
year    O
battle    O
with    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
a    O
form    O
of    O
leukemia    O
.    O

Marshall    O
died    O
June    O
2    O
,    O
2003    O
,    O
aged    O
80    O
,    O
at    O
his    O
home    O
in    O
Newtown    O
,    O
Connecticut    O
,    O
of    O
complications    O
of    O
myelodysplasia    B-BloodDyscrasia114053850
,    O
a    O
bone    O
marrow    O
disorder    O
.    O

As    O
FA    O
is    O
now    O
known    O
to    O
affect    O
DNA    O
repair    O
,    O
specifically    O
nonhomologous    O
end    O
joining    O
,    O
and    O
given    O
the    O
current    O
knowledge    O
about    O
dynamic    O
cell    O
division    O
in    O
the    O
bone    O
marrow    O
,    O
finding    O
patients    O
are    O
more    O
likely    O
to    O
develop    O
bone    O
marrow    O
failure    O
,    O
myelodysplastic    B-BloodDyscrasia114053850
syndromes    I-BloodDyscrasia114053850
,    O
and    O
acute    O
myeloid    O
leukemia    O
(    O
AML    O
)    O
is    O
not    O
surprising    O
.    O

Christian    O
Audigier    O
,    O
57    O
,    O
French    O
fashion    O
designer    O
(    O
Ed    O
Hardy    O
,    O
Von    O
Dutch    O
)    O
,    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

5q-    O
syndrome    O
;    O
see    O
Myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850

Madden    O
died    O
on    O
January    O
16    O
,    O
2014    O
in    O
Jacksonville    O
,    O
Florida    O
,    O
where    O
he    O
was    O
receiving    O
hospice    O
care    O
,    O
of    O
complications    O
of    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Her    O
only    O
son    O
,    O
Dirk    O
de    O
Brito    O
,    O
told    O
the    O
"    O
Los    O
Angeles    O
Times    O
"    O
that    O
she    O
died    O
of    O
complications    O
from    O
the    O
blood    O
disorder    O
myelodysplasia.    B-BloodDyscrasia114053850

Myelodysplastic    B-BloodDyscrasia114053850
syndromes    I-BloodDyscrasia114053850

Paul    O
Motian    O
,    O
80    O
,    O
American    O
jazz    O
drummer    O
,    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
.    O

Jaouad    O
’s    O
career    O
aspirations    O
as    O
a    O
foreign    O
correspondent    O
were    O
cut    O
short    O
when    O
,    O
at    O
age    O
22    O
,    O
less    O
than    O
a    O
year    O
after    O
graduation    O
,    O
she    O
was    O
diagnosed    O
with    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
acute    O
myeloid    O
leukemia    O
.    O

She    O
was    O
part    O
of    O
the    O
International    O
Working    O
Group    O
on    O
Morphology    O
of    O
MDS    B-BloodDyscrasia114053850
and    O
also    O
in    O
the    O
group    O
which    O
devised    O
the    O
2008    O
WHO    O
classification    O
of    O
tumours    O
of    O
the    O
lymphoid    O
haematopoietic    O
systems    O
.    O

ESAs    O
are    O
used    O
in    O
the    O
treatment    O
of    O
anemia    B-BloodDyscrasia114053850
in    O
chronic    O
kidney    O
disease    O
,    O
anemia    O
in    O
myelodysplasia    B-BloodDyscrasia114053850
,    O
and    O
in    O
anemia    O
from    O
cancer    O
chemotherapy    O
.    O

Erythropoietins    O
available    O
for    O
use    O
as    O
therapeutic    O
agents    O
are    O
produced    O
by    O
recombinant    O
DNA    O
technology    O
in    O
cell    O
culture    O
,    O
and    O
include    O
Epogen    O
/    O
Procrit    O
(    O
epoetin    O
alfa    O
)    O
and    O
Aranesp    O
(    O
darbepoetin    O
alfa    O
)    O
;    O
they    O
are    O
used    O
in    O
treating    O
anemia    B-BloodDyscrasia114053850
resulting    O
from    O
chronic    O
kidney    O
disease    O
,    O
chemotherapy    O
induced    O
anemia    O
in    O
patients    O
with    O
cancer    O
,    O
inflammatory    O
bowel    O
disease    O
(    O
Crohn    O
's    O
disease    O
and    O
ulcerative    O
colitis    O
)    O
and    O
myelodysplasia    B-BloodDyscrasia114053850
from    O
the    O
treatment    O
of    O
cancer    O
(    O
chemotherapy    O
and    O
radiation    O
)    O
.    O

The    O
last    O
chapter    O
is    O
an    O
account    O
of    O
his    O
struggle    O
with    O
myelodysplasia    B-BloodDyscrasia114053850
,    O
the    O
disease    O
which    O
finally    O
took    O
his    O
life    O
in    O
December    O
1996    O
.    O

Blood    O
cell    O
dysfunction    O
-    O
megaloblastic    O
anemia    O
,    O
myelodysplasia    B-BloodDyscrasia114053850
,    O
marrow    O
failure    O
,    O
marrow    O
replacement    O
,    O
acute    O
leukemia    O

In    O
August    O
2014    O
,    O
Yordano    O
was    O
diagnosed    O
with    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
MDS    O
)    O
.    O

Born    O
on    O
15    O
March    O
1945    O
to    O
Sukhdev    O
Singh    O
and    O
Iqbal    O
Kaur    O
Chawla    O
in    O
Amritsar    O
,    O
the    O
temple    O
town    O
in    O
the    O
Indian    O
state    O
of    O
Punjab    O
,    O
he    O
graduated    O
in    O
Dentistry    O
from    O
the    O
Government    O
Dental    O
College    O
and    O
Hospital    O
,    O
Amritsar    O
in    O
1967    O
and    O
followed    O
it    O
up    O
with    O
higher    O
studies    O
on    O
Myelodysplastic    B-BloodDyscrasia114053850
Syndrome    I-BloodDyscrasia114053850
at    O
the    O
same    O
institution    O
in    O
1970    O
.    O

Myelodysplastic    B-BloodDyscrasia114053850
Syndrome    I-BloodDyscrasia114053850

A    O
human    O
T    O
-    O
lymphotropic    O
virus    O
antibody    O
test    O
,    O
developed    O
by    O
Mucke    O
's    O
team    O
but    O
never    O
marketed    O
,    O
served    O
to    O
demonstrate    O
the    O
first    O
evidence    O
of    O
retrovirus    O
-    O
like    O
serological    O
reactivity    O
in    O
patients    O
with    O
the    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
a    O
finding    O
that    O
meanwhile    O
has    O
been    O
corroborated    O
on    O
the    O
genomic    O
level    O
.    O

Farrell    O
died    O
of    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
MDS    O
)    O
in    O
Los    O
Angeles    O
,    O
California    O
on    O
January    O
10    O
,    O
1986    O
at    O
the    O
age    O
of    O
48    O
.    O

The    O
disorder    O
may    O
be    O
caused    O
either    O
by    O
a    O
genetic    O
disorder    O
or    O
indirectly    O
as    O
part    O
of    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
,    O
which    O
can    O
evolve    O
into    O
hematological    O
malignancies    O
(    O
especially    O
acute    O
myelogenous    O
leukemia    O
)    O
.    O

Clonal    O
sideroblastic    O
anemias    O
fall    O
under    O
the    O
broader    O
category    O
of    O
myelodysplastic    B-BloodDyscrasia114053850
syndromes    I-BloodDyscrasia114053850
(    O
MDS    O
)    O
.    O

The    O
drug    O
is    O
also    O
being    O
evaluated    O
broadly    O
across    O
multiple    O
lines    O
of    O
therapy    O
in    O
patients    O
with    O
myeloid    O
malignancies    O
,    O
including    O
in    O
ongoing    O
and    O
planned    O
phase    O
I    O
and    O
II    O
clinical    O
trials    O
for    O
newly    O
diagnosed    O
or    O
relapsed    O
AML    O
and    O
for    O
newly    O
diagnosed    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
or    O
MDS    O
.    O

Tetrasomy    O
and    O
hexasomy    O
8    O
are    O
rare    O
compared    O
to    O
trisomy    O
8    O
,    O
which    O
is    O
the    O
most    O
common    O
karyotypic    O
finding    O
in    O
acute    O
myeloid    O
leukemia    O
(    O
AML    O
)    O
and    O
myelodysplastic    B-BloodDyscrasia114053850
syndromes    I-BloodDyscrasia114053850
(    O
MDS    O
)    O
.    O

severe    O
hemolytic    O
anemia    O
,    O
megaloblastic    O
anemia    O
,    O
hereditary    O
spherocytosis    O
,    O
heterotaxy    O
with    O
asplenia    O
and    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
(    O
MDS    O
)    O
.    O

In    O
2001    O
,    O
Bak    O
learned    O
that    O
he    O
had    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
and    O
died    O
from    O
it    O
the    O
following    O
year    O
.    O

Acquired    O
hemochromatosis    O
is    O
common    O
in    O
patients    O
with    O
certain    O
types    O
of    O
chronic    O
anemia    B-BloodDyscrasia114053850
(    O
e.g.    O
thalassemia    O
and    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
)    O
who    O
require    O
many    O
blood    O
transfusions    O
,    O
which    O
can    O
greatly    O
increase    O
the    O
amount    O
of    O
iron    O
in    O
the    O
body    O
.    O

On    O
July    O
20    O
,    O
2005    O
,    O
however    O
,    O
he    O
bowed    O
out    O
of    O
the    O
race    O
,    O
citing    O
myeloproliferative    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
a    O
blood    O
disorder    O
that    O
can    O
develop    O
into    O
leukemia    O
if    O
left    O
untreated    O
.    O

#    O
Engulfment    O
of    O
hemapoietic    O
cells    O
by    O
megakaryocytes    O
such    O
as    O
in    O
hematolymphoid    O
disorders    O
(    O
Hodgkin's    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
leukemia    O
,    O
acute    O
and    O
chronic    B-BloodDyscrasia114053850
myeloid    I-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
,    O
non-Hodgkin's    B-BloodDyscrasia114053850
lymphoma    I-BloodDyscrasia114053850
,    O
myeloproliferative    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850
,    O
myelodysplastic    B-BloodDyscrasia114053850
syndrome    I-BloodDyscrasia114053850
)    O

Transient    O
myeloproliferative    B-BloodDyscrasia114053850
disease    I-BloodDyscrasia114053850
,    O
a    O
disorder    O
of    O
blood    O
cell    O
production    O
that    O
does    O
not    O
occur    O
outside    O
of    O
Down    O
syndrome    O
,    O
affects    O
3–10%    O
of    O
infants    O
.    O

He    O
shared    O
the    O
stage    O
with    O
Weezer    O
,    O
Andrew    O
WK    O
,    O
Glassjaw    O
,    O
Ryan    O
Dunn    O
and    O
the    O
Misfits    O
before    O
retiring    O
from    O
performing    O
in    O
December    O
2011    O
to    O
battle    O
accelerated    O
phase    O
myeloprolifirative    B-BloodDyscrasia114053850
leukemia    I-BloodDyscrasia114053850
.    O

After    O
the    O
release    O
of    O
The    O
Rabbi    O
Is    O
Dead    O
,    O
Lieberman    O
was    O
diagnosed    O
with    O
myeloproliferative    B-BloodDyscrasia114053850
bone    I-BloodDyscrasia114053850
marrow    I-BloodDyscrasia114053850
cancer    I-BloodDyscrasia114053850
and    O
knew    O
he    O
would    O
soon    O
be    O
unable    O
to    O
perform    O
on    O
stage    O
or    O
in    O
the    O
studio    O
.    O

myeloproliferative    O
diseases    O
are    O
a    O
category    O
of    O
hematological    O
malignancies    O
disorders    O
created    O
by    O
the    O
World    O
Health    O
Organization    O
which    O
have    O
characteristics    O
of    O
both    O
myelodysplastic    B-BloodDyscrasia114053850
and    O
myeloproliferative    B-BloodDyscrasia114053850
conditions    O
.    O

When    O
a    O
hematological    O
malignancy    O
is    O
characterised    O
by    O
normal    O
differentiation    O
of    O
cells    O
of    O
myeloid    O
cell    O
line    O
,    O
it    O
is    O
referred    O
to    O
as    O
myeloproliferative    B-BloodDyscrasia114053850
.    O

Polycythemia    B-BloodDyscrasia114053850
vera    I-BloodDyscrasia114053850
(    O
PV    O
)    O
,    O
a    O
myeloproliferative    B-BloodDyscrasia114053850
disorder    I-BloodDyscrasia114053850
in    O
which    O
the    O
bone    O
marrow    O
produces    O
excessive    O
numbers    O
of    O
red    O
cells    O
,    O
is    O
associated    O
with    O
elevated    O
hematocrit    O
.    O

WBC    O
proliferative    O
disorders    O
can    O
be    O
classed    O
as    O
myeloproliferative    B-BloodDyscrasia114053850
and    O
lymphoproliferative    O
.    O

Leukemia    O
(    O
chronic    B-BloodDyscrasia114053850
myelogenous    I-BloodDyscrasia114053850
(CML))    I-BloodDyscrasia114053850
and    O
other    O
myeloproliferative    B-BloodDyscrasia114053850
disorders    I-BloodDyscrasia114053850

Myeloproliferative    B-BloodDyscrasia114053850
neoplasms    I-BloodDyscrasia114053850
–    O
platelets    O
are    O
both    O
elevated    O
and    O
activated    O


